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Abstract 
 
This thesis is studying nitric oxide (NO) as a fundamental basis for health and 
disease and investigating as well as modifying its properties for therapeutic 
purposes. In the UK, nearly 3.5 million people have angina symptoms or have had 
a myocardial infarction (MI), or both. The mainstay treatment for reducing the 
symptoms of angina and long-term risk of MI in patients with heart disease is stent 
implantation in the diseased coronary artery. While this procedure has 
revolutionised treatment, the incidence of secondary events remains a concern. 
These repeat events are thought to be due, in part, to an increased inflammatory 
state that predisposes to continued enhanced platelet reactivity, endothelial 
dysfunction, and ultimately restenosis of the stented artery. In addition, CVD in 
general including atherosclerotic disease occurs at a lower incidence in 
premenopausal females compared with age-matched males. There has been 
considerable interest in why this might be the case but whether sex differences in 
inflammation underlie these differences is uncertain. Greater understanding of the 
role of inflammation and strategies that might selectively reduce inflammation 
within the CVD setting may offer novel approaches to therapeutics.  
 
Thus, I prospectively investigated whether inflammation and components of the 
inflammatory response are altered in females compared with males using two 
healthy volunteer studies. In the first study, I assessed systemic inflammatory 
markers and vascular function using brachial artery flow-mediated dilation 
(FMD). Typhoid vaccine induced mild systemic inflammation at 8 hours, reflected 
by increased white cell count in both sexes. Systemic inflammation in turn caused 
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a decrease in FMD in males, but an increase in females, at 8 hours. To investigate 
the differences in inflammatory responses between the sexes further in a separate 
study, I measured inflammatory exudate mediators and cellular recruitment in 
cantharidin-induced skin blisters. At 24 hours, cantharidin formed blisters of 
similar volume in both sexes; however, at 72 hours, blisters had only resolved in 
females. The activation state of all major leukocytes was lower in blisters of 
females, which was associated with enhanced levels of the resolving lipids. 
Together these findings suggest that in females, resolution of inflammation is 
accelerated compared with males, and that within the cardiovascular system this 
is likely to result in improved vascular function.  
 
The second part of my thesis studies was focussed on using the techniques 
established in the healthy volunteer studies to investigate whether a once a day 
inorganic nitrate (NO3-) administration might, through modification of 
inflammatory pathways, favourably modulate platelet reactivity and endothelial 
function leading to a decrease in restenosis. This was conducted in the form of the 
NITRATE-OCT study, which is a phase II trial enrolling 246 patients with stable 
angina due to have elective stent implantation. Patients have been randomised to 
receive 6 months of a once a day dose of either NO3--rich beetroot juice or NO3--
deplete beetroot juice (placebo) before their procedure. The primary outcome is 
reduction of in-stent late loss assessed by quantitative coronary angiography 
(QCA) and optical coherence tomography (OCT) at 6 months. Thus far, we have 
baseline demographic data for 200 patients in total and the study is still ongoing 
to ensure the investigators remain blinded. At baseline there were no significant 
differences in demographic or procedural characteristics between the two groups.  
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1.0 Introduction 
Some cardiovascular disorders are characterised by an underlying vascular 
inflammation that is considered to play a major causative role in pathogenesis 
(Willerson and Ridker, 2004). 
 
This thesis is separated into two distinct sections. In the first part, we decided to 
use the typhoid-induced model of systemic inflammation to further interrogate 
the changes in endothelial regulation of vascular tone in the arterial circulation. In 
addition, to study the inflammatory response in humans more closely, we 
explored whether a suitable model of innate inflammation might be available.  
Since the cantharidin model allows us to explore localised inflammation, we 
decided to use this model to characterise the leukocytes, chemokines, cytokines 
and resolution factors generated during an inflammatory response.  
 
To test both of these methodologies and to establish both models of inflammation 
in our laboratory, we investigated the responses to typhoid and cantharidin in 
both healthy male and female volunteers in two healthy volunteer studies. 
 
In the second section, we decided to conduct a clinical trial to assess the effects of 
inorganic nitrate (NO3-) on restenosis and inflammation by conducting the 
NITRATE-OCT study. Inorganic NO3-, when converted to nitrite (NO2-) via the 
enterosalivary circuit, has been shown to reduce smooth muscle cell proliferation 
and promote endothelial cell growth in our laboratory. This thesis contains a sub-
analysis of our large Phase II double blinded randomised controlled trial 
(NITRATE-OCT) that is investigating whether there is a reduction in the growth of 
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smooth muscle cells (preventing restenosis within the stent), following ingestion 
of inorganic NO3- in patients undergoing percutaneous coronary intervention 
(PCI) with stent implantation for stable angina.  
 
The aim of the second part of the thesis is to explore the possibility that the 
beneficial effects of inorganic NO3- with regards to reducing restenosis in stable 
angina patients might relate to effects on inflammation, by assessing the levels of 
specific pro-inflammatory components and circulating cell subtypes as 
exploratory endpoints in the NITRATE-OCT cohort. 
 
 
1.1 Coronary Heart Disease  
In the last 20 years, the management of cardiovascular disease (CVD) has greatly 
improved, however despite this it remains the top cause of death worldwide (Lim 
et al., 2012). This level of mortality coupled with increasing levels of morbidity 
over the past 10 years have had huge economic implications both to developing 
countries (as western lifestyles continue to be adopted) and within developed 
countries including Europe. For instance, this health burden is estimated to cost 
the UK economy £9 billion in 2016. The UK remains one of the most affected 
countries in Europe in terms of CVD with 152,465 deaths out of a total mortality 
of 525,048 due to CVD in 2016, with the majority (66,076) a consequence of 
coronary heart disease (CHD), the latter remaining the single biggest cause of 
death in the UK (BHF, 2016). 
 
That said, overall figures for mortality in the UK continue to improve each year. 
Since the early 1970’s death rates from CVD have been on the decrease.  Indeed, 
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for the first time since CVD statistics have been compiled by the British Heart 
Foundation, mortality due to CVD (26%) has been surpassed by cancer (29%). In 
those under 75 years, death rates have fallen by 34% in the last ten years 
(http://www.bhf.org.uk/research/statistics/mortality.aspx). This has been 
attributed largely to improvement in lifestyle factors and to highly efficacious 
treatment advances following an acute event. Presently, timely PCI with stent 
implantation coupled with prolonged (1 year) anti-platelet therapy following a 
heart attack remains the most effective treatment strategy for limiting secondary 
events and improving clinical outcomes (Kastrati et al., 2005; Stone et al., 2013). 
However, despite these advances, substantial morbidity persists. Thus, there is an 
urgent imperative to identify and develop efficacious and sustainable approaches 
for primary and secondary prevention.  
 
CHD can manifest in a number of different ways, the main ones being angina 
(either stable or unstable) and myocardial infarction (MI). In particular, my PhD 
research has focused upon trying to identify therapeutic strategies for one of these 
i.e. stable angina. 
  
1.2 Stable angina and its management  
In the UK, nearly 3.5 million people have angina symptoms or have had a 
myocardial infarction, or both (www.bhf.org.uk). Angina is classed as a symptom 
and not a disease (the underlying disease is CHD). It is often defined as pain or 
discomfort in the chest that is a result of myocardial hypoxia, secondary to a 
restricted coronary blood flow caused by atheromatous plaque in the coronary 
arteries (National et al., 2011). Patients often complain of symptoms, including 
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chest pain, that can radiate to the surrounding area and these symptoms are 
known as angina pectoris. Stable angina symptoms often occur when the demands 
of the heart are high (i.e. during exercise) and the supply of blood and oxygen to 
the heart is unable to meet the demand due to CHD. In patients suffering from 
angina, one or more coronary arteries usually has a stenosis of more than 70%. 
Therefore, even though sufficient blood can be supplied to the myocardium during 
rest, the myocardium is not able to compensate when there is an increased 
demand (Lilly, 2007).  
 
The management of stable angina aims to relieve patient’s symptoms, improving 
quality of life and reducing morbidity and mortality. As a first line therapy, the 
current NICE guidelines recommend that patients with stable angina are 
prescribed anti-anginal medicines.  However, when these are ineffective, 
consideration is given to elective coronary revascularisation, either coronary 
artery bypass grafting surgery (CABG) or PCI (National et al., 2011), to help relieve 
angina symptoms by restoring the blood supply to the heart. 
 
1.3 Percutaneous Coronary Intervention for stable angina 
PCI (also known as balloon angioplasty, coronary angioplasty and percutaneous 
transluminal coronary angioplasty) was introduced by Andreas Gruntzig in 1977 
and is a procedure that is used to ‘re-open’ patients’ narrowed coronary arteries. 
Since this procedure is performed under local anaesthesia, it is considered a safe 
and less invasive option compared to CABG surgery which requires general 
anaesthesia (Lauck et al., 2009). In addition, CABG is generally restricted to 
patients with severe multi-vessel coronary artery disease while the 
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revascularisation modality of choice for more focal coronary disease is PCI (Patel 
et al., 2009). Although following significant advances in percutaneous coronary 
intervention in terms of both skills set as well as technology, more complex 
coronary disease has guideline approval for PCI as an alternate to CABG 
(Windecker et al., 2018). 
 
Currently in the UK, patients undergoing elective PCI procedures are often in 
hospital for less than 24 hours and advances in post-procedure care mean that the 
majority of patients are in hospital for just a few hours as a ‘day-case’ patient 
(Brayton et al., 2013; British Heart Foundation, 2014).  Furthermore, patients are 
often expected to return to normal activities and work, if appropriate, within two 
weeks (British Heart Foundation, 2009a; b).  During the PCI, patients are taken to 
a cardiac catheterisation laboratory in the hospital, the cardiologist makes a small 
incision (into the radial or femoral artery) and introduces a balloon catheter into 
the patient’s artery, which is then advanced to the site of the narrowing in the 
coronary artery (Reynolds et al., 2001). The balloon is then inflated several times 
which pushes the plaque into the inner wall of the artery, opening the blood vessel 
(Brar and Stone, 2009). A stent device (a small stainless steel mesh) is inserted to 
hold the artery open and improve the blood flow. Once the procedure is complete 
the balloon catheter is removed, the artery is ‘sealed’ and the patient transferred 
to a day case unit/ward area for a few hours prior to discharge (British Heart 
Foundation, 2014).  
 
The aim of PCI is to reduce or completely relieve the patients’ angina symptoms. 
However, despite this, the underlying CHD remains. Findings from the large BARI 
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longitudinal study (n = 1829) demonstrated that more than 75% (n = 915) of PCI 
patients require further revascularisation for symptom relief within ten years 
(Alderman et al., 2004; BARI Investigators, 2007). Such findings demonstrate that 
the underlying CHD continues to progress even after PCI and therefore, it is 
essential that this is managed as a chronic condition with long-term 
pharmacological treatment and risk factor modification to slow the progression of 
the disease.  
 
1.4 Bare metal stents and drug eluting stents 
Over the last 20 years, PCI has evolved to include the placement of intra-coronary 
bare metal stents (BMS) which act as scaffolding to prevent arterial recoil. Despite 
its short-term efficacy, long-term results with BMS have been limited by 
accelerated neo-intimal proliferation at the site of the stent placement, resulting 
in luminal restenosis (Smith et al., 2006). The rates of restenosis with BMS have 
been estimated to be between 10-30% (Weintraub, 2007). Restenosis is often 
accompanied by the recurrence of anginal symptoms and typically requires repeat 
PCI, or occasionally surgical revascularisation with CABG. To address this 
drawback of BMS, stents coated with anti-proliferative medications were 
developed (Smith et al., 2006). These drug-eluting stents (DES) slow down neo-
intimal proliferation by the controlled release of anti-proliferative medications 
into the tunica media of the coronary artery. In the year 2000, the first generation 
of polymer-based DES, the Sirolimus-eluting CYPHER stent (Johnson & Johnson) 
and the Paclitaxel-eluting TAXUS stent (Boston Scientific) were introduced into 
clinical practice.  
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Since the introduction of these two first generation DES, there have been a number 
of advances in the design of the stent platforms, associated polymers and anti-
proliferative medications that has led to the introduction of 2nd and 3rd generation 
DES (Akin et al., 2011), which are now available for use. All DES markedly reduce 
restenosis and recurrent angina when compared to BMS (Babapulle et al., 2004). 
However, even with the latest generation of DES, it has been estimated that in 
simple lesions, restenosis rates are less than 5% at 1 year but at 5 years, repeat 
intervention rates are approximately 10% (Weisz et al., 2009).  Furthermore, in 
more complex lesions, restenosis has been documented at 10% within 2 years 
(Steinberg et al., 2009). 
 
In addition, a number of studies have raised more serious concerns regarding the 
long-term safety of DES, suggesting a potential increase in late MI from very late 
stent thrombosis because of incomplete endothelisation of stent struts (Babapulle 
et al., 2004; Garg et al., 2008; Spaulding et al., 2007; Stone et al., 2007). Although 
late stent thrombosis is rare, with estimates suggesting a 0.13% increased risk per 
year compared to BMS, it has an extremely poor prognosis, with short-term 
mortality estimated at 20% (Garg et al., 2008). Compared to BMS, DES stents are 
marginally less deliverable and have significantly increased acquisition costs. 
Furthermore, extended administration of dual anti-platelet coverage (typically 
with a combination of aspirin and a thienopyridine such as clopidogrel) until 
adequate stent strut endothelisation, is essential in reducing the risk of stent 
thrombosis (Windecker et al., 2005). Moreover, it must be noted that the newer 
thienopyridines (such as prasugrel and ticagrelor (Wallentin et al., 2009; Wiviott 
et al., 2007)) are expensive and dual anti-platelet coverage has a non-trivial risk 
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of major bleeding (Ko et al., 2010). Finally, there is also data to suggest the 
inflammation that accompanies PCI with stent implantation is systematic as well 
as focal (Brasselet et al., 2007; Kozinski et al., 2005). 
 
1.5 Cellular and molecular pathogenesis of restenosis 
We now know that the long-term outcome of stent implantation is affected by a 
process called in stent restenosis (ISR). ISR is defined either clinically or on 
angiograms. This clinical definition includes the the presentation of recurrent 
angina or objective evidence of myocardial ischaemia. On the other hand, 
angiographic ISR is defined as the presence of stenosis (>50% in diameter) in the 
stented segment (Teirstein et al., 1997). Traditionally, ISR has been classified 
based on the length of the lesion, as diffuse (>10 mm) or focal (<10 mm). 
Angiographically, ISR is classified into six different groups (I–IV) depending on  
the pattern and extent of restenosis with relation to the affected vessel. According 
to this classification, focal pattern I can be further subdivided into IA–ID and 
diffuse pattern can be grouped  into II–IV (Mehran et al., 1999).  
With the advance of intravascular imaging, particularly Intravascular ultrasound 
(IVUS) (described further in section 1.6) , we have a greater understanding of the 
fundamental differences in the process of restenosis following PCI (Mintz et al., 
1996; Serruys et al., 1994; Williams et al., 2000). The pathophysiology of 
restenosis includes build-up of new tissue within the arterial wall (also known as 
neointimal hyperplasia - NIH). There is a cascade mechanism that involves 
platelets, polymorphonuclear leucocytes, and macrophage aggregation leading to 
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medial smooth muscle cell (SMC) migration and proliferation, which is the basis 
of NIH formation (Carter et al., 1994) (Figure 1.1). Furthermore, the hallmarks of 
the onset of restenosis are leucocyte recruitment at the site of the injury and the 
deposition of platelets and fibrin (Libby and Simon, 2001).  
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Figure 1.1:  Schematic of the “cascade” reaction of the vascular wall to stent injury 
involving several distinct steps. (A) injury to the endothelium and even the elastic lamina, 
triggers an inflammatory reaction, which causes (B) proliferative changes in the media. (C) There 
is phenotypic modulation of the medial VSMCs, which causes them to migrate into the intimal layer, 
where (D) increased ECM production by VSMCs adds bulk to the restenotic lesion. (E) The final 
healing phase results in stabilization of the fully formed lesion. Legend: SMCs; smooth muscle cells, 
ECM; extra cellular matrix, VSMCs; vascular smooth muscle cells, IEL; internal extracellular lamina, 
EEL; external extracellular lamina, SAPK; stress-activated protein kinases,  Adapted from (Mitra 
and Agrawal, 2006). 
(A) Injury 
• Endothelial denudation 
• Inflammation 
• Injury to IEL or EEL 
• Activation of SAPK 
(B) Medial proliferation 
• Release of growth factors 
• Activation of SMCs 
• Loss of inhibitory factors 
• Proliferation of SMCs 
(C) Intimal hyperplasia 
• Exposure of SMCs to plasma 
mitogens 
• Localised proliferation of 
SMCs 
(D) Migration of VSMCs 
• Migration of the SMCs 
across the IEL from medial 
intima 
• Breakdown of the ECM 
(E) Healing 
• Stabilisation of the ECM 
• Fully formed neointima 
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Experimental models have demonstrated that  thrombocytopenia has been found 
to reduce restenosis (Virmani and Farb, 1999). Furthermore, glycoprotein IIb/IIIa 
antagonists (which are antibodies to the platelet glycoprotein receptor IIb/IIIa) 
have been shown clinically to have similar effects (Kereiakes et al., 1998; Topol 
and Serruys, 1998). The glycoprotein IIb/IIIa inhibitors have opened the field to a 
rapidly developing area of anti‐integrin targeting as a therapeutic approach. 
Currently, the Fab fragment abciximab and the small molecule glycoprotein 
IIb/IIIa inhibitors eptifibatide and tirofiban are used in interventional cardiology 
practice (Ahrens et al., 2003). However, some studies challenge the benefit of 
these therapeutic agents in the clinical setting (Waksman et al., 2004). 
Transmigration of leucocytes occur across the platelet coated surface (Diacovo et 
al., 1996), mediated by P‐selectin (Yeo et al., 1994). Neutrophil–platelet and 
monocyte–platelet aggregates have been found in the peripheral blood of patients 
with CAD and have been proposed as predictors of disease activity (Furman et al., 
1998; Ott et al., 1996). A number of adhesion molecules and chemoattractant 
agents play a critical role in the recruitment of monocytes, platelet activation, and 
aggregation. These include Mac‐1 (CD11b/CD18), a component of leucocyte 
secretory granules, which promotes adhesion of polymorphonuclear leucocytes 
and monocytes to endothelial cells (Inoue et al., 1998). Furthermore, Mac‐1 
expression increases following stent implantation (Fuster et al., 1995). Monocyte 
chemoattractant protein (MCP)‐1 is a chemokine secreted by activated platelets 
(Rollins, 1997), the expression of which rises in endothelial cells and vascular 
smooth muscle cells (VSMCs) following stenting injury (Furukawa et al., 1999). 
Persistently elevated levels of MCP‐1 have been demonstrated in patients who 
developed restenosis (Cipollone et al., 2001). Events occurring at the platelet 
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surface involve CD40L, (described in more detail in section 1.9 below). Assembly  
of CD40L and its soluble fragment sCD40L inhibits re‐endothelialisation of the 
endothelial layer and predisposes to restenosis (Aukrust et al., 1999).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Schematic of the time course reactions of restenosis. Chronological sequence of 
events leading to instent restenosis can be divided into the early and the late phases. The early 
phase is the initial injury followed by the inflammatory reactions and the late phase essentially 
consists of the various mechanisms leading to increase in lesion volume (hyperplasia). Legend: 
ECM; extra cellular matrix, VSMCs; vascular smooth muscle cells. Adapted from (Mitra and 
Agrawal, 2006). 
 
ISR development has complex mechanisms, which can be divided into an “early” 
(days to weeks) and a “late” (weeks to months) phase (Figure 1.2). Each step is 
regulated by unique but inter‐related molecular and cellular events, the overall 
control of which is the result of interaction among growth factors and their 
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receptors, secondary messengers, cytokines and proto‐oncogenes involved in 
transcription, translation, and post‐translational events (Lincoff et al., 1994; Topol 
and Serruys, 1998). The early phase events start with restructuring of the 
thrombus, relocation of the plaque and an acute inflammatory response. In 
addition, studies have shown that elastic recoil is minimal in ISR compared to 
restenosis that occurs following PCI, due to the rigid scaffolding of the stents 
(Bennett, 2003). Endothelial injury produces some element of thrombus 
formation (Virmani et al., 2003) and fibrin and platelet deposition at the site of 
injury delivers the basis for the inflammatory aggregate. In addition, there is 
increased leucocyte trafficking (predominantly monocyte derived macrophages 
(Komatsu et al., 1998)) to the stent site and subsequent migration into the vessel 
wall (Dzavik, 2003). Un-interrupted production of adhesion molecules, 
chemoattractants, cytokines and growth factors by the monocytes, SMCs and 
platelets results in further leucocyte recruitment and infiltration. The following 
weeks after this injury leads the whole process into the late phase. The main 
outcome of the late phase is the phenotypic modification of medial SMCs followed 
by their migration and subsequent proliferation in the intima. Synchronised 
extracellular matrix (ECM) synthesis by these SMCs is responsible for the 
increasing volume of intimal tissue (Figure 1.3) and the bulk of the NIH is 
composed of ECM collagens and proteoglycans. Furthermore, cellular elements 
only make up approximately 11% of the restenosis body (Rollins, 1997). 
Therefore following stent implantation, there is a shift towards greater ECM 
synthesis rather than SMC proliferative activity over the months subsequent to 
stent implantation (Furman et al., 1998; Ott et al., 1996).  
61 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Schematic diagram of the cellular mechanism of ISR. Phenotypic modulation of the 
quiescent VSMCs and migration into the intimal layer. Continual SMC proliferation occurs in the 
intima with the deposition of de novo ECM. Legend: ECM; extra cellular matrix, ECs; endothelial 
cells, MMPs; Matrix metalloproteinases, PDGF; platelet-derived growth factor,  SMC; smooth 
muscle cells, Inf cells; Inflammatory cells, Adapted from (Mitra and Agrawal, 2006) 
1.6 Optical coherence tomography (OCT) 
Coronary angiography has been the gold standard technique for evaluating 
coronary artery disease for the past 50 years. Increasingly however, realisation of 
the limitations of coronary angiography, mainly the inability to supply information 
regarding the coronary wall, has prompted the design and development of 
adjunctive technologies to better evaluate not just luminal disease but also the 
burden and character of atherosclerotic plaque within the vessel. The 
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development of intracoronary imaging modalities namely IVUS and optical 
coherence tomography (OCT) has progressed quickly and these technologies now 
have established roles in the diagnosis and treatment of coronary artery disease. 
In general, intracoronary devices that can assess the coronary endothelium use 
either acoustic or optical signals that are received by a coronary catheter (IVUS 
uses ultrasound, OCT uses near infrared light).  
 
OCT was first developed by two Japanese researchers at the Yamagata University 
(Japan) and subsequently at the Massachusetts Institute of Technology in the USA 
in 1991.  OCT was initially performed in the retina but adopted in the coronary 
artery later in the same year (Mintz et al., 2001; Terashima et al., 2012).  OCT uses 
near-infrared light, which is absorbed by water, lipids and erythrocytes (Figure 
1.4).  The high-resolution of OCT has allowed use of this technology for both 
clinical and research purposes (Terashima et al., 2012).  OCT has widely been used 
in the assessment of coronary anatomy over the last decade, and has a wide range 
of clinical applications including coronary plaque anatomy, post PCI stent position 
and malapposition.  Within research, OCT has improved the evaluation of stent 
endothelisation post implantation. Although initial OCT systems consisted of time-
domain (TD-OCT) technology, this has been surpassed by frequency-domain (FD-
OCT) technology. While TD-OCT uses a moving mirror as its reference arm and a 
broadband light source, FD-OCT uses a fixed mirror with a variable frequency light 
source allowing simultaneous detection of reflections from all echo time delays 
(Takarada et al., 2010).  
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Current OCT catheters are 3.2 French (The French scale or French gauge system 
is commonly used to measure the size of a catheter and is three times the diameter 
in millimeters) flexible short monorail systems with an optical emitting 
transducer, that emits a near-infrared wavelength of about 13,000 nm.  The OCT 
catheter transducer lies 20mm behind the distal marker.  The transducer contains 
optical fibres with a micro-lens transducer that is placed beyond the target lesion 
along a standard guide-wire. The OCT catheter does not move during image 
acquisition, instead the transducer moves back inside the central part of the 
catheter.   
 
Figure 1.4 Schematic of OCT imaging system: The pulse of light from the laser source is split 
equally between the tissue wave (TW) and the reference wave (RW).  The RW reflects of the 
reference window (RW) to calculate distance of pullback.  The returning TW signal from the tissue 
is combined with the returning RW signal from the RM and this is converted to images within the 
main computer system. 
 
The catheters have an automated pullback system at a rate of 36 mm per second 
with an image range of 54 to 74 mm when adequate coronary preparation has 
occurred. As the light source is easily absorbed by blood there is a need for 
coronary preparation prior to image acquisition.  The use of pure contrast through 
a manifold to prepare the coronary artery with total blood removal is generally 
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recommended with most left coronary systems requiring 10-14 mls and right 
coronary arteries 8-10 mls.  The OCT system consists of an OCT imaging catheter 
(ImageWite TM, St Jude TM) and an OCT system console, which contains the 
optical imaging engine and computer signal acquisition (M2/M3 CV OCT Imaging 
System, LightLab Imaging, Inc.).   
 
Due to the need for complete coronary preparation, if any blood pooling remains, 
a high signal will remain within the image distorting the final image.  In addition, 
as the guide wire does not run through the entire length of the OCT catheter, all 
images will have a silhouette of the guide wire with reduction of image quality in 
these areas (Figure 1.5).   
 
The relatively low energy used in OCT (5.0 to 8.0 mW) does not cause functional 
or structural damage to the coronary tissue.  The main safety concern with OCT is 
the use of a contrast bolus in coronary preparation, however, studies have shown 
that no patients suffered contrast induced nephropathy, however there is a 
relatively small risk of coronary spasm and ECG changes during contrast 
administration (Imola et al., 2010).  
 
1.6.1 Assessment of Coronary Lesions with OCT 
1.6.1.1 Plaque Characterisation 
Since there is greater spatial resolution with OCT compared to IVUS (see Figure 
2), OCT can provide more detail regarding the microstructure of the vessel wall 
and specifically OCT has been shown to identify thin-cap fibroatheroma (TCFA).  
Studies have shown a high degree of correlation between OCT imaging and fibrous 
65 
 
cap thickness on histologic evaluation (Calvert et al., 2011; Garcia-Garcia et al., 
2011; Mintz et al., 2001).   In addition, OCT can identify TCFA by measuring the 
thickness of the fibrous cap and the arc of the lipid-rich plaque (Jang et al., 2002; 
Jang et al., 2005; Tanaka et al., 2009). Lipid pools are less sharply delineated than 
calcification and show lower signal intensity. Lipids also exhibit more 
heterogeneous backscattering than fibrous plaques (Prati et al., 2010; Yabushita 
et al., 2002).  
 
 
Figure 1.5 Intracoronary imaging of a normal coronary artery: (A) IVUS image (B) OCT image 
of normal coronary arteries.  Red circle indicates position occupied by imaging catheter and + 
shows the ‘drop-out’ signal produced by the guide-wire 
 
OCT has been shown to be helpful in determining prognosis by identifying 
vulnerable plaques. A prospective study of the characteristics of non-culprit 
lesions in 53 patients with coronary artery disease undergoing PCI showed that 
TCFA (as assessed by OCT) and the presence of micro-channels had a significant 
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correlation with plaque progression (defined as > 0.4 mm increase in minimal 
luminal diameter) at a 7-month follow-up (Uemura et al., 2012).  
 
1.6.1.2 Assessment of Neointimal Coverage with OCT 
Strut coverage is an important surrogate risk factor of stent thrombosis. Using 
OCT, strut coverage is clearly seen and both the coverage of individual struts and 
the thickness of neointimal coverage can be assessed accurately (Matsumoto et al., 
2007).  In one study, at 6-months follow-up, 89% of sirolimus-eluting stents (SES) 
lesions were covered by thin neointima, and 64% of the stent struts were covered 
with neointima that had a thickness of less than 100 μm (Matsumoto et al., 2007).  
 
Even though the introduction of DES has led to reduced rates of restenosis, this 
complication following PCI still occurs and our understanding of its 
pathophysiology is still poor.  OCT has helped advance our understanding with 
studies demonstrating that stent restenosis is not homogenous.  Furthermore, 
OCT imaging allows separation of restenotic tissue into homogenous, layered and 
heterogeneous groups.  This was demonstrated in a study where paclitaxel-eluting 
stent restenosis could be easily classified into these three groups using OCT 
(Gonzalo et al., 2009).  Figure 1.6 demonstrates the sensitivity of OCT in 
characterising the extent of restenosis after drug-eluting stent implantation. 
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Figure 1.6: Intracoronary optical coherence tomographic images of restenotic tissue 
following drug-eluting stent implantation.  A 10% luminal loss (* and blue arrow): B represents 
87% luminal loss (* and blue arrow) 
 
1.7 Quantitative coronary angiography (QCA) 
Coronary angiography using selective injection of radiopaque contrast agent into 
the coronary arteries is the gold standard for evaluating CHD. Due to significant 
intra-observer and inter-observer variability, subjective visual estimation of 
lesion severity has been shown to be inadequate (Topol and Nissen, 1995). Since 
the late 1980s methods and algorithms for QCA have been developed in order to 
objectively quantify the extent of CHD (Serruys et al., 1984). In addition, validation 
of specific QCA measurements associated with clinical outcomes has led to their 
incorporation into trials endpoint and scoring systems.  
 
 
68 
 
1.7.1 Two-dimensional QCA 
In this technique, contrast coronary angiograms allow parameters to be obtained 
that objectively quantify the coronary lumen and allow measurement of any 
significant coronary stenosis. Since coronary arteries can be highly tortuous 3D 
structures whereas a single coronary angiography image gives only a 2D 
radiographic image, at least two projections orthogonal to each other and both 
perpendicular to the analysed coronary segment are necessary to obtain the most 
complete data to avoid underestimation of stenosis severity and foreshortening. 
 
Recent systems are based on vessel edge to edge detection algorithms to designate 
the arterial lumen on conventional coronary angiograms allowing the assessment 
of the lesion in an operator-independent way and therefore exploiting specific and 
dedicated software. Over the years, several generations of QCA systems have been 
developed based on edge detection algorithms to improve measurement accuracy. 
Cardiovascular X-ray imaging systems are equipped with flat-panel (FP) detectors 
(Spahn et al., 2003), which have replaced the combination of image intensifier and 
charge-couple device camera providing better image quality and enabling 
improved image enhancement. Novel QCA third-generation system, which took 
advantage of digital FP detectors instead of the conventional image intensifier 
systems, were better able to determine smaller diameter vessels (Van Herck et al., 
2004) and analyse complex lesion morphology with irregular borders (van der 
Zwet and Reiber, 1994). Currently, there are different computer systems for QCA 
that have been validated: among them the most commonly employed are CAAS 
(PIE Medical, Maastricht, The Netherlands) and QAngio XA (Medis, Leiden, The 
Netherlands) (Garrone et al., 2009). 
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1.7.2 Clinical and research applications of QCA 
In clinical practice, QCA can be used during diagnostic coronary angiography, to 
provide an objective and independent parameter for the assessment of stenosis 
severity because the human eye does not have the resolution capability of 
software. Usually, visual interpretation of the severity of a coronary stenosis is 
expressed in intervals of percentage of stenosis while QCA produces a single 
specific measure for diameter stenosis, improving the accuracy and 
reproducibility of the severity assessment (Kalbfleisch et al., 1990). Studies have 
shown that the visual assessment tends to underestimate stenoses <50% and to 
overestimate those >50% (Fleming et al., 1991) therefore the online use of QCA 
assessing the lesion length and reference vessel diameter (RVD) might enable us 
to obtain objective parameters to decide which specific measures (mainly 
diameter and length) of the device (e.g., balloon or stent) should be chosen. 
 
Within clinical research, QCA permits serial analysis of the same coronary 
segment over time in an independent way. In trials involving coronary devices, 
typically at least three QCA analyses are performed, one before treatment, another 
immediately after treatment, and a final one at angiographic follow-up (at a 
specified time). Binary restenosis (defined as a >50% diameter stenosis at follow-
up (Mauri et al., 2005)) and late luminal loss (defined as the difference between 
the minimum luminal diameter (MLD) immediately after the procedure and the 
MLD at follow-up (Mauri et al., 2005)) have played an important role in several 
studies investigating various stents. These values, more specific and more 
applicable to the clinically relevant end-point of target lesion revascularisation 
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(TLR), allow researchers to compare different types of stents in clinical trials, with 
greater statistical power (and hence with fewer patients) (Tomasello et al., 2011).  
 
Finally, another useful application of QCA is the study of plaque progression and 
regression that is based on at least two QCA analysis made over a pre-specified 
interval of time, often 6 months or 1 year. The change in MLD of the pre-
determined coronary segments can then be used to determine efficacy of 
interventions to reduce restenosis.  
 
1.8 Inflammation and restenosis 
Although factors including anatomical features (e.g. lesion length), procedural 
variables (e.g. residual stenosis) and clinical factors (diabetes, unstable angina, 
smoking, older age) (Mercado et al., 2001) are known to contribute towards 
restenosis, the exact mechanisms of this process are not completely understood. 
In addition, these factors are of only limited use in predicting those in whom 
restenosis will occur (Singh et al., 2004).  
 
There is a growth of evidence suggesting that inflammation may play an important 
role in restenosis (Libby et al., 2003; Toutouzas et al., 2004), raising the possibility 
that measurement of inflammation may improve our ability to predict those at 
increased risk. Following PCI, balloon injury to the endothelium and vessel wall 
results in a ‘healing’ response characterised by inflammation in both the intimal 
and adventitial layers of the artery wall (Kornowski et al., 1998). This ‘healing’ 
response means that there is proliferation of fibrocollagenous tissues in 
association with the neovascularisation of the stent struts, which together 
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resemble granulation tissue in normal wound healing (Kornowski et al., 1998).  
Furthermore, as well as being prothrombotic, this inflammation has two 
important consequences namely, adventitial constriction and intimal hyperplasia 
(Kornowski et al., 1998), leading to the process of restenosis.  
 
Constriction of the adventitia results in an overall reduction in the arterial 
diameter at the PCI site and is a major component of restenosis following balloon 
angioplasty without stenting. Although this constrictive remodelling is prevented 
by stent deployment, there is much more intimal hyperplasia following stenting 
and this accounts for virtually all in-stent restenosis (Lowe et al., 2002).  
 
In both animal models and human pathology studies, there is a significant 
correlation between the extent of inflammatory reaction to angioplasty and the 
degree of restenosis (Kornowski et al., 1998). Experimental treatments aimed at 
decreasing inflammation have shown some promise in reducing restenosis 
(Phillips et al., 2003; Versaci et al., 2002), adding further emphasis to the theory 
that inflammation is a central component of the restenotic process (Farb et al., 
2002; Meuwissen et al., 2002).  
 
Hence, a better understanding of the components of the inflammatory response 
that contribute to restenosis may help in the development of anti-restenosis 
treatments. Furthermore, if measurement of circulating markers of inflammation 
improves our ability to predict those who will develop restenosis, they may be of 
use in targeting prevention strategies such as DES to those most likely to benefit. 
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Below, the associations between several inflammatory markers and restenosis are 
discussed in detail particularly those relevant to this thesis. 
 
1.9 Pre-PCI inflammatory markers and restenosis 
There have been a number of studies that have investigated whether 
inflammatory marker levels are predictive of restenosis in patients undergoing 
PCI (Buffon et al., 1999; Dibra et al., 2003; Gomma et al., 2004; Rittersma et al., 
2004; Segev et al., 2004; Walter et al., 2001). In particular, there has been a focus 
on C-Reactive Protein (CRP). CRP is an annular (ring-shaped), pentameric protein 
found in blood plasma, the levels of which rise in response to inflammation. It is 
an acute-phase protein of hepatic origin that increases following interleukin-6 
secretion by macrophages and T cells (Thompson et al., 1999). Its physiological 
role is to bind to lysophosphatidylcholine expressed on the surface of dead or 
dying cells (and some types of bacteria) in order to activate the complement 
system (Thompson et al., 1999). In mixed patient cohorts of unstable and stable 
angina, an association between raised CRP levels and subsequent angiographic 
restenosis has been demonstrated (Buffon et al., 1999; Walter et al., 2001). In the 
study by Walter et al. (2001) in 276 “high-risk” PCI patients (which included a 
number of patients with acute coronary syndrome (ACS)), pre-PCI CRP levels were 
predictive of angiographic restenosis, with a CRP level ≥5 mg/l associated with 
significantly higher restenosis rates than in those with a CRP <5mg/l (40% vs. 
19% respectively, p=0.002) (Walter et al., 2001).  
 
On the other hand, studies that are limited to a stable angina population alone have 
found no association between pre-PCI CRP levels and restenosis (Dibra et al., 
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2003; Gomma et al., 2004; Rittersma et al., 2004; Segev et al., 2004). In the largest 
study reported to date, Dibra et al. investigated baseline CRP, 6 month 
angiographic restenosis and 1 year clinical outcome in nearly 1200 patients 
undergoing elective PCI for stable angina (Dibra et al., 2003). In this study, CRP 
appeared predictive of clinical events (death or non-fatal myocardial infarction) 
but not of angiographic restenosis (CRP >5 mg/l, restenosis rate 25%, CRP ≤5 
mg/l, restenosis rate 24%, p=0.66). Hence, the differences in why CRP has been 
shown to be predictive of restenosis in some studies (Buffon et al., 1999; Walter 
et al., 2001) while others have not shown any difference (Dibra et al., 2003; 
Gomma et al., 2004; Rittersma et al., 2004; Segev et al., 2004) may be related to 
the differences in the population studied. As we already know, the underlying 
pathological processes in ACS are different from those of stable angina (Zipes et 
al., 2005). ACS patients have widespread coronary inflammation with evidence of 
unstable coronary plaques in non-culprit arteries (Buffon et al., 2002; Rioufol et 
al., 2002), and this is reflected in significantly higher pre-procedural CRP levels 
(Bogaty et al., 2001) and more marked elevation of CRP levels after PCI (Liuzzo et 
al., 1998) than those observed in stable angina patients (Azar et al., 2000). This 
may introduce confounding in studies that include a mixed population of stable 
and unstable angina patients, since unstable angina is associated with both raised 
CRP levels and increased rates of restenosis. It may also be that CRP is predictive 
of restenosis in ACS but not in stable angina; only study of a ‘pure’ ACS cohort 
would answer this question. 
 
It is possible other markers directly involved in the restenotic process might be 
more predictive of restenosis. CD40 ligand (CD40L, also known as CD154), a 
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transmembrane protein, was originally identified on CD4+ T cells, but has also 
been found on activated platelets (Henn et al., 1998). Both membrane-bound and 
soluble (s) forms of this ligand may interact with CD40, which is constitutively 
expressed on vascular cells, resulting in various inflammatory responses (Mach et 
al., 1997). In addition, soluble intercellular adhesion molecule-1 (sICAM-1) 
represents a circulating form of ICAM-1 that is constitutively expressed or is 
inducible on the cell surface of different cell lines. It serves as a counter-receptor 
for the lymphocyte function-associated antigen (LFA-1). Interaction between 
ICAM-1, present on endothelial cells, and LFA-1 facilitates leukocyte adhesion and 
migration across the endothelium. ICAM-1 and its circulating form have been 
implicated in the development of any number of diseases (Witkowska and 
Borawska, 2004). 
 
For example, sICAM-1 has been implicated in the pathogenesis of neointimal 
proliferation following vascular injury in animal models of PCI (Hwang et al., 
1997) and soluble CD40 Ligand (sCD40L) has been proposed to exacerbate 
inflammation and prevent re-endothelialisation of the injured vessel wall thereby 
promoting restenosis (Andre et al., 2002). Accordingly, in a study involving 70 
predominantly unstable angina patients who underwent PCI (stent deployment 
rate 50%) to a single non-occlusive coronary stenosis, all patients had sCD40L and 
sICAM-1 measured at the time of PCI and underwent 6 month angiographic follow-
up. Pre-procedural levels of both sCD40L and sICAM-1 were significantly higher 
in patients who subsequently developed angiographic restenosis than in those 
who did not, suggesting that sCD40L and sICAM-1 levels may be useful in 
predicting restenosis in patients with unstable angina (Cipollone et al., 2003). 
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However, whether this might be true for stable angina patients is unknown and 
warrant investigation. 
 
1.10 Post-PCI inflammatory markers and restenosis 
Since inflammation plays a major role in restenosis after PCI with stent 
implantation, measurement of post-PCI inflammatory markers could be useful in 
predicting rates of restenosis. There is some data suggesting a significant rise in 
CRP levels at 48 hours post-procedure (Azar et al., 1997; Gomma et al., 2004) and 
sCD40L levels between 18 and 24 hours post-procedure (Feldman et al., 2001; 
Quinn et al., 2004).  In addition, there is some evidence to suggest that the 
inflammatory response can be modified and reduced by using antiplatelet agents 
during PCI. A sub-analysis of the EPIC trial from 2001 showed that CRP levels at 
48 hours post procedure were reduced by 32% in patients receiving abciximab 
(glycoprotein IIb/IIIa inhibitor) compared to patients in the placebo arm of the 
study (Lincoff et al., 2001).  Similar findings were seen in the Cleveland Clinic 
registry data where the periprocedural increase in CRP was reduced by 65% in 
patients who received clopidogrel before their PCI (Vivekananthan et al., 2004).  
These studies suggest that measurement of inflammatory markers post-PCI could 
be used to guide therapy so that patients with high levels of inflammatory markers 
could benefit from an increased dose or further antiplatelet therapy. Furthermore, 
an improved understanding of the inflammatory response to PCI in the elective 
setting could also lead to novel treatment strategies targeting specific aspects of 
the inflammatory process. 
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There have only been a few studies that have investigated whether the 
inflammatory response to PCI is predictive of future restenosis.  One study 
involving 1800 patients with both stable and unstable angina showed an 
association between post-PCI inflammatory response and 6 month angiographic 
restenosis (Dibra et al., 2005). In this study, CRP levels were measured at 8 hours, 
16 hours and then daily until discharge post-PCI. Both pre-PCI CRP levels and post-
PCI rise correlated with angiographic restenosis (p=0.002).  However, this 
association was strongly influenced by the presence of unstable angina because 
after excluding unstable angina patients, the association was only borderline 
significant (p=0.05) in the remaining 73% of patients who had stable angina.  
Three other small studies have investigated the association between post-PCI CRP 
and restenosis in stable angina patients (Gomma et al., 2004; Gottsauner-Wolf et 
al., 2000; Segev et al., 2004). Segev et al. found no association between post-PCI 
CRP levels and angiographic restenosis in 43 stable angina patients undergoing 
coronary stenting (Segev et al., 2004). Here CRP was measured at multiple time-
points (6 hours, 24 hours, 3 days, 7 days, 1 month, 3 months and 6 months post 
stenting). Similarly, Gomma et al. measured CRP serially for up to 6 months post-
PCI in 58 stable angina patients undergoing elective coronary stenting, and found 
no association between post-PCI CRP levels and restenosis (Gomma et al., 2004). 
However, Gottsauner-Wolf et al. studied 40 consecutive patients with stable 
angina, and found that CRP levels 96 hours post-procedure were significantly 
higher in those who subsequently went on to develop restenosis (Gottsauner-Wolf 
et al., 2000).  Due to these discrepant results, further larger studies are needed to 
determine whether post-PCI levels of CRP and other inflammatory markers are 
predictive of restenosis in stable angina patients. 
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Finally, data on other inflammatory markers are very limited.  One study has 
shown post-PCI sCD40L and sICAM-1 levels to be predictive of restenosis 
(Cipollone et al., 2003). This study by Cipollone et al., measured levels sCD40L and 
sICAM-1 before, and 1, 5, 15 and 180 days after PCI. Patients who developed 
restenosis had higher baseline levels of these markers than patients who did not. 
Following PCI, there was a significant rise in levels of both markers at 24 hours, 
and this rise was more pronounced and more prolonged in those who developed 
restenosis. Although sCD40L and sICAM-1 levels returned to baseline by day five 
in those who did not develop restenosis, they remained elevated through to 6 
months in those with restenosis. Although this is an interesting finding suggesting 
support for the hypothesis that these markers may be involved in the restenotic 
process, it is worth noting that the study cohort was mainly patients with unstable 
angina and therefore whether similar observations might occur in stable angina 
patients is not yet known. 
 
1.11 Inflammatory markers and cardiovascular risk 
As mentioned above, inflammation has been implicated as playing a crucial role in 
the initiation, progression and even the final rupture of atherosclerotic plaques. 
 
A number of inflammatory mediators thought to be involved in these processes 
can be measured and quantified in the peripheral blood. These markers have 
proved useful in the study of mechanisms that underlie coronary events. In 
addition, their measurement may also improve clinical risk prediction in addition 
to offering new therapeutic targets (Libby et al., 2009; Pearson et al., 2003; 
Szmitko et al., 2003; Vishnevetsky et al., 2004). The inflammatory markers that 
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have been used for risk prediction in CVD can be classified as either systemic or 
localised markers of inflammation. 
 
Systemic markers, such as white blood cell count (WBC), CRP and fibrinogen have 
been proposed to be useful markers for risk prediction. Inflammation in local 
tissues stimulates the production of these makers from the liver (fibrinogen, CRP) 
or bone marrow (WBC) and levels reflect the overall inflammatory activity within 
the body. Although these markers are found in relatively high concentrations in 
the systemic circulation, making them easy to measure and quantify, they have 
low specificity since levels can be markedly elevated in response to any systemic 
illness and may not directly be a reflection of cardiovascular inflammation.  
Nevertheless, baseline levels have consistently been shown to be predictive of 
cardiovascular risk (Ernst et al., 1987; Ernst and Resch, 1993; Ridker and Morrow, 
2003). Furthermore, CRP is now being considered for routine clinical use, in risk 
prediction (Pearson et al., 2003) and guidance of therapy (Ridker et al., 2008). 
Furthermore, a recent large randomised, double-blind controlled trial involving 
10,061 patients with previous MI and a raised high-sensitivity (hs) CRP 
investigated the use of canakinumab (a therapeutic monoclonal antibody 
targeting interleukin-1β) in reducing nonfatal MI, nonfatal stroke, or 
cardiovascular death rates. The study found that rates of cardiovascular events 
were significantly reduced in the treatment arm secondary to the anti-
inflammatory effects of the intervention (Ridker et al., 2017). 
 
Local mediators of inflammation such as sCD40L, sICAM-1, and pregnancy-
associated plasma protein (PAPP-A) are produced locally within the 
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atherosclerotic plaque and are thought to contribute directly to disease 
progression.  In addition, they are also detectable in the systemic circulation and 
these have been shown to be predictive of cardiovascular risk (Zakynthinos and 
Pappa, 2009). However, due to very low systemic concentrations measuring 
changes in these may not be possible or as accurate as for the systemic 
inflammatory markers (Pearson et al., 2003). However, since these proteins are 
directly involved in the atheromatous process, they may be more specific for 
cardiovascular inflammation than systemic markers and as such have been 
proposed as potential therapeutic targets (Andre et al., 2002; Bayes-Genis et al., 
2001; Vishnevetsky et al., 2004). Understanding the exact role of such proteins in 
atherogensis and restenosis is therefore imperative for ascertaining the 
therapeutic opportunity in targeting atherosclerosis and inflammation. 
 
1.12 Atherosclerosis and inflammation 
1.12.1 Pathogenesis  
Atherosclerosis is a chronic inflammatory process (Ross, 1999a), with immune 
cells acting as important mediators from the formation of the earliest fatty streaks 
to late-stage complex plaques. Smooth muscle cells, endothelial cells, lymphocytes, 
monocytes and macrophages have all been implicated in the pathogenesis of 
atherosclerosis (Choudhury et al., 2005) (See Figure 1.7).  
 
After the initial activation of the endothelium due to disruptions in shear stress 
(an possibly the fatigue effect of pulse pressure on endothelial layer (Mehdizadeh 
and Norouzpour, 2009)), there is an increase in the permeability of the vessel to 
lipoproteins and upregulation of adhesion receptors (Tabas et al., 2007). This 
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change facilitates deposition of lipid from apolipoprotein B (apoB)-containing 
lipoproteins in the subendothelial space and encourages a monocytosis and 
recruitment of circulating monocytes to atheroma vulnerable sites respectively. 
The adhesion of monocytes is dependent on the upregulation of a number of key 
cell-adhesion molecules on the luminal surface of the endothelium (Cybulsky and 
Gimbrone, 1991), namely, P-selectin, ICAM1 and VCAM1; followed by the 
expression of three major chemokine receptor families, CCR5, CCR2 and CX3C 
chemokine receptor 1 (CX3CR1), that facilitate the cell transmigration process 
(Combadiere et al., 2008; Tacke et al., 2007).  After their recruitment from the 
spleen and bone marrow (Heidt et al., 2014) into the blood vessel wall, monocytes 
differentiate and locally proliferate into distinct functional phenotypes (M1 or M2) 
(Robbins et al., 2013), terminally differentiate into macrophages (Ley et al., 2011), 
or directly influence the phenotype of in situ cells (for example, lesional 
macrophages) (Khallou-Laschet et al., 2010). Via a number of processes lipids 
from retained apoB-containing lipoproteins are taken up, including pinocytosis of 
low desity lipoprotein (LDL) (Barthwal et al., 2013), phagocytosis of aggregated 
LDL (Schissel et al., 1996), uptake by CD36 and uptake of modified apoB-
lipoproteins by scavenger receptors. Ongoing lipid accumulation induces their 
transformation into macrophage-derived foam cells. Finally, as the foam cell 
population grows within lesions in the arterial wall, the rate of accumulation 
overcomes the rate of clearance, and eventually the foam cells amalgamate into a 
lipid-rich necrotic core.  
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Figure 1.7 (Chavez-Sanchez et al., 2014): Schematic of the pathways involved in 
inflammation. Endothelial cells, lymphocytes, smooth muscle cells, monocytes, and macrophages 
are all involved in the pathogenesis of atherosclerosis from earliest foam cell formation through to 
development of advanced plaques. Initial activation of the endothelium from disruptions to normal 
shear stress results in and facilitates deposition of lipid in the subendothelial space. Endothelial 
activation also promotes recruitment of circulating monocytes where they terminally differentiate 
into macrophages, or differentiate and locally proliferate into distinct functional phenotypes (M1 
or M2). Activated macrophages take up lipid, which results in their transformation into 
macrophage-derived foam cells. As the foam cell population grows within lesions in the arterial 
wall, the rate of accumulation exceeds the rate of clearance, and eventually the foam cells coalesce 
into a lipid-rich necrotic core. CR, C-C chemokine receptor; CRP, C-reactive protein; ICAM1, 
intercellular adhesion molecule 1; MMP, matrix metalloproteinase; TNF, tumour necrosis factor; 
VCAM1, vascular cell adhesion protein 1, TLR4, toll-like receptor 4; oxLDL, oxidised-low density 
lipoprotein. 
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Secreted cytokines also play an important role in the pathogenesis of 
atherogenesis.  Cells of both the adaptive (T and B lymphocytes, dendritic cells) 
and innate (macrophages) immune systems can modulate the local inflammatory 
setting through the secretion of cytokines. T cells can be stimulated to secrete 
proinflammatory TH1 cytokines such IL-1, IL-6, and TNF; or TH2 cytokines such 
as IL-4, IL-10, and IL-13, which promote resolution of inflammation (Kucharzik et 
al., 1998; Raphael et al., 2015). IL-1 and TNF signalling is primarily mediated by 
p38 mitogen-activated protein kinase (MAPK) / nuclear factor (NF)-κB pathways 
(Chan et al., 2000). Conversely, activation of IL-6 signals via signal transducing 
protein gp130, which activates JAK1 and STAT1 and 3 (Ait-Oufella et al., 2011) 
results in the activation of endothelial cells and macrophages to produce adhesion 
molecules and chemokines (Gharavi et al., 2007).  
 
The structure and environmental conditions within the plaque can also impact 
upon the propagation of the atheroma over the inflammatory response within the 
lesion. In human plaques, neovascularisation originating from the vasa vasorum 
(See Figure 1.4) is believed to contribute to intraplaque haemorrhage, which 
accelerates plaque expansion and inflammation as well as predicts future plaque 
rupture (Hellings et al., 2010; Michel et al., 2011). In the large lipid-rich necrotic 
core of advanced atheromas, the hypoxic environment induces hypoxia inducible 
factor (HIF) 1α, which produces vascular endothelial growth factor and in turn 
drives angiogenesis (Sluimer and Daemen, 2009; Vink et al., 2007). In vitro 
experiments have shown that hypoxia and HIF1α expression alter macrophage 
lipid handling and suppress cholesterol efflux via ABCA1 (the ATP-binding 
cassette subfamily A member 1) in both mouse (Parathath et al., 2011) and human 
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(Ugocsai et al., 2010) macrophages. Furthermore, in vitro and ex vivo experiments 
have linked hypoxia and HIF1α in driving enhanced glucose uptake, metabolic 
activity, and polarisation of macrophages in human atheroma (Folco et al., 2011). 
Rong and colleagues (Rong et al., 2003) reported in 2003 that cholesterol-loaded 
vascular smooth muscle cells lost their differentiation markers and instead 
expressed macrophage markers. A number of experiments in both mice and 
humans (Allahverdian et al., 2014; Feil et al., 2014; Shankman et al., 2015; 
Vengrenyuk et al., 2015) have shown in vivo data consistent with these 
phenomena: 30–40% of cells classified as plaque macrophages were of vascular 
smooth muscle cell origin.  
 
1.12.2 Inflammatory markers of atherosclerosis 
The association between CRP (as measured by high-sensitivity assay, which has 
been used as a surrogate biomarker for ‘inflammation’) and atherosclerosis has 
been an area of great research and interest. A number of studies and meta-
analyses have demonstrated a relationship between elevated CRP levels and an 
increased risk of CVD (Danesh et al., 2004). Furthermore, a statin trial (the 
JUPITER Study (Ridker et al., 2008)) noted that a reduction in CRP level was an 
independent predictor of outcome (Nissen et al., 2005). In this study, which used 
high-sensitivity (hs) CRP to identify patients at increased risk of vascular events 
(without elevated LDL-cholesterol levels), patients with high basal hsCRP levels 
were at a significantly increased risk of future vascular events.  
 
In addition, other circulating proteins including ICAM1 (Hwang et al., 1997), 
VCAM1 (Semaan et al., 2000), and P-selectin (Blann et al., 1997) have been 
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measured in the plasma of patients and have been demonstrated to be associated 
with the severity of atherosclerosis. However, as with hsCRP, exactly what these 
biomarkers represent ‘downstream’ is currently unclear.  
 
Circulating monocytes have been the focus of research as a key cellular biomarker 
in the pathogenesis of atherosclerosis (Swirski et al., 2009). With the use of flow 
cytometry, the number of circulating CD14+CD16++ monocytes has been shown 
to be inversely related to plasma high-density lipoprotein (HDL) levels, and CD16+ 
monocytes are proportional to the severity of atherosclerosis (Schlitt et al., 2004). 
On the other hand, a reduction in the monocyte subpopulation is associated with 
a reduction in intima–media thickness (Poitou et al., 2011).  
 
To explore the functional characteristics of these ‘inflammatory’ cells at the level 
of atherosclerotic plaque, a new technique using laser-capture microdissection 
(LCM) has been used to attain intralesional cells in a cell-type-specific and 
location-specific fashion. In mice, immuno-LCM coupled with downstream gene or 
protein expression analysis has been used to study lesional macrophages in 
various stages of atherogenesis, including atherosclerosis regression. The 
inflammatory state of plaque macrophages was shown to be dynamically 
regulated as the severity of disease varied (Feig et al., 2011). In humans, there 
have been studies that used LCM on surgical plaque explants, which has identified 
genes involved in lipid metabolism (such as LEP and FABP4) and activation of the 
adipokine / peroxisome proliferator-activator receptor (PPAR) signalling 
pathways (Lee et al., 2013), as well as a range of inflammatory gene ‘signatures’ 
(Puig et al., 2011), that might be important in mechanistic staging. Circulating 
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microvesicles derived from monocytes, platelets and erythrocytes have also been 
characterised specifically with regard to the miRNA that they contain, and have 
been shown to have roles in activation of plaque macrophages, in cell-to-cell 
signalling (Hulsmans and Holvoet, 2013) and VCAM1 inhibition that play a key 
role in the progression of atherosclerosis (Rautou et al., 2011). One of the other 
key phenomena critical to recruitment of cells to a site prone to atherosclerosis or 
restenosis is endothelial dysfunction. Indeed, not only is dysfunction a 
consequence of the pathology but it is also proposed as a useful biomarker. Finally, 
studies looking at human and murine atherosclerosis have found that the 
histology of lesion development in murine and humans has more similarities than 
differences. Unfortunately, plaque rupture and thrombosis rarely occur in mice 
and therefore this is a major limitation in studying atherosclerosis in murine 
models (Bentzon and Falk, 2010). In addition, large animal models suitable for 
interventional procedures and imaging (such as porcine models) are more 
routinely used in animal studies to develop the field of interventional cardiology 
(Kornowski et al., 1998; Waksman et al., 2017).  
 
1.13 Differences between the sexes and cardiovascular disease 
The link between atherosclerosis and cardiovascular health has been investigated 
for many years. In 1933, an association between female serum cholesterol levels 
and dietary changes was described (Okey and Stewart, 1932). Later in 1958, 
during a conference on “Hormones and Atherosclerosis,” researchers found that 
cholesterol deposition was directly linked to blood cholesterol levels. However, 
other factors (such as lipid levels, sex differences, diet, hormones and stress) were 
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also felt to be just as important. Furthermore, it was noted that ethinyl oestradiol 
reduced plasma lipid levels in a group of men with previous myocardial infarction 
(MI), although there was no significant reduction in morbidity or mortality from 
coronary events as compared to the control group (Anonymous, 1958).  
 
Apart from the traditional risk factors, researchers have also actively investigated 
other potential causes of CVD. In recent times, there has been a a large amount of 
interest investigating the role of sex hormones in CVD. In a study involving a small 
series of men with deficient oestrogen action (due to mutations in the genes for 
oestrogen receptor [ER] or aromatase), found that they developed 
hyperinsulinemia, early-onset atherosclerosis and increased visceral adipose 
tissue as well as the constellation of risk factors known as metabolic syndrome. 
Interestingly, these same pathologies have also been identified in men with 
sufficient oestrogen action but low testosterone levels (Phillips, 
2005). Furthermore, one hypothesis suggests that these changes in sex hormone 
may result in these cardiovascular abnormalities and that infact, atherosclerotic 
CVD may possibly be due to an endocrinological disorder (Phillips, 2005).  
 
There is experimental, epidemiological as well as clinical data suggesting that 
there are specific variations between the two sexes that affect cardiovascular risk. 
In fact, many medical comorbidities, including hypothyroidism, diabetes and 
depression are more prevalent in post-menopausal women and have been 
demonstrated to be associated with increased cardiovascular risk (Perez-Lopez et 
al., 2009). One example of this is that women are more likely than men to 
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experience an episode of depression and to be subsequently diagnosed with 
metabolic syndrome (Kinder et al., 2004). Another example is that occurrence of 
subclinical hypothyroidism increases with age and is higher in women and 
numerous studies have demonstrated an association between CAD and thyroid 
(Fatourechi, 2009). Finally, women with diabetes are less likely to have ‘well-
controlled blood sugars’ and are more likely to develop and die from CVD 
(Evangelista and McLaughlin, 2009).  
 
In addition to these comorbidities, the menopausal period in itself seems to be an 
important time of transition to increased cardiovascular risk (Mankad and Best, 
2008). The incidence of CVD (that is not related to diabetes) is lower in 
premenopausal women compared to age-matched men (Kaseta et al., 
1999). There is an association of increased cardiovascular events due to ovarian 
hormone insufficiency at the time of the menopause. Hence, studies have found 
that the development of CVD is approximately 10 years later in women compared 
to men (Lorenzo et al., 2007). These observations and studies have led to the 
hypothesis that oestrogens may infact protect women against atherosclerotic 
complications. 
 
At the cellular level, experimental data has suggested that sex differences in the 
regulation of physiological mechanisms are directly influenced by genetic 
polymorphisms. Some studies have linked CVD with variations in the nuclear 
hormone family of ER genes, including ER-α gene (ESR1) and ER-β gene (ESR2) 
(Shearman et al., 2006). These receptors function as ligand-dependent 
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transcription factors and predominate in vascular endothelial and smooth muscle 
cells (Hodges et al., 2000). Oestrogen receptor α gene polymorphisms may affect 
the response to peripheral oestradiol and, indirectly, the prevalence of different 
menopause-related conditions (Schuit et al., 2004). Furthermore, 
postmenopausal women who carry a particular ESR1 variant are at increased risk 
of MI and CHD, independent of known cardiovascular risk factors (Schuit et al., 
2005). This association has not been found in men (Liu et al., 2005).  
 
Oestrogen receptor β gene expression prevails in human VSMCs (Christian et al., 
2006). Experiments in rat models have shown there was an increased expression 
of ESR2 following vascular injury and its expression is associated with increased 
coronary artery plaque surface area in both women and men (Lindner et al., 1998; 
Rexrode et al., 2007). Some ESR2 polymorphisms are associated with increased 
risk of MI that is specific to certain sex. For example, women with a particular 
variant allele had significantly increased risk of CVD and MI, while men with a 
different rare variant were at reduced risk. However, other variants confer an 
increased risk of MI in men only (Domingues-Montanari et al., 2008). Moreover, a 
near-significant association was found between some ESR2 haplotypes and 
obesity (which adds a significant risk to CVD) in postmenopausal women (Goulart 
et al., 2009). 
 
Studies have also found that selective stimulation of a second type of ER, the 
intracellular G protein-coupled ER (GPER), dilates human arterial blood vessels 
and decreases rat blood pressure (Haas et al., 2009). In GPER knockout mice, this 
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effect is abolished and increased visceral obesity has been demonstrated. Female 
GPER knockout mice had hyperglycaemia (and subsequently impaired glucose 
tolerance), increased blood pressure, reduced insulin-like growth factor blood 
levels and reduced body growth (Martensson et al., 2009).  
 
Endogenous sex hormones in females (especially oestrogens) are cardioprotective 
via a number of different mechanisms: decreased LDL, increased HDL and release 
of vasodilators such as nitric oxide (NO) and prostacyclin (PGI2) from vessel walls, 
which results in inhibition of vascular constriction and lowering of blood pressure 
as well as decreased platelet aggregation (described in more detail below) 
(Barrett-Connor and Bush, 1991). In addition, during the menopausal transition, 
there is an increase in the prevalence of the metabolic syndrome, elevated body 
weight, hypertension dyslipidaemia and hyperinsulinemia (Ho et al., 2005; Perez 
Lopez F et al., 2009). Interestingly, treatment with hormone replacement therapy 
does not significantly reduce blood pressure in postmenopausal women. This 
suggests that oestrogen deficiency may not be the only factor involved in 
postmenopausal hypertension (Perez Lopez F et al., 2009).  
 
In comparison to age-matched men, the lower prevalence of CVD in 
premenopausal women has been partly explained by differences in plasma 
lipoprotein levels, body fat distribution and indices of plasma glucose-insulin 
homeostasis (Lemieux et al., 1994; Tomaszewski et al., 2009) females appear to 
have higher plasma HDL levels and lower plasma insulin, triglyceride (associated 
with abdominal visceral adipose tissue) and apolipoprotein B levels (Mohlke et al., 
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2008). Finally, oestrogen appears to contribute to glucose homeostasis via 
increased glucose transport into the cell and studies have suggested a positive 
effect of hormone replacement therapy on HbA1C levels in postmenopausal 
women (Okada et al., 2003).  
 
1.14 The healthy endothelium and nitric oxide 
In 1980, Furchgott and Zawadzki confirmed that the presence of intact 
endothelium is important for acetylcholine (ACh) to induce relaxation in an 
isolated rabbit aorta (Furchgott and Zawadzki, 1980). They showed that if the 
endothelium is damaged, the vessel no longer relaxes, but still responds to the NO 
donor glyceryl trinitrate (GTN). This highlighted the role of endothelium in ACh-
induced vasorelaxation, which occurs via a messenger, initially labelled as 
“endothelium-derived relaxing factor” (Furchgott and Zawadzki, 1980). This 
sparked the interest of researchers to identify EDRF. In 1986, Ignarro and 
Furchgott independently proposed that NO has the same biological properties as 
EDRF (Furchgott, 1988; Ignarro et al., 1988). This finding was then confirmed in 
the following year (Ignarro et al., 1987; Palmer et al., 1987). 
 
NO generated by the endothelium is made from the guanidine-nitrogen atoms of 
the amino-acid L-arginine. This reaction is catalysed by the endothelial isoform of 
NO synthase and generates the by-product L-citrulline (Palmer et al., 1988; 
Schmidt et al., 1988). NO has a short half-life in blood of approximately 6 seconds 
(Knowles and Moncada, 1992); as it gets oxidised to NO2- and then to NO3- by 
oxygenated haemoglobin and superoxide anions; and is excreted into urine 
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(Moncada and Higgs, 1993; Wennmalm et al., 1992).  The synthesis of NO from L-
arginine involves cofactors such as NADPH, tetrahydrobiopterin, oxygen and 
calmodulin (Bredt and Snyder, 1990; Moncada and Higgs, 1995).  
Three NO synthase isoforms have been identified: neuronal (nNOS), inducible 
(iNOS) and endothelial (eNOS) isoforms (Forstermann et al., 1994). They all have 
roles in the regulation of vascular tone. eNOS is located in cell membrane 
invaginations called calveolae (Shaul et al., 1996). The activity of eNOS is blocked 
by caveolin-1 which is found bound to calmodulin (Garcia-Cardena et al., 1997). 
Stimuli such as shear stress, bradykinin, substance P, acetylcholine and adenosine 
5’-triphosphate, trigger the release of calcium from intracellular stores (Furchgott 
and Vanhoutte, 1989). This promotes calcium binding to calmodulin, which 
releases caveolin-1 and activates eNOS, thus catalysing the production of NO 
(Figure 1.8). 
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Figure 1.8 Schematic of endothelium derived NO generation. NO is generated in the 
endothelial cell via endothelial nitric oxide synthase (eNOS). NO rapidly diffuses into the 
underlying smooth muscle cell and leads to the generation of cGMP, resulting in relaxation of the 
smooth muscle cell. NO generated from the endothelium also inhibits platelet adhesion and 
aggregation, and leucocyte adherence.  -----I means inhibition 
 
1.14.1 Measurement of endothelial function in humans 
Approaches to measure endothelial function in humans were first described in the 
1980’s. In 1986, Ludmer and colleagues infused intracoronary ACh and measured 
the coronary artery diameter in humans with CHD (Ludmer et al., 1986). This 
study included a mixture of patients ranging from normal coronary arteries, mild 
coronary artery disease to severe coronary artery stenosis. They found that 
patients with normal coronary arteries demonstrate dose-dependent dilatation 
following ACh infusion compared to baseline coronary artery diameter. However, 
in all 8 patients with severe coronary stenoses, there was a dose-dependent 
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constriction. A similar pattern of vasoconstriction following ACh was also seen in 
5 out of 6 patients with mild CHD. Furthermore, all of the coronary arteries 
demonstrated dilatation following GTN. This study found that the paradoxical 
vasoconstriction induced by ACh occurs early as well as late in the natural history 
of coronary atherosclerosis and that the abnormal vascular response to ACh is 
likely representative of endothelial dysfunction. A further study in 1989 
demonstrated dysfunction of the endothelium in patients with coronary 
atherosclerosis following intracoronary adenosine infusion, which resulted in an 
increase of blood flow through the coronary arteries (Cox et al., 1989). In patients 
with atherosclerosis, the increase in flow was impaired compared to individuals 
with no evidence of atherosclerosis. Further studies have shown that even in some 
apparently normal coronary arteries, there can be a degree of coronary 
endothelial dysfunction (Hodgson and Marshall, 1989; Werns et al., 1989).  
 
The main disadvantage of coronary endothelial function measurement is the 
invasive nature of the study. Hence, this technique has been replaced in clinical 
trials with brachial artery flow mediated dilatation (FMD) measurement using 
ultrasonography. This is a cheap and non-invasive measurement that uses an 
ultrasound machine with computer software to accurately measure endothelial 
function. Although it is operator dependent, the technique is reproducible as 
demonstrated in a number of clinical trials (Charakida et al., 2013; Deanfield et al., 
2007). 
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1.15 Endothelial Dysfunction 
The healthy vascular endothelium has vasodilator, anti-adhesive, anti-
inflammatory and anti-coagulant properties, that are measurable and are induced 
by a number of endothelial derived mediators, with the most important being NO. 
Endothelial dysfunction is an early event in the pathogenesis of atherosclerosis 
(Creager et al., 1990; Steinberg et al., 1997) and is characterised by reduced 
endothelium-dependent dilator function, increased inflammatory cell and platelet 
adhesion (Goldsmith et al., 2000), and increased coagulation activity (Bombeli et 
al., 1997). These changes are thought to tip the balance at a site of dysfunction in 
favour of vasospasm, thrombosis, and inflammation and may contribute to the 
transition between “stable” and “unstable” atheroma. 
 
Reduced bioavailability of NO is thought to be a major contributor to the 
endothelial dysfunction phenomenon. This may be due to a diminished ability of 
the endothelium to produce NO (due to substrate or co-factor deficiency), or due 
to a profound imbalance in the relative amounts of oxidants that will scavenge NO 
(Verma and Anderson, 2002). One potential trigger for this endothelial 
dysfunction is inflammation (Libby et al., 1997; Mamode et al., 1995; Meier et al., 
1998; Quartin et al., 1997; Ross, 1999a; Thom et al., 1992). Moreover, 
inflammatory cytokines have been shown to impair endothelial function in animal 
models (Ohkawa et al., 1995) and isolated human veins (Bhagat and Vallance, 
1997). 
 
Experimentally, endothelial dysfunction is often identified through measurement 
of endothelium dependant relaxation of blood vessels. The mechanisms by which 
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inflammation may impair endothelium-dependent relaxation are not fully 
understood. One possibility is that certain cytokines induce de novo expression of 
the inducible isoform of nitric oxide synthase (iNOS) in the vessel wall (an isoform 
implicated in the high-output NO production seen in inflammation and sepsis), 
and this high output of NO, coupled with the generation of superoxide, causes 
endothelial damage and scavenging of NO (Beckman and Koppenol, 1996). An 
alternative possibility is that the cytokines cause a decrease in the expression of 
the constitutive endothelial eNOS that drives endothelial NO generation. Evidence 
also suggests that differences in key co-factors necessary for NO generation 
contribute to dysfunction. Oxidation of BH4 resulting in increased BH2 and loss of 
an electron donor for NO generation has been implicated in endothelial 
dysfunction (Bendall et al., 2014; Maier et al., 2000). However, targeting this 
phenomenon has proven difficult in CVD (Channon, 2012). Separately, decreases 
in L-arginine due to increased expression of arginase and the competition with 
NOS for substrate has been implicate in CVD (Durante et al., 2007).  
 
There has been evidence that has suggested that diet has an important role to play 
in improving or indeed protecting endothelial function. Nutrients, such as fish oil, 
antioxidants, L-arginine, folic acid and soy protein have all been shown to cause 
an improvement in endothelial function that can mediate, at least partially, the 
cardioprotective effects of these substances. Attention has been focused on dietary 
patterns in populations with lower prevalence of CVD. There is some evidence 
suggesting that Mediterranean diet characterised by high consumption of 
vegetables, fish, olive oil and moderate wine consumption may have a positive 
effect on endothelial function (Cuevas and Germain, 2004). A very recent review 
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of dietary flavanols has also demonstrated their benefit in improving vascular and 
endothelial function (Al-Dashti et al., 2018). These results give us evidence on the 
significant role of diet on endothelial function and its impact on the pathogenesis 
of atherosclerosis 
 
1.16 Diets rich in fruits and vegetables confer beneficial effects against CVD 
The UK initiative of the “5-a-day” campaign, approved by the Department of Health 
(DOH) and implemented within the National Health Service (NHS), underpins the 
drive in the UK to encourage increased intake of fruit and vegetables across the 
general population. This approach has been taken in response to compelling 
evidence pointing to a reduced incidence of many modern day diseases, namely 
some cancers and CVD (DOH, 2003) with increased consumption. Similar 
campaigns have likewise been instigated across Europe and the USA. In the latter, 
the campaign has focused on promoting a 7-a-day approach through their most 
recent campaign of ‘half a plate’ (http://www.fruitsandveggiesmorematters.org). 
More recently in a large meta-analysis, which included studies with up to 26 years 
follow-up, 833,234 participants and with 56,423 deaths, assessing the 
relationship between mortality and fruit and vegetable consumption, it was 
confirmed that 5 really is the ‘magic’ number (Figure 1.9). Furthermore, a recent 
meta-analysis involving 95 studies found that we should be consuming at least, up 
to 10 portions (800g) a day (Aune et al., 2017). However quite surprisingly, the 
beneficial effects of such diets relate completely to reductions in CVD and not 
cancer mortality (Wang X, 2014). In addition, a study by Tektonidis et al. assessed 
the benefit of the Mediterranean diet in a population-based cohort of 32,921 
women through a self-administered questionnaire. They found that over the 10 
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year follow-up, better adherence to a Mediterranean diet was associated with 
lower risk of MI, heart failure and ischemic stroke (Tektonidis et al., 2015). Finally, 
a multicentre randomised trial in Spain assessed the Mediterranean diet in 7447 
participants between 55 to 80 years of age. The study found that in participants 
that were at high cardiovascular risk, a Mediterranean diet supplemented with 
extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events 
(Estruch et al., 2013). 
 
 
Figure 1.9: Graph and Forest Plot demonstrating the relationship between consumption of 
fruit and vegetables and all-cause mortality. (a) Relationship between fruit and vegetable 
consumption and risk of all-cause mortality. (b) Risk of cardiovascular mortality associated with 
consumption of fruit and vegetable (servings per day). CI = confidence interval; HR = hazard ratio. 
Adapted from Wang et al., (Wang et al., 2014). 
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Diets rich in fruits and vegetables reduce cardiovascular morbidity and mortality 
(Joshipura et al., 1999; Joshipura et al., 2001). These beneficial effects have, in part, 
been attributed to well documented reductions in blood pressure (BP). The 
Dietary Approaches to Stop Hypertension (DASH) study (Appel et al., 1997) 
showed that implementation of 7 portions of fruit and vegetables a day more than 
a control diet (average American diet at that time) for 8 weeks resulted in a small, 
but significant and persistent, decrease of 2.8 mmHg in systolic BP (SBP) and 1.1 
mmHg in diastolic BP (DBP) in pre-hypertensive individuals. These observations 
have translated into a real world primary care environment. Delivery of dietary 
advice of a 5-a-day fruit and vegetable intake at the start and mid-way in a 6 month 
intervention trial was associated with a 4/1.5 mmHg decrease in BP (John et al., 
2002). Whilst such BP decreases may seem trivial, at a population level such 
reductions are likely to have a marked effect on cardiovascular mortality. It has 
been estimated that a 1 mmHg increase in SBP increases cerebrovascular incident 
mortality by 2% and a 1 mmHg increase in DBP increases stroke mortality by 3% 
(Palmer et al., 1992). In addition, a large scale-meta-analysis of 354 studies 
totalling 56,000 patients has demonstrated that a decrease in SBP of 5 mmHg 
results in a decrease in incidence of stroke of 34% in addition to a 21% reduction 
in incidence of acute MI (AMI) (Law et al., 2003). Similarly, in a meta-analysis of 1 
million adults in 61 prospective studies a 2 mmHg increase in SBP is associated 
with 10% increase in stroke and 7% increase in myocardial infarction (Lewington 
et al., 2002). Thus, it is possible that the reduction in BP caused by fruit and 
vegetable rich diets accounts for the associated reported decreases in CHD and 
stroke. In the Health Professionals and Nurses’ Health study cohorts, risk of 
ischaemic stroke was significantly reduced in individuals consuming 5 portions of 
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fruit and vegetables a day (Joshipura et al., 1999) as well as reducing risk of CHD 
(Joshipura et al., 2001). In addition, there is limited data to separate the effects of 
diet from changes in behaviour and weight (Foster-Schubert et al., 2012) and no 
large-scale clinical trial has been able to delineate this difference. 
 
Despite substantial research efforts focusing on identifying the exact mediator of 
the beneficial effects of fruits and vegetables on cardiovascular health, the issue 
still remains unresolved. The belief that anti-oxidant vitamins may be accountable 
for these effects has lost favour with several large-scale clinical trials of different 
antioxidant vitamins failing to reproduce the effects of a diet rich in fruits and 
vegetables; an observation reinforced by recent meta-analyses (Bjelakovic et al., 
2007; 2012). However, fruits and vegetables are also rich in a number of minerals 
including potassium (K+). Indeed, K+ supplementation exerts beneficial effects 
upon the cardiovascular system particularly with respect to BP lowering (He et al., 
2006; Whelton et al., 1997). Although challenging this view, no significant effect of 
single K+ supplementation on BP in meta-analyses (Dickinson et al., 2006), and no 
effect in studies assessing the effect of K+ in combination with other dietary 
components including magnesium and fibre (Al-Solaiman et al., 2010) in 
hypertensive patients have been found.  
 
Perhaps a clue to the key beneficial elements of healthy diets, was provided by 
Willett’s group who found in The Nurses Health and Health Professionals cohorts 
that the greatest benefits conferred by a fruit and vegetable rich diet, in preventing 
complications of atherosclerosis, was provided by green leafy vegetables 
(Joshipura et al., 1999; Joshipura et al., 2001). This observation has been 
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supported by several further studies, most notably a meta-analysis extending the 
reach of benefits of fruit and vegetable rich diets from stroke and CHD to metabolic 
syndrome and type 2 diabetes (Carter et al., 2010; Li et al., 2014). Considering 
these observations, there has been recent interest in the possibility that inorganic 
(dietary) NO3- might underlie the protective effects of a fruit and vegetable rich 
diet (Kapil et al., 2010b; Lundberg et al., 2006). This proposed benefit is thought 
to stem from its capacity to elevate levels of NO in the body. Evidence suggests that 
this process is two step with a sequential reduction of inorganic NO3- to NO2- and 
then NO2- to NO. This possibility has been proposed since green leafy vegetables 
are particularly rich in the NO3- anion. Indeed, all vegetables contain some 
inorganic NO3- since it is required for plant growth. Analysis of a range of 
foodstuffs indicate that the highest levels occur in vegetables such as cabbage, 
lettuce and rocket (Santamaria, 2006). In addition very high levels are also found 
in beetroot, with lesser amounts in other root vegetables such as carrots and 
potatoes (Chan, 2011). Assessment of the NO3-  content of the DASH diet has 
suggested that it might contain high levels with estimates indicating potentially up 
to 20 mmol (1240.10 mg) of NO3- daily (Hord et al., 2009a).  
 
The underlying rationale for a role for NO3- comes from a growing body of 
evidence demonstrating clear BP lowering, anti-inflammatory, anti-platelet and 
anti-hypertrophic effects of dietary NO3- / NO2- regimes. These observations have 
been made not only at the pre-clinical level but have been effectively translated in 
a number of phase 2 studies in patients.  
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1.17 Historical medicinal therapeutic uses of inorganic NO2- and NO3- 
In 1880 Reichert and Mitchell published detailed writings on the physiological 
actions of potassium nitrite (KNO2) in humans and animals. It was noted that a 
small dose of approximately 30 mg acutely increased and then decreased BP, with 
larger doses resulting in pronounced hypotension. Over the following 20 years 
others expanded on these findings and in the early part of the twentieth century 
inorganic NO2- was marketed as a treatment for hypertension and vasospasm 
(Butler and Feelisch, 2008; Kevil et al., 2011). Inorganic NO3- also has a significant 
historical presence in therapeutics. It has been used in traditional Chinese 
medicine for over a millennium to treat angina. In a manuscript discovered at the 
Buddhist grotto of Dunhuang the patient is advised to take KNO3 under the tongue, 
then swallow the saliva (Butler and Feelisch, 2008). The advice to swallow the 
saliva is of particular importance as it is now known that the bioactivation of NO3- 
requires bacterial NO3- reductases which reside in the oral cavity  (Duncan et al., 
1995; Ishiwata et al., 1975; Lundberg et al., 2004). Western physicians did not 
realise the therapeutic worth of inorganic NO₃⁻ noted by the Chinese for many 
years, despite the fact that in 1932 Edward Stieglitz demonstrated that oral 
ingestion of bismuth subnitrate induced hypotension. Moreover, Stieglitz  
proposed that the bacteria B. coli (known today as E. Coli) found in the intestine 
“breaks down bismuth subnitrate to cause liberation of considerable amounts of 
NO2-” (Stieglitz, 1936).   
 
Irrespective of these promising early findings, the widely accepted view of NO3- 
has been that of a chemically inert product of the primary pathway of endogenous 
NO metabolism (Doyle and Hoekstra, 1981), that does not take part per se in any 
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important chemical reactions (Ignarro et al., 1993b). This is in contrast to NO2-. Of 
note the reaction of NO2- with oxyhaemoglobin to form methaemoglobin and NO3- 
was described by Gamgee in 1868 (Gamgee, 1868) and several others since (Doyle 
et al., 1981; Kosaka et al., 1979; Marshall, 1945). This reaction remains of interest 
with respect to organic and inorganic NO2--induced methaemoglobinaemia, of 
which there have been a few case reports, limiting the use of drugs such as amyl 
NO2- clinically (Modarai et al., 2002; Pierce and Nielsen, 1989). However, major 
concerns were raised following evidence of apparent NO3--induced infantile 
methaemoglobinaemia. In 1945 Comly reported several cases of infantile 
methaemoglobinaemia linked to well water contaminated with high levels of NO3- 
(Comly H.H., 1945). Further mechanistic interrogation has, however, challenged 
this view suggesting that it is the conversion of NO3- to NO2- by contaminating 
bacteria in the water, either through environmental contamination or due to 
endogenous infection, that results in very high levels of NO2--dependent 
methaemoglobin formation (Avery, 1999).  
 
The vasodilatory properties of pharmacological doses of exogenous NO2- 
(Furchgott, 1955) have also long been known, however, it wasn’t until 2001 that 
it was appreciated that low µM physiological levels of NO2- could relax contracted 
rat aorta under acidic pH (6.6) conditions (Modin et al., 2001). Subsequently, it 
was shown that an infusion of sodium nitrite (NaNO2) at doses  resembling 
physiological concentrations (400 nmol/min for 15 min) into the human forearm 
resulted in vasodilatation with associated increased blood flow which was further 
increased with exercise (Cosby et al., 2003). This effect of NO2- was attributed to 
its chemical reduction to NO within the circulation.   
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The above observations have collectively heralded a renaissance in assessment of 
the therapeutic potential of both anions in therapeutics. Several recent clinical 
trials assessing the utility of both NO3- and NO2- have reported, generating 
substantial optimism that strategies exploiting appropriate delivery of these 
anions may provide important clinical benefits, through the delivery and restoring 
of NO levels with the circulation.   
 
1.18 Levels of dietary NO3- and NO2- intake 
Daily NO3- intake in European countries is estimated to range between 0.8-2.2 
mmol (50-140 mg) and approximately 80% of human NO3- intake is derived from 
eating vegetables with a minor contribution from drinking water, animal products 
and grain (AICR, 2007; Efsa, 2008). The acceptable recommended daily intake of 
NO3-, set by the EU, is 3.7 mg/kg/day, equivalent to ~4.2 mmol (260.42 mg) per 
day in a 70 kg person (Fao/Who, 2003). Maximum levels for NO3- in vegetables 
were first set in the EU in 1997 by Commission Regulation (EC) No 194/97. These 
regulations have been modified several times in recent years but regulated 
maximum levels remain.  In addition, water supplies in the EU are also regulated 
with maximum levels set at 50 mg/L NO3- equivalent to 0.8 mM. These restrictions 
have been imposed largely due to concerns over methaemoglobinaemia and 
carcinogenesis (this is described in more detail in sections 2.20.1 and 2.20.2).  
 
In contrast to dietary NO3-, dietary NO2- intake is not as substantial and can be 
attributed to cured meat, cereal and vegetable intake with drinking water 
contributing a negligible amount. Estimates of daily NO2- intake approximate to 
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0.3-0.9 mg/day in the Western world equating to 6-20 µmol NO2-  ingested daily 
(Schuddeboom, 1993). 
 
1.19 An alternative pathway of NO generation: the enterosalivary circuit of 
NO3- 
In vivo, NO3- is derived from either the oxidative metabolism of endogenously 
generated NO from the conventional L-arginine-NOS pathway (Figure 1.10), or 
from dietary ingestion of NO3-, as mentioned above. NO3- concentrations in the 
plasma of healthy individuals have been reported to range between 20-40 µM 
(Gladwin et al., 2000; Lundberg and Govoni, 2004; Webb et al., 2008) and are a 
reflection of the levels derived from both sources. Orally ingested NO3- is rapidly 
taken up into the circulation from within the gastrointestinal (GI) tract with 
almost 100% bioavailability, due to the bypassing of first-pass metabolism (van 
Velzen et al., 2008). Studies in healthy volunteers have shown that plasma NO3- 
levels rise within 15 minutes of oral ingestion with levels peaking within an hour 
(Lundberg and Govoni, 2004; McKnight et al., 1997; van Velzen et al., 2008; Webb 
et al., 2008). Following ingestion of spinach, beetroot or lettuce, all of which are 
rich sources of NO3-, the effective plasma t1/2 of NO3- has been calculated to be 5.7-
6.7 hours (van Velzen et al., 2008). The majority of plasma NO3- is excreted in the 
urine (60-75%) with peak excretion occurring around 6 hours following 
supplementation (Pannala et al., 2003), with relatively small amounts excreted 
through perspiration and excreted in faeces (Bartholomew and Hill, 1984; Wagner 
et al., 1983). 
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Figure 1.10: Schematic of the pathways for endogenous NO generation: The L-Arginine:NO 
synthase pathway, the NO3-- NO2- pathway of NO generation and the enterosalivary 
circulation.  In health circulating NO3- and NO2- levels are derived from two distinct sources. These 
are from the diet through a sequential in vivo process of chemical reduction and secondly from the 
oxidation of NO generated from the constitutively active conventional pathway involving L-
arginine and NO synthase (NOS).  
 
However, NO3- is also extracted from the circulation by the salivary glands and 
then secreted into the saliva resulting in approximately 10-fold greater NO3- levels 
than in plasma (Spiegelhalder et al., 1976). Salivary NO3- levels also increase 
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within 15 min following oral NO3- ingestion (McKnight et al., 1997; Webb et al., 
2008) with approximately one quarter of any ingested NO3- thought to be 
concentrated within the salivary glands (Spiegelhalder et al., 1976; Tannenbaum 
et al., 1976). The pathway for this NO3- extraction from the circulation has been 
elucidated. Qin and co-workers identified the sialin (sialic acid) transporter 
through 2NO3-/H+ exchange (Qin et al., 2012) as responsible for NO3- uptake using 
human salivary gland cell lines. These findings displace the previous school of 
thought that NO3- uptake was primarily facilitated by means of competitive 
inhibition of the anionic iodide transporter in the salivary glands (Edwards et al., 
1954). 
 
1.20 NO3- reduction to NO2- 
Although, at the time, the enterosalivary circuit (Figure 1.10) was thought to be 
physiologically redundant it was noted that increases in salivary NO3- 
concentration were accompanied by increases in NO2-: a phenomenon thought to 
be important in the formation of potentially harmful nitrosamines via NO2-. 
Ishiwata revealed an absence of NO2- in saliva analysed directly from the salivary 
glands as opposed to saliva in the mouth intimating a conversion of NO3- to NO2- 
taking place within the oral cavity. These findings also suggested that the presence 
of NO2- in the saliva was likely the result of NO3--reducing bacteria (Ishiwata, 
1975). Subsequently, it was discovered that a single use of anti-bacterial 
mouthwash resulted in significantly reduced salivary NO2- levels following a 
dietary NO3- load in the form of celery juice, when compared to basal levels, 
providing further compelling evidence of oral bacterial NO3- reduction 
(Tannenbaum et al., 1976).  
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Studies in healthy volunteers confirmed the importance of the oral bacteria 
intimating that Veilonella strains were the most prominent bacteria contributing 
to oral NO3- reduction (Doel et al., 2005). Using rat tongue samples NO3- reduction 
was localised to the posterior third of the dorsal aspect of the tongue (Duncan et 
al., 1995), but significant NO3- reduction has also been shown to occur within 
dental plaque and dental biofilms (Schreiber et al., 2010). Recently further 
candidate NO3--reducing species, in addition to Veilonella, have been identified in 
healthy volunteers (Hyde et al., 2014a). In this study 7 bacterial species never 
previously implicated in NO3- reduction were identified, including Granulicatella 
adiacens, Haemophilus parainfluenzae, Actinomyces odontolyticus, Actinomyces 
viscosus, Actinomyces oris, Prevotella melaninogenica and Prevotella salivae.  
Studies exploring oral  NO3--reducing potential in rodents have demonstrated 
some similarity with humans with respect to  the relevant NO3- reducing bacterial 
strains within the oral cavity, including Haemophilus parainfluenzae (Hyde et al., 
2014a; Hyde et al., 2014b). These observations suggest that the rat may provide a 
suitable laboratory model to assess the impact of dietary NO3- on the oral 
microbiome.  
 
Some investigations have also been conducted in pigs. Feeding of inorganic NO3- 
to healthy pigs changed the diversity of the oral microbiota (Trevisi et al., 2011), 
with decreases in the Shannon Index (a measure of both the number of different 
types of bacteria and the relative abundances). This change was associated with 
acute increases in oral NO3- to NO2- conversion followed by decreases with high 
doses of NO3-, suggesting concentration-dependent changes in the oral 
microbiome (although exact identification of which bacteria were altered was not 
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determined). The authors suggested that the results indicate that persistent (2 
week) dietary NO3- provision either reduces the richness of the community or 
causes numbers of certain species to rise, thus reducing evenness, and resulting in 
changes in NO3- processing. Interestingly in contrast, no change in the Shannon 
Index was observed with NO3- feeding in rats (Hyde et al., 2014b).   
 
1.21 NO2- reduction to NO 
Two independent groups, the Benjamin group in the UK and Lundberg & 
Weitzberg in Sweden, demonstrated concurrently in 1994 that following a dietary 
NO3- load NO levels in the stomach increased. In both studies it was demonstrated 
that following ingestion of NO3-, a rise in salivary NO3- associated with a 
concomitant rise in salivary NO2- occurred. This NO2- upon swallowing entered the 
acidic environment of the stomach where it became protonated to release free NO. 
This free NO was measured in air expelled from the gut using an ozone-based 
chemiluminescence analyser (Benjamin et al., 1994; Benjamin and Vallance, 1994; 
Lundberg et al., 1994). Allied In vitro studies demonstrated that increasing 
concentrations of NO2- caused anti-microbial activity against a range of gut and 
oral pathogens that was concentration and pH-dependent (i.e. the more acidic the 
greater NO generation including assessment at pH 2 to mimic gastric acid) 
(Dykhuizen et al., 1998; Xia et al., 2006). This activity has also recently been 
extended to clostridium difficile (Cunningham et al., 2014). It has been speculated 
that the high levels of NO generated under acidic conditions in the stomach, with 
dietary NO3- ingestion (Dykhuizen et al., 1998)), provides a mechanism of host 
defence as a consequence of the bactericidal activity of NO preventing  GI infection. 
The critical importance of acidic pH was demonstrated by the observation that 
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elevations in NO levels in expelled air following dietary NO3-, were attenuated by 
95% in healthy volunteers following pre-treatment with omeprazole, the proton 
pump inhibitor (Lundberg et al., 1994). Indeed, the increased risk of infection with 
Clostridium difficile in patients on proton pump inhibitors has been attributed to 
loss of the anti-microbial activity of NO2- due to increasing gastric pH  
(Cunningham et al., 2014). 
 
However, importantly not all NO2- produced in the oral cavity and swallowed is 
converted to NO in the gut. At least some of this NO₂⁻ is able to overcome passage 
through the stomach, to enter the systemic circulation. The process of NO2- 
absorption from the gastric lumen is rapid with a halving of NO2- levels within 10 
min (Licht et al., 1986). Curiously, it is not yet fully understood exactly how NO2-, 
a charged anion, enters the circulation from the gut. It has been postulated that in 
the acidic gastric lumen passive movement of nitrous acid (HNO2) into the neutral 
circulation may underlie the apparent transport of NO2- across the gastric wall 
(Webb and Ahluwalia, 2010), mirroring NO2- transport across the erythrocyte 
membrane (Samouilov et al., 2007). Furthermore, there is now evidence to 
suggest that nitrosothiol formation occurs in the stomach and by lowering the 
gastric pH this might reduce the absorption NO2- (Montenegro et al., 2017; 
Pinheiro et al., 2015). Similarly, except in the case of the salivary gland, uncertainty 
remains with respect to the pathways resulting in uptake of both anions into 
tissues throughout the body. In 2005 Bryan et al. demonstrated that within 
minutes of intravenous injection of NO2- in rats, measurable increases in levels of 
the anion could be found in tissues throughout the body (Bryan et al., 2005). 
Similarly following ingestion of dietary NO3-, elevations in tissue NO2- 
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concentrations occur, but interestingly the magnitude of change is very tissue 
dependent with plasma levels tending to be the lowest in vivo and some of the 
highest levels found in blood vessels and the heart (Bryan et al., 2005) but also the 
erythrocyte. Indeed, the erythrocyte has been proposed to be the likely carrier of 
circulating NO2- (Dejam et al., 2005). Despite all of the uncertainties pertaining to 
the mechanism behind  NO3- and NO2- transport from the gut into the circulation 
and from the circulation into the tissues, it is certain that as a consequence of 
ingestion and entero-salivary processing of inorganic NO3-, plasma NO2- levels rise 
steadily and peak within the circulation within 2.5-3 hours (Lundberg and Govoni, 
2004; Webb et al., 2008) but perhaps more importantly that ingestion of dietary 
NO3- is an effective method to deliver NO2- in vivo. 
 
It is important to appreciate that whatever the mechanisms for uptake of NO2- into 
the circulation from the gut, the amount of the anion or nitrous acid available for 
uptake will also depend upon the extent of reactions of these with other 
substances found in the gut at the same time, and the pH of the stomach.  Nitrous 
acid in the stomach will decompose to dinitrogen trioxide (N2O3) and H2O , but the 
N2O3 is highly susceptible to hydrolysis  generating nitrous acid. If, however, there 
are nitrosatable substrates in high concentration then it is possible that the N2O3 
will react with these substrates rather than undergo hydrolysis. In addition, the 
extent of nitrosation increases sharply in acidic environments with increasing 
NO2- concentrations. Both of these phenomena would result in less potential 
nitrous acid available to cross the gut (Habermeyer et al., 2015; Heinrich et al., 
2013). The possibility that N-nitroso compounds might be formed, as a result of 
this nitrosation, is of potential concern due to associations with carcinogenicity 
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(described in more detail in sections 2.20.1 and 2.20.2), but in contrast in the 
presence of thiols an increase in the levels of nitrosothiols would likely occur; 
generating a group of compounds often associated with positive effects on 
physiology (Heinrich et al., 2013). Indeed several groups have recently postulated 
this theory (Pinheiro et al., 2015). Furthermore, we have recently demonstrated 
that following a 6 week ingestion of dietary NO3-, there was only a small increase 
in total N-nitroso compounds in the urine (Velmurugan et al., 2016), levels that 
are not associated with significant toxicity concerns. 
 
The first demonstration that NO2- could be reduced to NO within the 
cardiovascular system came from Jay Zweier and colleagues in 1995. This group 
demonstrated, in the ischaemic Langendorff rat heart preparation, that despite 
NOS inhibition significant NO production continued to occur; implying the 
existence of a NOS-independent pathway for NO production. Following a series of 
iterative experiments Zweier demonstrated that this NO generation was 
attributed to the simple mechanism of disproportionation of stored tissue NO2-, 
triggered  by the local acidosis (pH 5.5) that developed within the myocardium 
during ischaemia (Zweier et al., 1995). These observations were the first 
demonstrating NO2- reduction to NO within the cardiovascular system and 
heralded the birth of a now highly active area of research focussing on utilising the 
reductive potential of this anion as a method of NO delivery in CVD scenarios.  
 
Since the above seminal studies it is now appreciated that in addition to simple 
acidic disproportionation (Zweier et al., 1995) a number of mammalian 
biochemical pathways exist that facilitate NO2- reduction (Shiva et al., 2010; 
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Sparacino-Watkins et al., 2014; van Faassen et al., 2009; Webb and Ahluwalia, 
2010). Amongst others, deoxyhaemoglobin, myoglobin, eNOS, mitochondrial 
aldehyde dehydrogenase and xanthine oxidoreductase (XOR) (Figure 1.11) have 
all been identified as functional NO2- reductases (van Faassen et al., 2009); the role 
of each being dependent upon the environmental conditions, particularly pH and 
level of oxygenation. Of all of these pathways, currently there is a growing 
perception that in acidotic, hypoxic conditions and in CVD pathology, XOR 
predominates as the NO2- reductase, whilst the globins are more likely to dominate 
in more physiological conditions (Gladwin et al., 2005). 
 
Figure 1.11: Schematic of deoxyHb and XOR‐facilitated reduction. XOR is expressed on both 
erythrocytes and the endothelium. Under ischaemic conditions XOR is also able to reduce 
plasma NO2- to NO, this occurs in part due to the increased activity of XOR under reduced oxygen 
and acidotic conditions. XOR - Xanthine oxidoreductase. 
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1.22 Clinical potential of NO2- and  NO3- therapy 
1.22.1 NO2- / NO3- and blood pressure (BP) 
Whilst the BP-lowering activity of NO3- has been appreciated for some time 
(Stieglitz, 1936); a recent renaissance of the field was ushered in by the study of 
Larsen et al. published in 2006. In this study the effect of a 3-day supplementation, 
with either NaNO3 (at a dose of 0.1 mmol/kg/day; 8.50 mg/kg/day) or placebo 
(sodium chloride, at a dose of 0.1 mmol/kg/day; 8.50 mg/kg/day), on BP. was 
examined in 17 physically active healthy volunteers.  The authors reported a 
statistically significant reduction in DBP of 3.7 mmHg in the NaNO3 group 
compared to the placebo, that was associated with higher plasma NO3- and NO2- 
levels (Larsen et al., 2006).  
 
Soon after Webb et al. demonstrated, in healthy volunteers, that a single dose of 
22.5 mmol (1395.11 mg) of a dietary source of NO3- (500 mL of beetroot juice) 
reduced SBP by 10.4 mmHg and DBP by 8 mmHg; an effect peaking at 2.5-3 hours 
following ingestion.  These changes in BP were correlated directly to plasma NO2- 
but not plasma NO3- levels, intimating that the effector of the BP-lowering was 
NO2- rather than NO3- (Webb et al., 2008). Further studies have demonstrated that 
these effects of dietary NO3- are dose-dependent and estimate a threshold dose of 
4 mmol (248.02 mg) for significant BP-lowering in healthy volunteers (Kapil et al., 
2010a). This observation is of particular interest, since in a study in stage 1 
hypertensive patients Ghosh et al. demonstrated that a dose (3.5 mmol, 217.02 
mg) lower than this threshold dose caused substantial lowering of BP (11.2/9.6 
mmHg): an effect comparable to any single dose of any current anti-hypertensive 
vasodilator therapy (Ghosh et al., 2013). The authors hypothesised that these 
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results suggest an increased potency of NO3- in hypertensive individuals. Indeed, 
the study investigated this possibility and discovered that the NO2-  reductase 
activity, localised to erythrocytes, was enhanced in hypertensive individuals (rats 
and humans), and that this was associated with an elevated XOR activity; a 
phenomenon that has been reported previously in hypertension  (Laakso et al., 
1998; Suzuki et al., 1998). 
 
The acute BP effects of dietary NO3- have been shown to persist over a longer 
period.  The Japanese diet, which is rich in NO3- has been studied in a cross-over 
randomised controlled trial over a 10 day period. This study of 25 healthy 
volunteers, demonstrated a reduction in DBP of 4.5 mmHg compared to a control 
group with a low NO3- control diet (Sobko et al., 2010).  Similarly, using beetroot 
juice to deliver a daily NO3- dose (500 mL/day containing 5.2 mmol (322.43 mg) 
of NO3-) for 15 days a significant reduction in BP compared to the control group 
has been demonstrated in healthy volunteers (Vanhatalo et al., 2010). Further 
recent studies have confirmed these findings (Ashworth et al., 2015; Bondonno et 
al., 2012; Joris and Mensink, 2013; Liu et al., 2013a). 
 
Finally, in a double-blind, placebo-controlled, randomised clinical trial involving 
68 patients with hypertension, daily dietary supplementation of 250 mL of 
beetroot juice containing approximately 6 mmol (372.03 mg) dietary NO3- (versus 
a NO3--free beetroot juice placebo) for 4 weeks has been shown to produce 
sustained BP-lowering.  The primary end-point in this study was change in clinic, 
ambulatory and home BPs compared to the placebo group after 4 weeks of 
treatment. A significant reduction in clinic BP (7.7/2.4 mmHg), 24 hour 
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ambulatory BP (7.7/5.2 mmHg) as well as home BP measurements (8.1/3.8 
mmHg) was reported (Kapil et al., 2015). However, a recent paper by Blekkenhort 
and colleagues investigated whether daily consumption of NO3- - rich vegetables 
(∼150 mg nitrate/day) compared to NO3- - poor vegetables (∼22 mg NO3-/day), 
or no increase in vegetables (control; ∼6 mg NO3-/d) over 4 weeks in  would result 
in lower BP. They found that infact, increased intake of NO3- - rich vegetables did 
not lower BP in prehypertensive or untreated grade 1 hypertensive individuals 
when compared with increased intake of NO3- - poor vegetables and no increase 
in vegetables (Blekkenhorst et al., 2018). 
 
1.22.2 NO2- / NO3- and vascular function 
Vascular dysfunction is thought to play a major role in the progression of CVD 
including in atherosclerosis (Deanfield et al., 2007). This change occurs at the very 
earliest stages of CVD development, preceding any evidence of disease 
(Celermajer et al., 1992) and is associated with most risk factors, including 
hypercholesterolemia and BP (Kannel et al., 1979; Steinberg et al., 1989; 
Vanhoutte, 1996). Indeed, measures of vascular function, particularly brachial 
artery FMD and arterial stiffness reflected through measurement of PWV, have 
been proposed as important markers of CVD. Evidence suggests that these 
measures inform not only upon the extent of atherosclerotic disease (Deanfield et 
al., 2007; Drexler and Zeiher, 1991; Halcox et al., 2009) but also of future risk of 
cardiovascular events (Celermajer et al., 1992; Yeboah et al., 2009). Wide-scale 
preventative strategies for CVD, such as statins, show improved FMD and pulse 
wave velocity (PWV) responses in hypercholesterolemics (Laurent et al., 2006; 
Masoura et al., 2011; Vlachopoulos et al., 2010).  
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Mechanistically, vascular dysfunction is characterised by reduced bioavailability 
of endothelium-derived NO. Dysfunction of the conventional L-arginine/NO 
synthase pathway and enhanced scavenging of NO underlie this reduced 
bioavailability in individuals at risk of CVD, including those with 
hypercholesterolemia (Hermann et al., 2006; Jeserich et al., 1992; Marin and Sessa, 
2007). Thus, approaches that might restore this ‘lost’ NO have obvious therapeutic 
potential. Indeed, replacement of NO using organic nitrate improves vascular 
function and vice versa NOS inhibition causes reduced elastic artery distensibility 
and hence stiffness in vivo (Bellien et al., 2010; Schmitt et al., 2005; Wilkinson et 
al., 2002).  However, the long term utility of organic NO3- therapy is limited due to 
the rapid tolerance that develops and the eventual precipitation per se of vascular 
dysfunction particularly targeting the endothelium (Munzel et al., 2013). Thus, 
identification of strategies that deliver sustained NO elevation without tolerance 
or any associated negative vascular effects has been mooted as a potential useful 
therapeutic strategy in limiting CVD progression.  
 
Studies of inorganic NO2- supplementation, delivered in the drinking water, in 
mice for 3 weeks demonstrated a reversal of age-associated large elastic artery 
stiffness. The authors of this study speculated that this improvement likely related 
to a reduction in advanced glycation end-products’ which have been implicated in 
arterial stiffness in humans (Fleenor et al., 2012; Sindler et al., 2011). Clinical 
studies have confirmed these findings demonstrating improvement in measures 
of vascular stiffness with elevation of circulating NO2- levels following oral NO3- 
delivery.  In healthy volunteers an 8 mmol (496.04 mg) KNO3 supplement, in the 
form of a capsule, caused a significant reduction in PWV at 3 hours compared to 
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matched KCL placebo (Bahra et al., 2012) . Similar findings in healthy volunteers 
have been reported using dietary sources of NO3- including spinach (Liu et al., 
2013b) but also in patients with hypertension.  Indeed, a single dose of dietary 
NO3- (3.5 mmol (217.02 mg) in the form of beetroot juice) significantly reduced 
PWV compared to baseline measurements in stage 1 (drug naïve) hypertensive 
individuals  (Ghosh et al., 2013). A small study in a cohort of elderly volunteers 
with risk factors for CVD also found an improvement in PWV and augmentation 
index in the group who received NaNO3 versus NaCl control (Rammos et al., 2014). 
More recently, sustained daily intake of dietary NO3-, in the form of beetroot juice 
for 4 weeks, effected a persistent improvement in PWV in patients with 
hypertension. Thus, taken together these studies suggest that dietary NO3- may 
have a role in preventative strategies to reduce cardiovascular risk by causing a 
sustained reduction in arterial stiffness (Kapil et al., 2015).  
 
Interestingly, the effects of NO2- or NO3- on FMD show a distinct pattern to that 
with PWV. A randomised cross-over double-blind study in 14 healthy volunteers 
demonstrated that, whilst an 8 mmol (496.04 mg) dose of KNO3 improved PWV 
and reduced BP measured 3h following ingestion, no change in the FMD response 
was evident (Bahra et al., 2012). More recently, Kim and co-workers in a study 
assessing the increase in flow and brachial artery diameter following hand-grip 
exercise in healthy volunteers, also demonstrated improved PWV but no effect on 
endothelial function with dietary NO3- administration (Kim et al., 2014). These 
observations contrast with two other published studies. In 2012, Heiss et al. 
demonstrated an increase in FMD in response to dietary NO3- in healthy 
volunteers and suggested that this effect was due to an increased mobilisation of 
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circulating angiogenic cells (Heiss et al., 2012). More recently the same group has 
shown, in studies delivering NO3- through spinach consumption, a dose-dependent 
improvement in FMD responses with doses above ~4 mmol (248.02 mg) 
(Rodriguez-Mateos et al., 2015). Exactly why these differences between the 
studies occur is uncertain but may relate to the mode and dose of NO3- delivery.  
Although arguing against such a reason is the fact that two distinct groups, one 
using a NO3- salt and the other a dietary source, identified no effect on endothelial 
function in healthy volunteers. Moreover, in the studies demonstrating positive 
effects these were invariably evident with doses of NO3- that were lower than 
those used in the studies demonstrating no effect. Further assessments of this 
discord would be of value. 
 
Interestingly, in healthy volunteers where transient endothelial dysfunction is 
induced by an ischaemic insult to the forearm, inorganic NO3-  delivered either in 
the form of beetroot juice or through supplementation with KNO3 reversed 
dysfunction (Kapil et al., 2010a; Webb et al., 2008). In addition, most recently it 
has been demonstrated that sustained dietary NO3- ingestion in hypertensives 
(who characteristically display reduced FMD responses that have been attributed 
to endothelial dysfunction) results in an improvement in the FMD response; a 
view supported by a recent meta-analysis (Siervo et al., 2014). The exact 
mechanism involved in mediating this effect is uncertain. However, there is 
evidence to suggest that BP-lowering per se will result in improvements in 
vascular function and in all studies where improvements in vascular function were 
noted BP decreases were also reported. Further studies by Joris et al (Joris and 
Mensink, 2013). and Gilchrest et al (Gilchrist et al., 2013). have confirmed the 
119 
 
improvement of FMD following ingestion of dietary NO3-. Currently, it is unknown 
whether the improvements in both PWV and FMD are due to reductions in BP or 
whether other pathways might underlie these effects. More recently there has 
been some evidence to suggest that the beneficial effects of NO2-/ NO3- in CVD may 
also relate to improvements in circulating lipid levels and this is discussed more 
fully below.   
 
1.22.3 NO2- / NO3- and lipids 
NO2- has been shown to modify the oxidation of LDL-cholesterol. Atherogenic 
modifications of LDL by a cell-free macrophage myeloperoxidase/hydrogen 
peroxide/chloride system were prevented following incubation of LDL with NO2- 
(12.5-200 µM) in vitro (Carr and Frei, 2001). More recent research has shown that 
C57BL6 mice fed a high fat diet but supplemented with NO2—containing drinking 
water for 3 weeks exhibited reduced leukocyte adhesion and arteriolar 
endothelial dysfunction together with a reduced triglyceride level compared to 
those fed NO2--deplete water (Stokes et al., 2009). Interestingly, in a small study in 
patients with hypercholesterolemia a significant reduction in triglyceride levels 
following dietary NO2- has been reported (Zand et al., 2011). In this study 23 
hypercholesterolemic patients were given a commercially available supplement 
containing a number of different herbal constituents proposed to enhance NO3- 
and NO2- delivery in vivo. After 30 days of a twice a day ingestion, triglyceride 
levels were significantly reduced. The authors speculated that such an effect might 
be useful in limiting the progression of atherosclerotic disease, highlighting a 
potential preventative strategy that might be utilised on a population level to 
control rates of atherosclerosis.  
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1.22.4 NO2- / NO3- and platelet reactivity 
It is widely accepted that NO plays a critical role in regulating platelet function 
(Gkaliagkousi et al., 2007).  In health, this takes the form of a repressive effect 
limiting platelet activation and adhesion to the blood vessel wall. It is thought that, 
in CVD, dysfunction of the endothelium and the resulting loss of tonic bioavailable 
NO results in removal of a critical repressive influence of the endothelium on 
platelets (Radomski et al., 1987a; 1990). Thus, strategies that restore NO-
dependent platelet regulation are of obvious potential.  Studies in healthy 
volunteers have shown a reduction in ex vivo platelet aggregation following NO3- 
ingestion. Ingestion of oral KNO3 (2 mmol; 124.01 mg) in a small cohort of seven 
healthy volunteers resulted in inhibition of platelet aggregation assessed ex vivo 
in response to collagen (Richardson et al., 2002). This was followed in 2008 by a 
study, in healthy volunteers, demonstrating that platelet aggregation in response 
to both ADP and collagen were inhibited 2.5 hours after consumption of 500 ml of 
beetroot juice delivering 24 mmol (1488.12 mg) of inorganic NO3- (Webb et al., 
2008). In this study the anti-platelet effects of NO3- were abolished when the 
entero-salivary circuit was interrupted, by asking the volunteers to spit all saliva 
out following NO3- ingestion, and thus preventing the re-entry of NO₂- into the 
body.  
 
Confirmation that NO2- underlies these anti-platelet effects has been 
demonstrated. Early studies showed that ex vivo incubation of platelet-rich plasma 
(PRP) with very high supraphysiological concentrations of NO2- (~60 µM) 
attenuated platelet aggregation in response to ADP, arachidonic acid and collagen 
(Schafer et al., 1980). However, further studies using concentrations of NO2- better 
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reflecting the physiological range  (1-100 µmol/L; 46.01-4600.6 µg/L) have shown 
no activity of the anion on PRP in vitro (Radomski et al., 1987b). However, Srihirun 
et al. have demonstrated that the anti-platelet activity of NO2- is critically 
dependent upon its bioactivation by erythrocytes. Their studies demonstrated 
that with reduced oxygen tension greater activity of NO2- became apparent as a 
consequence of its reduction to NO by deoxyhaemoglobin. The authors suggested 
that NO2- might have a role in altering platelet activity in the circulation, under 
hypoxic conditions, but also in the normal transit of blood through the circulation 
within the reduced oxygen tension present on the venous versus the arterial side 
of circulation (Akrawinthawong et al., 2014; Srihirun et al., 2012). 
 
A follow-up study by the same group investigated how NO2- may affect overall 
clotting processes via modulating platelet function using thrombelastography. In 
their study, they showed that NO2-, as well as NO, exhibited inhibitory effects on 
coagulation processes resulting in increasing reaction time of fibrin formation, 
decreasing the rate of clot formation and reducing clot strength. These inhibitory 
effects of NO2- were greatly enhanced by the deoxygenation of blood, again 
implicating deoxyhaemoglobin in the reduction of NO2- to NO under hypoxic 
conditions (Park et al., 2014). In a separate study in mice, Park et al. found that 
dietary restriction of NO2- and NO3- reduced the levels of both anions in whole 
blood to a greater extent than inhibition of NOS, resulting in alterations of platelet 
function.  This group suggested that dietary NO2- and NO3- could play an important 
role, possibly more important than NO generated by the conventional L-
arginine/NOS pathway, in regulating basal haemostasis and thrombosis by 
affecting platelet reactivity (Park et al., 2013). Interestingly, Emerson and co-
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workers group has suggested that NO3- exerts an antiplatelet effect during eNOS 
deficiency.  Hence, dietary NO3- may have a role in reducing platelet activity during 
endothelial dysfunction (Apostoli et al., 2014). Together, these data suggest that 
provision of dietary NO3-, might offer an effective strategy providing modest anti-
platelet activity that could be effective in preventative strategies. 
 
1.22.5 NO2- / NO3- and intimal hyperplasia and restenosis 
Vascular smooth muscle cell proliferation is believed to underlie the pathogenesis 
of intimal hyperplasia and restenosis (Ross, 1993; Vogt et al., 2008). Pre-clinical 
models have shown that the delivery of NO in the form of L-arginine, 
pharmacological NO donors, or overexpression of NOS can inhibit proliferation of 
VSMCs, which in turn can reduce the injury responses within the blood vessel wall 
(Kibbe et al., 2000; Napoli et al., 2001; Napoli et al., 2013). Furthermore, VSMCs 
transfected with eNOS have demonstrated inhibition of cell proliferation and of 
key cell cycle regulatory molecules (Sharma et al., 1999). However, this has not 
been translated successfully in humans with neointimal hyperplasia. The 
Angioplastic Coronaire Corvasal Diltiazem (ACCORD) study found that patients 
undergoing PCI who received NO from intravenous linsidomine, followed by oral 
molsidomine for 6 months, had a reduction in angiographic luminal diameter of 
10% (Lablanche et al., 1997). Conversely, another study found that patients 
receiving high-dose oral molsidomine for 6 months after PCI did not show any 
effect on restenosis rates (Wohrle et al., 2003). Recently it has been demonstrated 
that low dose of NaNO2 given prior to balloon injury in vivo prevents vascular 
intimal hyperplasia in both rat and mouse injury models (Alef et al., 2011). 
Moreover, there is also evidence to suggest that NO2- delivered after the 
123 
 
establishment of intimal hyperplasia could reverse the pathological process (Alef 
et al., 2011). This study demonstrated that NaNO2 was metabolised to biologically 
active NO by XOR and limited the proliferation of VSMC via a p21Waf1/Cip1 
dependent-mechanism. However, a study by Vavra et al. found that neither NO2- or 
NO3- inhibited rat aortic VSMC proliferation in vitro (Vavra et al., 2011), which 
would suggest that NO2- is being reduced by a cell other than VSMC. Both these 
studies did suggest a benefit of NaNO2 in the treatment of restenosis in vivo (Alef 
et al., 2011; Vavra et al., 2011).  
 
1.22.6 NO2- / NO3- and ischaemia-reperfusion (IR) Injury 
There are a number of pre-clinical studies demonstrating beneficial effects of NO2- 
supplementation against the damaging effect of ischaemia-reperfusion (IR) injury, 
including improvement of left ventricular function and reduction in infarct size in 
the heart (Duranski et al., 2005; Gonzalez et al., 2008; Webb et al., 2004a).  In the 
isolated Langendorff rat heart preparation, perfusion of hearts with 10 and 100 
µM NO2-, before and throughout an IR insult, reduced infarct size by more than 
60% with matching improvements in left ventricular function (Webb et al., 
2004b). These findings were followed by translation into in vivo models of 
myocardial IR injury demonstrating beneficial effects of the anion administered 
locally in the heart in mice  (Duranski et al., 2005), with similar outcomes following 
parenteral administration of NO2- in a canine model of IR injury (Gonzalez et al., 
2008). Mechanistic studies have suggested that the processing of NO2- within the 
ischaemic myocardium is likely to involve both XOR (Webb et al., 2004b) and 
deoxymyoglobin (Hendgen-Cotta et al., 2008; Shiva et al., 2007a; Shiva et al., 
2007b). Furthermore, Bryan et al. have shown that the effects with parenteral NO2- 
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administration can be recapitulated through dietary supplementation with NO2- 
or NO3- for 7 days (Bryan et al., 2007). 
 
Most interestingly these studies have now been translated into the clinical setting. 
Two separate phase 2 clinical trials of intravenous and intra-coronary NO2- have 
been reported (Jones et al., 2014; Siddiqi et al., 2014).  Siddiqi et al. conducted a 
multi-centre randomised, double-blind, placebo controlled trial (NIAMI) where 
229 patients with AMI received a continuous infusion of NO2- for 5 minutes prior 
to balloon inflation, delivering a total dose of 70 µmol of NaNO2 or NaCl placebo 
(Siddiqi et al., 2014).  In this study an important inclusion criteria for all patients 
was that the culprit vessel was occluded at the time of infusion i.e. the 
thrombolysis in myocardial infarction (TIMI) score was either 0 (complete block) 
or 1 (minimal flow). The primary endpoint in this study was the difference in 
infarct size (expressed as a percentage of LV myocardial mass) between the active 
and placebo groups at 6–8 days post-infarct assessed on cardiac magnetic 
resonance (CMR) (Siddiqi et al., 2014).  Disappointingly, no significant difference 
in infarct size between the two groups was evident.  However, Jones et al. 
conducted a randomised double-blind study of intra-coronary NO2- during AMI 
(NITRITE-AMI) where 80 patients were randomised to receive a single bolus of 
intra-coronary 1.8 µmol NaNO2 (124.19 µg) or NaCl (105.19 µg) placebo (Jones et 
al., 2014).  The study did not demonstrate a reduction in infarct size (assessed by 
measurements of the primary outcome-creatinine kinase).  However, in a sub-
group analysis of patients where only patients with TIMI ≤1 flow (i.e. patients with 
no or little flow beyond the blocked vessel) were included, there was a significant 
reduction in myocardial infarct size assessed by creatinine kinase between the 
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NO2- and control group.  Furthermore, there was a statistically significant decrease 
in CMR-determined myocardial infarct size in the NO2--treated patients (Jones et 
al., 2014). Furthermore, a second manuscript from this study demonstrated 
reductions in the systemic inflammatory response post PCI, which were 
associated with nitrite treatment. They also found that in NO2--treated patients, 
there was a sustained long-term reduction in MACE in the nitrite group compared 
with the placebo group (Jones et al., 2017). Whether one might be able to use a 
dietary approach to recapitulate these effects is uncertain, but may prove difficult. 
A likely explanation for the difference between the two studies described above 
relates to the concentration of NO2- achieved within the culprit artery prior to 
reperfusion. With intra-coronary administration, it was estimated that local 
concentrations of between 3-10 μmol/L were achieved in the patients, although 
direct measurement of this was not provided. In the Siddiqui study circulating 
levels achieved were 1.42 μmol/L. This concentration was measured 5 minutes 
following ceasing of anion infusion and so may not accurately reflect the peak 
levels.  However, previous studies in pre-clinical models in vivo suggest that local 
concentrations less than 3 μmol/L of NO2- are unlikely to produce substantial 
reduction in infarct size. In general, dietary NO3- or NO2- interventions achieve 
rises in circulating levels of NO2- somewhere in the region of 0.2 to at the very most 
1 μmol/L, and thus it seems unlikely that a diet-based intervention will impact 
sufficiently on infarct size in the AMI setting to result in measurable benefits. 
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1.23 Concerns regarding NO2- / NO3- therapy 
1.23.1 NO2- / NO3-- and methaemoglobinaemia 
After ingestion of NO3- and its subsequent reduction to NO2‐, NO2‐ will bind to 
haemoglobin resulting in the oxidation of the ferrous iron (Fe2+) in haemoglobin 
to the ferric (Fe3+) state.  This consequently forms methaemoglobin (Doyle et al., 
1981). In this state haemoglobin cannot bind oxygen and requires 
methaemoglobin reductases (cytochrome b5 reductase) to restore haemoglobin 
back to its oxygen-binding ferrous state. Methaemoglobinaemia results in 
insufficient oxygen-carrying capacity of the blood, and when levels exceed 5–10% 
clinical symptoms ensue such as cyanosis, shortness of breath, irritability and 
altered mental status (Greer and Shannon, 2005). 
 
Early observational data reported in 1945 by Comly indicated that 
methaemoglobinaemia in infants resulted as a consequence of milk formula being 
made using well water with high NO3- levels (Comly H.H., 1945).  Shortly after, 
Walton in 1951 found that there were no reported cases of methaemoglobinaemia 
at drinking-water NO3- levels <10 mg/L (Walton, 1951).  Hence, currently the 
maximum limit of 50 mg/L (which is equivalent to < 1 mmol/L) is implemented in 
the UK, Europe and USA provincial water supplies. The increased susceptibility of 
infants to methaemoglobinaemia was proposed to be due to the fact that at less 
than ~6 months of age methaemoglobin reductase pathways are insufficiently 
developed, allowing high levels of methaemoglobin to persist.   
 
However, the aetiological role of high NO3‐-containing water in the 
methaemoglobinaemia evident in young children has been challenged.  The 
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original descriptions of ‘blue-baby’ syndrome made by Comly were in infants who 
also had co-existing diarrhoea, probably as a result from enteric infections caused 
by faecal bacteria contamination in wells (Avery, 1999).  Moreover, there are 
numerous studies demonstrating a strong association of diarrhoea and 
methaemoglobinaemia in the absence of NO3--contaminated water (Avery, 1999).  
Support for this view comes from a study where infants exposed to 157-170 mg of 
NO3- a day did not experience methaemoglobinaemia levels greater than 7.5% 
(Cornblath and Hartmann, 1948). 
 
In adults, a randomised three-way crossover study in healthy volunteers has 
demonstrated that relatively high concentrations of NO2- are required before 
clinically significant levels of methaemoglobinaemia are achieved. Single doses of 
NaNO2 ranging from 150–380 mg (2.17-5.51 mmol) were administered 
intravenously (Kortboyer J, 1997) and resulted in methaemoglobin 
concentrations of 12.2% in volunteers receiving the highest dose of NO2- and 4.5% 
for those receiving the lowest dose. In a separate study up to 110mg/kg/min of 
NO2- was infused for 5 minutes into the brachial artery of healthy volunteers and 
achieved methaemoglobin concentrations of only 0.7% to 3.2% in adults (Dejam 
et al., 2007). In another 18 participant healthy volunteer study where intra-
arterial infusion of NO2- was performed, systemic concentrations of 16 µmol/L of 
NO2- were measured, however, methaemoglobin levels were measured at ~1% 
(Cosby et al., 2003). Finally, a recent study looking at the safety and feasibility of 
long-term intravenous NaNO2 infusion in healthy volunteers used doses up to 534 
µg/kg/hour (7.74 µmol/kg/hour) intravenously for 3 to 9 hours.  This resulted in 
significant reductions of BP (up to 20 mmHg in one participant) but only a 
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maximum increase of methaemoglobin levels to  5% (Pluta et al., 2011). Together, 
these studies suggest that extremely high levels of NO2- are required before 
clinically significant methaemoglobinaemia occurs, but also that it is unlikely that 
the ingestion of NO3-  poses any significant methaemoglobinaemia risk. Indeed, 
daily ingestion of a dietary NO3-  dose of approximately 5 mmol for 4 weeks 
produced significant beneficial functional effects but was not associated with any 
evidence of methaemoglobin formation in adults (Kapil V, 2015). 
 
1.23.2 NO2- / NO3-  and carcinogenesis 
Although NO3‐ itself  is  not  thought  to  be  carcinogenic (Speijers and van den 
Brandt, 2003), the conversion of NO3‐ to NO2‐ and then further reaction of NO2‐ 
with secondary amines to form N-nitrosoamine, is thought to result in potential 
carcinogenesis (Hord et al., 2009b).  In addition, the rate of nitrosation of amino 
acids is proportional to the square of the NO2- concentration, which would suggest 
that the production of nitrosation compounds in the stomach would increase 
suddenly with higher intake of NO3- and NO2-. Also, previous studies have 
demonstrated that the most common natural amino acids are the most efficient 
precursors of the most powerful alkylating agents (Garcia-Santos Mdel et al., 
2001). Hence, the stomach environment could potentially augment the nitrosation 
of common amino acids and therefore increase the risk of carcinogenesis.  
 
Studies in rats conducted  in the 1960s demonstrated that the nitrosamine, 
dimethylnitrosamine, produced liver carcinoma (Magee and Barnes, 1956; 
Sakshaug et al., 1965). A number of distinct N-nitrosoamine species have been 
tested and tumours have been induced in 39 species which belong to 36 genera, 
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25 families, 17 orders and five class of animals (Bogovski and Bogovski, 1981), 
indicating that these compounds show no species selectivity in terms of their 
carcinogenicity. In vitro studies have shown that N-nitrosoamines can be formed 
in humans by incubating gastric juice, NO2‐ and secondary amines (Sen et al., 
1969). Although in vivo studies have demonstrated that dietary ingestion of NO2‐ 
containing foods can form N-nitrosamines (diphenylamine) (Fine et al., 1977), 
other studies have failed to demonstrate tumour formation in rats despite chronic 
feeding of NO2- (Druckrey et al., 1963). In fact, a recent study by Sodring et al. 
found that NO2- had a suppressive effect on colorectal cancer promotion in the 
small intestine of mice (Sodring et al., 2015). Moreover, recent evidence from the 
EPIC study suggests no link of such cancers with endogenous nitrosamine 
formation and NO2- ingestion (Loh et al., 2011). 
 
Recent studies have also shown that NO2‐ and NO3‐ in meats increase the risk of 
colorectal, bladder and prostate cancer (Cross et al., 2010; Dellavalle et al., 2014; 
Ferrucci et al., 2010; Sinha et al., 2009).  A study by Cross et al. suggested an 
increased risk of colorectal cancer with red [HR, 1.24; 95% CI, 1.09–1.42; P < 
0.001] and processed meat [HR, 1.16; 95% CI, 1.01–1.32; P = 0.017] (Cross et al., 
2010). Worryingly, a positive association between the frequency of maternal 
intake of cured meat and the risk of childhood brain tumours (Dietrich et al., 2005) 
has also been identified. Ferrucci et al. showed modest support for an increased 
risk of bladder cancer with total dietary NO2‐ and NO3‐ but the results did not reach 
statistical significance (Ferrucci et al., 2010).  Finally Sinha et al. found NO2‐ (HR = 
1.24, 95% CI: 1.02, 1.51) and NO3‐ (HR = 1.31, 95% CI: 1.07, 1.61) intake was 
associated with advanced prostate cancer but no clear associations for fatal 
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prostate cancer (Sinha et al., 2009).  Other epidemiological studies assessing risk 
of stomach, brain, oesophageal, and nasopharyngeal cancers have been 
inconclusive (Eichholzer and Gutzwiller, 1998).  Conversely, patients with 
Barrett’s oesophagus have an increased risk of adenocarcinoma at the gastro-
oesophageal junction, which is the site where increased N-nitrosamine formation 
has been identified (Winter et al., 2007).  Finally, studies have also demonstrated 
increased risk of follicular thyroid cancer with high NO3‐ levels (Kilfoy et al., 2011).  
Thus, collectively there does seem to be some evidence of a link between the 
anions and cancer. However, it is important to appreciate that all of these 
associations have been made with ‘estimated’ exposure to NO3‐ and NO2‐. 
Currently there is limited data that have confirmed exposure with measurement 
of either anion in blood, urine or any other sample in any cohorts. Very recently, 
Data on 17 618 adult participants in the NHANES (National Health and Nutrition 
Examination Surveys), conducted between 2005 and 2014 in the United States, 
was analysed and published. The study found that urinary NO3- was significantly 
lower in individuals with hypercholesterolemia, diabetes mellitus, hypertension, 
myocardial infarction, or stroke. Interestingly, the study found that urinary NO3- 
was not associated with cancer prevalence or mortality (Mendy, 2018). Further 
such studies would be of great value in ascertaining whether the associations 
described above relate to actual in vivo exposure. 
 
A review of data by the World Health Organisation Expert Committee on Food 
Additives found that there was no evidence that NO3- was carcinogenic to humans 
(Speijers and van den Brandt, 2003).  In addition, The International Agency for 
Research on Cancer (IARC) reported that “There is inadequate evidence in humans 
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for the carcinogenicity of nitrate in food and in drinking water”. However, they 
also reported that “There is limited evidence in humans and animals for the 
carcinogenicity of NO2- in food – Nitrite in food is associated with an increased 
incidence of stomach cancer”……There is sufficient evidence in experimental 
animals for the carcinogenicity of nitrite in combination with amines or 
amides”…..There is limited evidence in experimental animals for the 
carcinogenicity of NO2- per se.” (International Agency for Research on Cancer et 
al., International Agency for Research on Cancer). However, large prospective 
studies do not support the hypothesis of an association between ingestion of NO3- 
or NO2- and stomach cancer (Bryan et al., 2012). Thus, whilst it seems that the risk 
of cancer with NO3- is negligible concerns still remain with respect to NO2-. 
 
1.24 Summary 
A growing body of evidence now supports the view that the beneficial effects seen 
with inorganic NO2‐ and NO3‐ might also, at least in part, explain the benefits seen 
in diets that are composed of high volumes of vegetables (i.e. the Mediterranean 
diet). Such observations reopen the discussion of what an acceptable level of 
intake of these anions should be (Oyebode et al., 2014). Although there are on-
going concerns regarding dietary NO3‐ and carcinogenesis, reassuringly, these 
concerns to date remain unsupported. On the other hand, thus far there have been 
no studies exploring the beneficial effects of NO3- supplementation in humans 
beyond 4 weeks.  Hence, the NITRATE-OCT study carried out as part of this PhD 
will aim to identify the role of inorganic NO3- in reducing restenosis in patients 
undergoing PCI for stable angina.  
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In addition, whether the beneficial effects of NO3- might relate to effects upon the 
inflammatory components of CHD is unknown and so to address this I have 
established two models of inflammation in healthy volunteers in the laboratory 
with a view to testing the effects of NO3- upon inflammatory responses in healthy 
volunteers. 
 
1.25 Hypotheses 
 
The primary aim of my PhD is to test the hypothesis that dietary NO3- ingestion, in 
addition to conventional therapy, might improve outcome in patients with stable 
angina undergoing PCI. 
 
1.26 Aims 
 
(i) To conduct mechanistic studies in healthy volunteers in order to establish 
techniques and protocols for investigating anti-platelet and anti-inflammatory 
effects of dietary NO3- in a large clinical study.  
(ii) To determine whether it is safe to deliver dietary NO3- in patient undergoing 
PCI and stent implantation and whether the randomisation is effective. 
(iii) To determine whether dietary NO3- ingestion exerts anti-platelet effects or 
anti-inflammatory effects and the mechanisms involved in this effect. 
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2.0 General Methods 
2.1 Healthy Volunteer Study Methods 
2.1.1 Volunteers 
Equal numbers of male and female healthy volunteers were recruited for each 
study. Volunteers were included if they fulfilled the following Inclusion criteria: 
18–45 years of age, body mass index (BMI) of 18–40 kg/m2, and had not received 
typhoid vaccination in the previous 2 years. Exclusion criteria included: History of 
hypertension, diabetes or hypertensive on BP measurement, pregnant, or any 
possibility that a subject may be pregnant unless in the latter case a pregnancy test 
is performed with a negative result, history of any serious illnesses, including 
recent infections or trauma, subjects taking systemic medication (other than the 
oral contraceptive pill), subjects with self-reported use of mouthwash or tongue 
scrapes, subjects with recent or current antibiotic use, subjects with a history, or 
recent treatment of (within last 3 months) of any oral condition (excluding caries), 
including gingivitis, periodontitis and halitosis and subjects that have recently 
participated (preceding 3 months) in any clinical studies involving administration 
of an inflammogen.  Female volunteers’ appointments were scheduled to fall at a 
maximum of 2 weeks and no less than 1 week prior to the due-date of their next 
menstruation when oestrogen levels at their highest. 
 
All clinical studies were performed in a quiet temperature-controlled laboratory 
(24°C to 26°C) and individuals were studied at the same time of day during each 
day of the study they were involved in. Volunteers refrained from caffeine 
consumption and strenuous exercise the day before and the day of the respective 
study, and were fasted overnight before all study visits. 
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2.1.2 Healthy volunteer study 1 – typhoid-induced systemic inflammation 
study 
A total of 24 healthy volunteers (12 males and 12 females) were consented for this 
3 day study. On day 1 volunteers attended the clinic at 3 pm and measured their 
own BP using a portable BP device. Body temperature was measured using a 
standard Braun Thermoscan Ear Thermometer TM. Following this PWA, PWV and 
FMD were determined.  Blood was then collected. On day 2, the volunteers 
attended in the morning to receive the typhoid vaccination into the gluteal or 
deltoid region at 8 am in the morning and returned at 3 pm for a repeat of all the 
previous measurements. On day 3, volunteers attended the clinic at 3 pm for the 
final time and had a final repeat of all measurements (Figure 2.1A).  In a separate 
study we recruited a further 16 healthy volunteers-8 males and 8 females to assess 
endothelium-independent vasodilation using GTN as per previous 
recommendations (Donald et al., 2006). Briefly, the volunteers attended the clinic 
as above but received a sublingual (0.4 mg) dose of GTN spray (Nitrolingual Pump 
Spray, Merck, UK) in the place of the reactive hyperemia stimulus.  Whole blood 
differentials and flow cytometry were measured to assess both leucocyte and 
platelet numbers and activation state and plasma collected for assessment of NO2- 
and NO3- (NOx) levels and CRP.  
 
2.1.3 Healthy volunteer study 2 – Cantharidin-induced blister study 
A total of 32 healthy volunteers (16 male and 16 female) were consented for this 
4 day study. On day 1, the volunteers measured their own BP/ using a portable 
blood pressure device. After this cantharidin solution was applied to the ventral 
aspect of a forearm.  Blood, was then collected. On day 3 (48 hours after the initial 
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cantharidin application), the volunteer returned to have cantharidin applied to a 
separate area, no less than 5 cm away from the initial.  Finally, on day 4 (72 hours 
after the initial cantharidin application), the volunteers measured their BP again 
and then blister fluid was sampled from both blisters and blood, urine and saliva 
samples were collected (Figure 2.1B). Blister fluid volume, cell count, flow 
cytometric analysis of cell type and activation state and cytokine/chemokine 
analysis were also run.  
 
For the application of cantharidin solution 10 μL cantharidin (cantharone 0.1%, 
Dormer Laboratories, Toronto, Canada) was applied to filter-paper discs and 
placed on the ventral aspects of the forearm as previously described (48-51) and 
dressed appropriately. Blister fluid was then harvested at 24 hours (acute phase) 
and 72 hours (resolution phase) by carefully piercing the side of the blister with a 
25G needle and rolling a pipette tip over the surface of the blister to express blister 
fluid, which was then collected in a siliconised pipette and the fluid was then 
stored on ice until further analysis. 
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Study 1-Typhoid-induced systemic inflammation study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 (A) Flow chart of the typhoid clinical study 1. 
 
PWV: pulse wave velocity; PWA: pulse wave analysis, FMD: flow mediated dilatation.  
  
Screening 
Eligibility assessed 
Consent for study 
12 female healthy volunteers 
recruited 
 
12 male healthy volunteers 
recruited 
 
Day 1, Visit 1 at 3 pm [Pre-vaccine] 
Blood pressure and tympanic temperature recorded 
Blood samples collected 
PWV, PWA and FMD performed 
Day 2, Visit 2 at 8 am [Vaccine] 
Typhoid vaccine administered 
Day 2, Visit 3 at 3 pm [8 hours Post-vaccine] 
Blood pressure and tympanic temperature recorded 
Blood samples collected 
PWV, PWA and FMD performed 
Day 3, Visit 4 at 3 pm [32 hours Post-Vaccine] 
Blood pressure and tympanic temperature recorded 
Blood samples collected 
PWV, PWA and FMD performed 
All 24 healthy volunteers were followed-up to the end of the study 
and data were analysed for all 24 participants in the study. 
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Study 2-Cantharidin-induced blister study 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 (B) Flow chart of the cantharidin clinical study . 
 
  
Screening 
Eligibility assessed 
Consent for study 
16 female healthy volunteers 
recruited 
 
16 male healthy volunteers 
recruited 
 
Day 1, Visit 1 [First cantharidin application] 
Blood pressure and tympanic temperature recorded 
Blood samples collected 
Cantharidin applied on the ventral aspect of a forearm 
Day 3, Visit 2 [Second cantharidin application] 
 Second cantharin application ( ≈5cm away from first blister) 
Day 4, Visit 3 [Harvesting of 24 and 72 hours blisters] 
Blood pressure and tympanic temperature recorded 
Blood samples collected 
Both blisters harvested and blister fluid collected 
All 32 healthy volunteers were followed-up to the end of the study 
and data were analysed for all 32 participants in the study. 
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2.1.4 Power and statistical analysis 
Based upon previous observations demonstrating typhoid vaccine induced 
endothelial dysfunction (Hingorani et al., 2000b) and our previous studies 
suggesting important sex differences in responses to inflammation (Villar et al., 
2011), the primary outcome measure was change in %FMD, with an expected 
difference between the sexes of 1.5% and a SD of 1.5 with a power of 80%. For this 
a total of 12 subjects are required in each group.  
 
For the cantharidin study, based upon previous observations demonstrating that 
cantharidin triggers a total cell response of 0.6 x106 cells/ml with an SD of 0.2  
(Evans et al., 2008) and in pre-clinical models where leucocyte recruitment was 
reduced by 50% in females (Villar et al., 2011),  with a power of 0.9 a total of 12 
individuals are required for each sex for statistical power.  However, due to the 
limited sample size available for all analyses we pre-specified an n=16 for each 
group to enable sufficient independent samples to assess soluble mediators. 
Where n values shown are less than 16 this is due to insufficient sample size for 
full analysis. 
 
Data are shown as mean  SD. Comparisons between the sexes have been made 
using unpaired t-tests or two way ANOVA as appropriate.  With respect to the 
latter post–hoc comparisons have been made if the F statistic achieved P<0.05 and 
there was no significant variance inhomogeneity between groups using Holm-
Sidak’s multiple comparison tests. For multivariate statistical analysis, orthogonal 
partial least squares-discriminant analysis (PLS-DA) (Janes and Yaffe, 2006) was 
performed using SIMCA 13.0.3 software (Umetrics, Umea, Sweden) following unit 
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variance scaling of LM amounts. PLS-DA is based on a linear multivariate model 
that identifies variables that contribute to class separation of observations (Blister 
exudates) on the basis of their variables (LM levels). During classification, 
observations were projected onto their respective class model (Males vs Females). 
The score plot illustrates the systematic clusters among the observations (closer 
plots presenting higher similarity in the data matrix). Loading plot interpretation 
identified the variables with the best discriminatory power (Variable Importance 
in Projection close or greater than 1) that were associated with Males (Blue) or 
Females (Green) and contributed to the tight clusters observed in the Score plot.  
 
Analysis was performed using GraphPad™ Prism software version 5.0 for Mac OsX 
and SPSS version 19, (SPSS Inc, Chicago, Ill). Power calculations were performed 
using Graphpad statmate (Graphpad Software) and are represented in the 
experimental protocols in each chapter. 
 
2.1.16 Trial approval and registration 
The studies were peer-reviewed by the institutional review board and were 
granted full ethics approval by NRES Committee London - City Road & Hampstead 
(11/LO/2038). Informed, written consent was taken after satisfying the inclusion 
criteria. The studies have been registered on ClinicalTrials.gov NCT01582321. 
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2.2 Stable Angina Patient Methods 
2.2.1 NITRATE-OCT Clinical Trial 
NITRATE-OCT is a randomised, double-blind, placebo-controlled study 
investigating the effects of inorganic NO3- on vascular function, platelet reactivity 
and restenosis in stable angina. 
 
2.2.1.1 Study Protocol 
The full protocol was submitted for ethical approval to the National Research 
Ethics Service London – City Road and Hampstead (Reference: 15/LO/0555) for 
ethical human research and sponsored by Queen Mary University of London 
Research and Development (R&D) department. The trial was conducted according 
to Barts Health NHS Trust and Queen Mary University of London R&D guidelines 
and performed in agreement with the Declaration of Helsinki. Any serious adverse 
event or reaction during the course of the study was reported to the R&D 
department as per adverse event guidelines. The study was registered with the 
following public registries: United Kingdom Clinical Research Network (UKCRN) 
(Study ID 20060), http://clinicaltrials.gov (NCT02529189) and International 
Standard Randomised Controlled Trials Number (ISRCTN):17373946.  
 
2.2.1.2 Patient selection 
Commencing November 2015, we commenced a randomised double-blind 
placebo-controlled trial of stable angina patients referred to a single tertiary 
cardiac centre for PCI (Figure 2.1). We obtained written informed consent from 
all study patients. This is a single-centre trial and patients have been recruited at 
Barts Health NHS Trust within the Barts and The London Heart Attack Centre, 
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based at The Barts Heart Centre, St. Bartholomew’s Hospital.  In addition, we have 
been identifying patients from King George Hospital which is part of Barking, 
Havering and Redbridge NHS Trust.   
 
2.2.1.3 Inclusion Criteria  
Patients were included in the study if they met the following inclusion criteria 
1. Patients with stable angina diagnosed by a cardiologist on optimal medical 
therapy undergoing angioplasty to treat residual symptoms. 
2. Aged 18-85  
3. Patients able and willing to give their written informed consent. 
4. Patients undergoing successful PCI procedure. 
 
2.2.1.4 Exclusion Criteria 
Patients were excluded if they had any of the following exclusion criteria.  
1. Unstable ischaemic heart disease, with an episode of chest pain in less than 
24 hours before inclusion into the study.  
2. Patients who have had previous coronary artery bypass surgery (CABG), if 
they are undergoing angioplasty within a non-native vessel.  
3. Patients undergoing angioplasty with a bio-absorbable stent since the 
stents will likely start dissolving prior to 6 months and therefore this would 
confound measures of restenosis. 
4. Current diagnosis of, or treatment for, malignancy other than non-
melanoma skin cancer. 
5. Current life-threatening condition other than vascular disease that may 
prevent a subject completing the study. 
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6. Use of an investigational device or investigational drug within 30 days or 5 
half-lives (whichever is the longer) preceding the first dose of study 
medication. 
7. Patients considered unsuitable to participate by the research team (e.g. due 
to medical reasons, laboratory abnormalities, or subject’s unwillingness to 
comply with all study related procedures). 
8. Severe acute infection, or significant trauma (burns, fractures). 
9. Pregnancy tested by urine HcG measurement 
10. History of alcohol or drug abuse within the past 6 months. 
11. A history of heart failure NYHA class 3-4 or severe LV dysfunction 
LVEF<30% regardless of symptom status. 
12. Systemic autoimmune disease such as rheumatoid arthritis, connective 
tissue disease, or other conditions known to be associated with chronic 
inflammation such as inflammatory bowel disease.   
13. Patients who have donated > 500 ml blood within 56 days prior to study 
medication administration.  
14. Anaemia with Hb <10g/dl, or any other known blood disorder or 
significant illness that may affect platelet function, and coagulation.  
15. A history of chronic viral hepatitis (including presence of hepatitis B 
surface antigen or hepatitis C antibody or other chronic hepatic disorder) 
or HIV. 
16. Abnormal liver function due to acute or chronic liver conditions 3 x upper 
limit of normal at screening. 
17. Renal impairment with creatinine clearance (eGFR) of 35ml/min at 
screening. 
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18. If patients are on mouthwash, they must be willing to stop using this at least 
1 week before the start of the study and throughout the duration that they 
are involved in the study. 
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Figure 2.2: Summary of NITRATE-OCT Study Scheme. hsCRP: high sensitivity C-Reactive 
Protein, IL-6: Interlukin 6, MACE: Major Adverse Cardiac Events, OCT: Optical Coherence 
Tomography, TVR: Target Vessel Revascularisation, XOR: Xanthine Oxidoreductase 
Patients with stable angina identified 
Consent for study 
Randomisation 
Intervention: 70 ml of beetroot juice 
concentrate (containing 4-5 mmol 
nitrate) from one day prior to PCI up 
to 6 months  
 
Control: 70 ml of nitrate deplete 
placebo juice concentrate from 
one day prior to PCI up to 6 
months 
 
Secondary end point at 6 months: Flow-mediated dilatation at 6 months post PCI.  Markers of inflammation: 
plasma and erythrocyte nitrite reductase and XO activity, hsCRP and IL-6.  Platelet activation (P-Selectin and 
platelet-monocyte aggregates) and aggregation ex vivo (ADP, collagen, arachidonic acid). Reduction in TVR and 
MACE. 
 
Primary end point: Assessment of in-
stent late loss using angiogram and 
OCT at 6 months ± 1 month 
 
Baseline measurements: Flow-mediated dilatation.  Markers of inflammation: plasma and erythrocyte nitrite 
reductase and XO activity, hsCRP and IL-6. Platelet activation (P-Selectin and platelet-monocyte aggregates) and 
aggregation ex vivo (ADP, collagen, arachidonic acid) measured. 
 
Secondary end point at 12 months: Markers of inflammation: plasma and erythrocyte nitrite reductase and XO 
activity, hsCRP and IL-6.  Platelet activation (P-Selectin and platelet-monocyte aggregates) and aggregation ex 
vivo (ADP, collagen, arachidonic acid). Reduction in TVR and MACE. 
 
Secondary end point at 24 months: Reduction in TVR and MACE. 
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2.2.1.5 Procedures 
Potentially eligible patients were identified, screened and approached from pre-
assessment clinic at St. Bartholomew’s Hospital. Entry in to the trial was not 
confirmed until they had fulfilled the pre-specified inclusion criteria and did not 
meet any excluding criteria, as detailed in section 2.2.1.4.  
 
2.2.1.6 Study Design and Intervention 
This is a prospective double-blind, placebo controlled, clinical study. A total of 246 
patients (male and female, age 18-85) with stable angina as per requirements 
indicated above have been recruited. Figure 2.2 shows a summary of the study 
scheme. Since patients who are diabetics are at high risk of developing restenosis, 
these patients have also been included in the study with stratification in both 
groups. Patients have been stratified according to the type of stent (i.e. bare metal 
stent or drug eluting stent) as both these groups have differing characteristics 
resulting in differing rates of restenosis. Follow-up has taken place in the Clinical 
Trials Unit, William Harvey Heart Centre. Since patients have had other co-
morbidities (including hypertension, hypercholesterolemia, previous PCI etc.) 
these have also been recorded. Patients have been block randomised (using an on-
line randomisation database) to receive 70 ml of a beetroot juice concentrate 
containing ~5 mmol NO3- or NO3--depleted placebo juice concentrate (James 
White Drinks, UK) control. The volunteers have commenced taking their daily 
dose at home the day before the scheduled angioplasty and continued this daily 
for 6 months. Patients have been advised to take their dose of juice at the same 
time each day, preferably in the morning with their breakfast. Patients have also 
been provided with dietary advice in relation to the calorific content of the juice:  
147 
 
a daily dose of 70 ml of the juice concentrate (approximately 70 g) contains about 
100 kcal.  
 
On the day of index procedure, patients have been treated as per Barts Health 
Trust protocols. Here the patient arrives to the day case ward in the morning of 
the procedure and the senior interventional trainee registrar and consultant 
cardiologist have performed the coronary angiogram. At the time of the 
procedure, the operator has determined the route of access (either via the radial 
artery or femoral artery) and the consultant cardiologist has determined the size 
(diameter and length) and type of stent (DES or BMS) to be inserted. Following the 
procedure, the patient was transferred back to the day case ward and discharged 
by either the nurse in charge or the cardiology registrar depending on the 
complexity of the procedure. Patients have been followed-up according to the 
clinical plan suggested by the consultant cardiologist at the time of the procedure. 
 
2.2.1.7 Randomisation and Blinding Process 
Patients have been block randomised on a 1:1 basis to receive either dietary NO3- 
or placebo, using a binary random number sequence (www.random.org).  
Treatment assignment for volunteers in both the dietary NO3- and placebo groups 
has remained blinded until data lock and statistical analysis at the end of the study. 
If at any point un-blinding is required, the Chief Investigator for the study will be 
informed. A list of the un-blinded treatments is kept in a secure location at the The 
William Harvey Heart Centre. The un-blinding procedure is available at all times 
(24 hrs day/7 days a week).  
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2.2.1.8 Study Endpoints 
2.2.1.8.1 Primary Endpoint:   
The primary endpoint is reduction of in-stent late loss assessed by angiography 
(quantitative coronary angiography – QCA) at 6 ± 1 month. Assessment of 
restenosis is being made by measurement of in-stent late-loss assessed by 
angiography (using QCA) and OCT at 6 ± 1 month. 
 
2.2.1.8.2 Secondary Endpoints:  
(i) Improvement in endothelial function assessed by FMD of the brachial 
artery at 6 months compared to pre-procedure assessment. 
(ii) Reduction in target vessel revascularisation (TVR), restenosis rate 
(diameter >50%) and in-segment late loss at 6 ± 1 month. 
(iii) Reduction in major adverse cardiac events (i.e. MI, death,) at 6, 12 and 24 
months in addition to CVA and TVR. 
(iv) Reduction in plaque size as assessed using OCT at 6 ± 1 month. 
(v) Reduction in inflammatory markers and changes in plasma XOR activity, 
hsCRP, IL-6 at 6 and 12 months.  
(vi) Reduction in platelet aggregation ex vivo at 6 and 12 months compared to 
pre-procedure. 
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2.2.2.3 Index angiogram 
2.2.2.3.1 Percutaneous Coronary Intervention 
Angiography has been performed at baseline prior to stent placement and after 
stent placement prior to completion of the index PCI procedure. Either the radial 
or femoral vascular access has been used for the procedure. The baseline 
angiograms of the involved vessel have been performed in at least two near 
orthogonal views. Visual angiographic assessment has been used to determine if 
the lesion meets angiographic entry criteria. Further information collated from the 
index coronary angiography procedure has been collected, comprising of date of 
the angiogram, vessel dominance, number and location of diseased vessels, 
location, presence and severity of lesions for all 14 segments of the coronary tree 
and any complications. The PCI procedure has been completed according to 
normal practice by the operator.  
 
2.2.2.3.2 Index PCI 
Procedural information for the index PCI has included the date of the PCI, which 
coronary vessels and segments were treated, diameter, length and type of stent 
implanted, the procedural success for each segment, the adjunctive 
pharmacological therapy and any complications and information on lesions not 
treated have also been recorded. 
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2.2.2.4 Repeat coronary angiography with OCT assessment of vessel treated 
PCI 
Repeat angiography with OCT has occurred at 6 ± 1 month after the index PCI.  
Either radial or femoral access sites have been used and angiograms of the 
involved vessel has been performed in at least 2 near orthogonal views. 
Quantitative angiographic assessment of the involved vessel will be undertaken to 
determine late loss. In addition, the same angiographic images have been recorded 
as those obtained post-stent implantation at the time of the index procedure. 
 
2.2.2.5 Quantitative Coronary Angiography (QCA) 
Quantitative analysis will be performed using a Coronary Angiography Analysis 
System (Medis Inc., The Netherlands). There will be automated detection of the 
boundaries of a selected coronary vessel segment using digitised and optically 
magnified sections of the cine frame. If a wrong centreline is chosen because of 
large daughter branches, then correction is possible manually. The vessel 
diameter will be calculated in absolute values (mm). This will be done using the 
boundaries of a section of the contrast catheter and comparing the computed 
mean catheter diameter in pixels with the known catheter size in mm. To detect 
the contours of the vessel, the user will indicate the vessel by choosing two centre 
positions proximal and distal to the area of interest. QCA will be analysed in a 
blinded fashion by two experienced and independent cardiologists and 
adjudicated by a senior cardiologist if there are any discrepancies in the analysis 
(of >5%). For the analysis, the same Cine images of pre- and post-stent will be used 
as well as the same image at 6 months depicting the same part of the coronary 
artery in all three cases. QCA will be carried out in the same segment of the 
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coronary artery which contains part of the vessel free of disease before and after 
the stent and the whole stent itself. This will be done at baseline (pre- and post-
stent) and at 6 months. 
 
2.2.2.5.1 Calibration 
Initially, the tip of the catheter, whose diameter in French or millimetres is known, 
will be used as the basic tool for calibration (i.e., to estimate the proportion 
between pixels in the digitalised images and mm of length). Then, a central line 
will be drawn by hand along the stretch of the catheter tip and the software will 
automatically recognise its margins by using specific algorithms that, by means of 
digital images, recognise the change from radiopaque pixels (black or dark grey) 
to radio-transparent pixels (light grey or white) according to a densitometric 
analysis. The software will then transform every pixel into a square with sides 
characterised by known dimensions (mm). (Figure 2.3). 
 
Figure 2.3: Angiogram image of the Image calibration using contrast-filled injection 
catheter. 
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2.2.2.5.2  Arterial automatic contour detection 
The above parameter will be then employed to measure the coronary segment of 
interest that is focused on the stenosis or lesion undergoing treatment. The 
proximal and distal coronary segments will be relatively free of disease and are 
referred to as reference segments. Afterwards, a central line will be traced 
manually and the software will automatically recognise the margins of the 
coronary segment under consideration taking advantage of the automatic contour 
detection. This procedure will determine the vessel edge based on the weighted 
sum of the first and second derivative functions of the brightness values of 
scanlines perpendicular to the center-line, which in turn undergoes an analysis 
that determines the optimal contour path along the segment (Figure 2.4). 
 
Figure 2.4: Angiogram demonstrating that after having traced a central line, the software 
recognises the margins elaborating automatically the contours. 
 
A further step allows, always automatically, the reconstruction of the 
hypothetically normal coronary lumen. An algorithm then creates a line of the 
coronary margin that interpolates the coronary segment considered free from 
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illness located proximally and distally to the region of interest with the ones of the 
region of interest. The algorithm then reconstructs the reference coronary 
segments (i.e., those apparently free from disease) (Figure 2.5). 
 
 
Figure 2.5: Angiogram showing that software algorithm reconstructs the reference 
coronary segment. 
 
This technique is essentially based on the calculation of a mean value of the 
diameters of the lumen in the segments of reference located upstream and 
downstream to the lesion. It appears thus clear the importance of including two 
coronary segments in the QCA analysis, one proximal and one distal to the target 
segment and both angiographically-free from significant disease. These steps 
produce different parameters, some measured directly and others derived with 
interpolation techniques. 
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2.2.2.5.3 Parameters 
All angiographic measurements of the target lesion will be obtained in the “in-
stent” zone, within 5 mm proximal and distal to each stent edge, and over the 
entire segment (“in-segment” zone). The following QCA parameters will be 
calculated: reference vessel diameter, minimal lumen diameter, percent diameter 
stenosis (difference between the reference vessel diameter and minimal lumen 
diameter/reference vessel diameter x 100) and late lumen loss (difference 
between the post-procedure and follow-up minimal lumen diameter). Binary 
restenosis will be defined as stenosis of 50 percent or greater in the target lesion 
or segment at the 6-month angiographic follow-up. The coronary parameters of 
major interest are summarised in Table 2.1. 
 
2.2.2.6 Optical coherence tomography (OCT) 
OCT imaging of the previously stented segment was undertaken with motorised 
pull-back at 1 mm/s in all patients at 6 ± 1 month after index PCI using an OPTIS 
TM system (St-Jude Medical, Westford, MA, USA). OCT images have been acquired 
at 180 frames per second (500 angular pixels x 250 radial pixels), from a 0.15mm 
micro-optic core, 0.36 mm image wire, displayed with an inverse gray-scale 
lookup table, and digitally archived.  
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Parameter 
 
Range 
commonly 
used 
Meaning 
 
Minimal Luminal Diameter 
(MLD) 
0–6.00 mm The smallest lumen diameter in the 
segment of interest 
Reference Vessel Diameter 
(RVD) 
1.5–6.0 mm The averaged diameter of the coronary 
assumed without atherosclerotic disease 
Lesion length 0–60.0 mm Length of the stenosis as measured by 2 
points where the coronary margins 
change direction, creating a shoulder 
between the angiographically normal 
subsegment and the diseased 
subsegment 
Acute gain 0–4.0 mm Post-procedural MLD – pre-procedural 
MLD 
Late loss (LL) 0.10 to 3.00 Post-procedural MLD – MLD at follow-
up 
Diameter stenosis (DS) 0–100% (RVD-MLD)/RVD 
Binary restenosis (BR) Yes or no DS >50% at follow-up coronary 
angiography in the treated coronary 
segment 
 
Table 2.1. Main parameters obtained with QCA (adapted from Garrone, P.; Biondi-Zoccai, G. & 
Salvetti, I. (2009). Quantitative coronary angiography in the current era: principles and 
applications. J Interv Cardiol 22:527-536.) (Garrone et al., 2009). 
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2.2.2.6.1 Segmentation of optical coherence tomographic data 
OCT imaging analysis will be performed offline using proprietary software (QCM-
CMS Leiden University Medical Center, Leiden, The Netherlands). The stented 
segments will be identified and the OCT frames in these segments will be analysed 
at 0.4 mm interval by two independent analysts blinded to stent type and patient 
characteristics. The lumen and the stent border will be detected, and the 
neointima will be defined as the tissue between the lumen and the endoluminal 
border of the struts. Neointima burden will be defined as 100 x neointima area vs. 
stent area. Neoatherosclerosis will be defined as either neointima and with a lipid 
or a calcific tissue (Tearney et al., 2012). The border of the fibrous cap over lipid 
tissue will be segmented using semi-automated software (QCM-CMS) and the 
minimum and mean cap thickness will be calculated (Radu et al., 2016). The 
borders of the lipid and calcific tissue will be detected and the lipid area, the lipid 
arc, and the calcific area will be estimated. The lipid/calcific burden will be defined 
as: 100 x lipid/calcific area vs. neointima area. Thin-cap fibroatheroma (TCFA) 
will be defined as lipid tissue with a fibrous cap thickness ≤ 65 µm while this with 
a cap thickness > 65 µm will be characterised as fibroatheroma. 
 
Neoatherosclerotic lesions will be defined as calcific tissue, TCFA, or 
fibroatheroma in the neointima. A gap of at least 0.5 mm will be used to define the 
boundary between two neoatherosclerotic lesions. In addition, the two observers 
will identify the presence of macrophages, neo-vessels, cholesterol crystals, 
thrombus and neointima discontinuities (i.e. flaps, cavities, double lumen and 
fissures) (Bourantas et al., 2015). 
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2.2.2.6.2 Attenuation and backscatter analysis 
In each OCT cross-section the attenuation and backscatter indices will be 
estimated for the neointima tissue using established methodologies, by a module 
developed by the Leiden University Medical Center (Leiden, The Netherlands) 
(Schmitt et al., 1993; Vermeer et al., 2013). In contrast to previous reports, the 
analysis will be performed in the entire circumference of the neointima (Yonetsu 
et al., 2012). In order to exclude the strut effect in each cross section, the stent 
border will be moved 100 µm inwards to the original border and the region of 
interest will be defined by this curve and the lumen border. The guidewire artefact 
will be also removed and then the 95 percentile values will be estimated for each 
frame. The output of this analysis will be colour coded displayed in each cross 
section and in spread-out stent plots. Frames portraying lipid-rich neointima are 
anticipated to have a higher attenuation and backscatter indices in the inner 
border of the lipid tissue and lower indices in the lipid tissue resulting in low mean 
attenuation values. Therefore the 95 percentile attenuation and backscatter 
values will be used to identify degenerative changes in the neointima. We will 
compare the 95 percentile attenuation and backscatter values: 1) between 
difference stent types and 2) between sub-segments with neoatherosclerosis, sub-
segments located adjacent (2 mm), and sub-segments located distally (> 2 mm) to 
neoatherosclerotic lesions. Only frames with attenuation/backscatter values for 
an arc >1800 of the circumference of the neointima will be included in the analysis. 
frames with poor flushing and thrombus will be also excluded.  
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Finally, OCT imaging have not be used for clinical decision making regarding need 
for a repeat revascularisation procedure. All repeat revascularisation decisions 
have been based upon a recurrence of clinic symptoms and/or non-invasive 
imaging evidence of myocardial ischaemia and made by the treating physician. 
 
2.2.2.7 Planned recruitment and power calculations 
2.2.2.7.1 Statistical Analysis 
2.2.2.7.1.1 Sample Size 
In order to achieve an 80% probability that the study will detect a treatment 
difference at a two sided 5% significance level, if the true difference in late loss 
between the treatments is 0.22 mm, sample size calculations determined that a 
total of 246 patients will be required to enter a two treatment parallel design 
study. This absolute difference is calculated from a mean late loss of 1.27mm with 
a standard deviation of the response variable of 0.550. These values being the 
mean and average of the standard deviations of 22 trials measuring late loss in 
both drug eluting and bare metal stents described in the review by Mauri et al 
(Mauri et al., 2005). Recruitment also takes into account an additional 10% to 
account for drop-out or withdrawal/non-compliance. This value is based upon 
previous experience in our unit.     
 
The sample size of 246 enables sufficient power for estimation of the hard 
endpoint of MACE at 6 months. Very recently, in stable angina patients who have 
undergone elective angioplasty a remote ischaemic preconditioning intervention 
resulted in a significant reduction in MACE at 6 months with 4/110 (3.6%) in the 
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treatment group versus 13/104 (12.5%) in the control group (Davies et al., 2013). 
Using these data as a basis for power calculations, a total number of 230 patients 
are needed for 80% power using one-tailed analysis. Thus, to account for potential 
loss to follow-up we will recruit 246 patients in total. 
 
Power calculations for FMD suggest that the above numbers provide sufficient 
power for detecting differences in FMD (n=60). To calculate power we used data 
provided  in dietary studies including one demonstrating improvements in FMD 
following six weeks of artichoke juice (Lupattelli et al., 2004) a further chronic 
study with walnuts (Katz et al.) and one meta-analysis (Kay et al.) assessing the 
effects of chronic polyphenol dietary interventions published in 2012. Calculating 
an averaged improvement of FMD of 1.1% with no change in the control and an 
averaged SD of 1.45  (determined from the average of the above studies) a total of 
30 volunteers would be needed in each group requiring a total of 60 volunteers. 
Using our own data with dietary NO3- in patients with hypercholesterolemia 
increases of FMD of 1% with a SD of 1.5% (Velmurugan et al., 2016) a total of 74 
patients are needed for sufficient power. If we assume a potential 10% drop-out 
rate a total of 80 patients are required. 
 
All statistical analysis will be conducted by the trial statisticians supported by the 
Imperial Clinical trials unit (CTU). Data will be analysed on an intention-to-treat 
basis.  We will also conduct further per protocol analyses and a subgroup analysis 
on patients who are on organic NO3- as part of their routine therapy, patients on 
statin therapy and a comparison of DES versus BMS by incorporating these 
variables in a cox regression analysis model. 
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Baseline demographic and clinical variables were summarised for each arm of the 
study. Descriptive summaries of the distributions of continuous baseline variables 
are presented in terms of percentiles (e.g. median, 25th and 75th percentile), while 
discrete variables are summarised in terms of frequencies and percentages. 
Comparisons are between the nitrate- treated and placebo control-treated group 
for the primary and secondary outcomes. Statistical analyses were conducted 
blind to the treatment groups. The statistical comparisons of the treatment arms 
with respect to the primary endpoint was performed using an unpaired T-test. For 
comparisons between normally distributed data statistical comparisons were 
performed using unpaired T-test, for parametric data either the Mann-Whitney or 
Wilcoxon rank sum tests were used.    
 
For comparisons between treatment groups assessing platelet reactivity data are 
expressed as mean ± SEM and analysis was performed using two-way repeated 
measures ANOVA.  
 
2.2.2.7.1.2 Project timetables including recruitment rate  
The duration of the study will be 36 months. Approximately 2000 elective 
angioplasties are performed over 12 months, equal to 19 per week. If 
approximately half of these are elective stable angina patients and about half of 
these are suitable for the study, we would expect a recruitment rate of 2 per week, 
to achieve 100 patients in approximately 12 months (Figure 2.6). 
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Figure 2.6. Graph showing the projected recruitment for NITRATE-OCT Study 
 
2.2.2.8 Ethical Considerations 
The study protocol and any subsequent amendments, along with any 
accompanying material provided to the patient, in addition to any advertising 
material, was submitted by the Investigator to an Independent Research Ethics 
Committee. Written Approval from the Committee was obtained and subsequently 
submitted to the sponsor to obtain Final Sponsorship approval and NHS 
permissions. 
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2.2.2.9 Safety considerations 
The intervention is 70 ml of a beetroot juice concentrate or NO3- free placebo juice 
(James White Drinks, UK). The NO3- is extracted using the same extraction 
technique used to remove inorganic NO3- from the general drinking water 
supplies. There are no known harmful side effects from these interventions and 
this NO3--free juice is not considered to be a drug or medicine and is classified as 
a foodstuff. In addition, several recent publications using the placebo juice are now 
available (Gilchrist et al., 2013; Gilchrist et al., 2014; Lansley et al., 2011).  In the 
unlikely event of an adverse event occurring directly as a result of the 
intervention, the trial would be stopped. 
 
2.2.2.10 Safety reporting  
An adverse event (AE) if not defined as serious, will be documented in the 
participants’ medical notes (where appropriate) and the CRF and followed up by 
the research team. Any serious adverse events (SAE) that occur will be reported 
to the Sponsor and main REC where in the opinion of the Chief Investigator the 
event was either ‘related’ (that is, it resulted from administration of any of the 
research procedures) and ‘unexpected’ (that is, the type of event is not listed in 
the protocol as an expected occurrence). 
 
SAEs that are considered to be ‘related’ and ‘unexpected’ will be recorded in the 
participants’ notes, the CRF, the sponsor SAE form and reported to the Research 
Office of the Trust within 24 hours of research staff being notified, and to the Main 
REC within 15 days.  The co-investigators in this study will be authorised to sign 
the SAE forms in the absence of the Principal Investigator. Since this study will be 
163 
 
blinded, the treatment code for the patient will be broken in the reporting of an 
‘unexpected and related’ SAE.  This will be performed by an individual who is 
independent of the study and will allow the rest of the research team to remain 
blinded.  The unblinding of single cases by the Principal Investigator in the course 
of this study will only be performed if necessary for the safety of the trial subject. 
 
2.2.2.11 Monitoring 
2.2.2.11.1 Trial Steering Committee (TSC) 
The TSC is composed of three independent experts in the fields of: pharmacology, 
interventional cardiology and clinical trials along with the investigators and the 
data monitor and medical statistician and 1 lay member. This committee has met 
before patient recruitment and will meet annually to assess safety, feasibility or 
any other arising problems (e.g. with recruitment) and their recommendations 
will be followed. 
 
2.2.2.11.2 Data Safety and Monitoring Board (DSMB) 
An independent DSMB has been formed to monitor patient safety as the study 
progresses. The DSMB has been selected by and communicates directly to the 
study's TSC. The committee includes a consultant cardiologist, an interventional 
cardiologist and a statistician. The DSMB met prior to initiation of the clinical 
study, after the recruitment of 10 patients and will meet at 3 monthly intervals. 
The DSMB will have access to unblinded patient data. If a serious concern with the 
safety of the patients in the trial arises, the DSMB may recommend early 
termination of the study.  
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2.2.2.12 Follow up 
After 2 years, the participant will be contacted by telephone for assessment of 
major adverse cardiac events (MACE). The whole duration of the study will be 2 
years. Participants have no obligation to complete the whole study and if they 
decide to withdraw at any point then they are free to do so. 
 
2.2.2.13 End of Study Definition  
The study will end after 2 years after the telephone follow-up of the last patients.  
At this time all the samples will be analysed. 
 
2.3 Biochemical Measurements 
2.3.1 Blood sampling 
Blood was collected into EDTA tubes for differential count analysis conducted by 
St Bartholomew’s Hospital Haematology Department. A further 4 ml of blood was 
collected in 1.8 mg ethylenediaminetetraacetic (EDTA) per ml of blood for NOx 
measurement, and another 4 ml in 3.2% buffered trisodium sodium citrate for 
aggregation assays and platelet flow cytometry. All blood was collected into 
vacutainers (BD Biosciences) through a 21-gauge butterfly needle inserted into an 
antecubital vein. For measurement of NOx levels, blood samples were centrifuged 
immediately (1300g, 4 °C, 10 min) and the supernatant was collected and stored 
at -80 °C pending analysis by ozone chemiluminescence as previously described 
(Ignarro et al., 1993a; Kapil V, 2015). Specific blood sample preparation for each 
protocol is described later in association with the technique used to analyse the 
relevant samples. With regards to the NITRATE-OCT study, the blood sampling 
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was performed on visit two, where patients had one blood test before starting the 
treatment or placebo juice.  They then had a further blood test at visit three (6 
months – prior to angiogram and OCT) and visit five (12 months).  Blood samples 
were centrifuged immediately for platelet reactivity experiments and plasma and 
red blood cell storage only for the purposes of making biochemical measurements 
(e.g. NO3-/ NO2-/cGMP) and were discarded once used. 
 
2.3.2 Urine and saliva samples 
Mid-stream urine samples were collected into sterile pots and an aliquot stored at 
–80 oC pending measurement of NOx levels at a later date. Unstimulated saliva was 
collected into sterile eppendorfs and centrifuged (14000g, 4 oC, 10 min) and the 
supernatant was transferred to a separate eppendorf and stored at -80oC pending 
measurement of NOx levels at a later date. The pellet generated from the 
centrifuged saliva oral bacteria that have dislodged from the oral cavity.  This 
pellet has been frozen for identification and analysis of the oral microbiota by 
second generation genome sequencing will be performed at a later date. With 
regards to the NITRATE-OCT study, the urine and saliva samples were taken on 
visit two, where patients had these taken before starting the treatment or placebo 
juice.  They then had a further urine and saliva sample taken at visit three (6 
months – prior to angiogram and OCT) and visit five (12 months).   
 
2.3.3 Blood pressure measurement 
Blood pressure was measured at baseline to confirm healthy volunteer status. An 
Omron 705IT was used for all BP measurements while participants were seated 
and readings were performed in triplicate according to established guidelines 
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(Williams et al., 2004). Laminated coverings were used for the machine and the 
printer so that both investigators and participants were blinded to the readings. 
The means of the 2nd and 3rd readings were used to calculate the final BP 
measurement. 
 
2.3.4 PWV and PWA measurements 
A Vicorder device (Skidmore Medical Limited, Bristol, UK) was used to 
simultaneously record the pulse wave from the carotid and femoral site using an 
oscillometric method. All arterial stiffness measurements were performed with 
the patient rested for 10 min in a supine position with their head at a 30 ° incline 
and awake. A small, inflatable neck pad is placed directly over a single carotid 
artery and secured around the neck by a Velcro tab. A cuff is placed around the 
subject’s ipsilateral upper thigh. Both carotid and femoral cuffs are inflated 
automatically to 65 mmHg and the corresponding oscillometric signal from each 
cuff is digitally analysed to extract the pulse time delay. The distance between the 
sternal notch and the thigh cuff is measured and used as a standard estimate for 
the aortic length. From these measurements aortic PWV can be derived as 
PWV=aortic distance/pulse time delay (Hickson et al., 2009). (Figure 2.7). 
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Figure 2.7. Schematic showing the determination of PWV using Vicorder device. Carotid and 
femoral oscillometric signals are detected and the time delay from the foot of carotid pulse 
waveform to foot of femoral pulse waveform is used as the pulse transit delay (t). Estimation of 
aortic length by sternal-femoral distance is used as distance (d). Aortic distance/pulse transit delay 
= aortic PWV. (PWV = pulse wave velocity). Adapted from Boutouyrie (Boutouyrie, 2008). 
 
Pulse wave analysis (PWA): A mean brachial BP reading was obtained from 2 
readings made using an Omron 705IT and used for calibration of peripheral 
waveforms.  After 5 min supine rest, a 100 mm inflatable cuff was attached to the 
Carotid pulse waveform 
Femoral pulse waveform 
= oscilometric cuff 
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non-dominant arm and statically inflated to 65 mmHg. Brachial artery waveforms 
were digitally computed by Vicorder (Skidmore Medical Limited, Bristol, UK). The 
vicorder software subsequently applied a brachial to aortic transfer function to 
calculate the waveform and values for central BP as previously described 
(O'Rourke, 1970). The Augmentation index (AIx) which is the difference in 
amplitude between the first and second systolic peak/pulse pressure x 100) was 
calculated automatically from the first and second central systolic peaks which 
were automatically defined by the software (Figure 2.8).   
 
 
 
 
 
 
 
 
 
Figure 2.8. Schematic showing the definition of AIx. (A) Aortic pressure pulse wave. (B) 
Peripheral arterial pressure wave. AIx=augmentation index; AP=augmentation pressure; PP=pulse 
pressure; P1 represents the amplitude of the early systolic peak; P2 represents the amplitude of 
the late systolic peak adapted from (Shimizu and Kario, 2008). 
 
2.3.5 Measurement of brachial artery diameter 
Non-invasive ultrasound assessment of endothelial function of the brachial artery 
in subjects has been determined by measurement of FMD.  FMD is a non-invasive 
AP 
PP 
AIx (%) = AP / PP 
P1 
P2 
AIx (%) = P1 / P2 
(A) (B) 
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method of assessing endothelial function in vivo. It utilises vascular ultrasound to 
measure the increase in the diameter of the brachial artery in response to 
increased flow (Celermajer et al., 1992) and has been conducted according to 
published guidelines (Corretti et al., 2002). FMD can be affected by a number of 
factors including temperature, food, drugs, and sympathetic stimuli. Therefore, it 
was essential that the conditions for each study were identical on each occasion 
for each participant. Thus, studies were performed in a quiet, dimly-lit, and 
temperature controlled room (22-24 °C). Participant skin temperature was 
measured by using a temperature probe placed between the thumb and forefinger 
and a temperature of 30°C was required prior to performing the measurements. If 
a temperature less than 30°C was recorded, the hand was warmed using a heated 
microwave wheat pack. 
 
2.1.8.1 Image acquisition 
The participant would lay on a bed in a supine position with their right arm placed 
comfortably in a foam protected arm rest, to image the brachial artery. Figure 2.9 
depicts the FMD setup used during the study. A 7 cm-wide BP cuff was placed ~1 
cm below the antecubital fossa around the forearm (one thumbs-width from the 
medial epicondyle.) 
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Figure 2.9. Photograph of FMD being performed on a volunteer. A) The volunteer was asked 
to lie supine. A longitudinal section of the brachial artery was obtained and FMD was determined 
after cuff deflation. B) Image showing the Doppler ultrasound device used to obtain brachial artery 
image for FMD measurement. 
 
Brachial artery diameter in the right arm was measured with high-resolution 
external vascular ultrasound (Acuson 128XP/10 with a 7.0-MHz linear-array 
transducer). The vessel was scanned in longitudinal section, and the centre was 
identified when the clearest views of the anterior and posterior artery walls had 
been obtained. Images were magnified with a resolution box function and gated 
with the R wave of the ECG (Figure 2.10). End-diastolic images of the artery were 
acquired every 3 seconds with customized data-acquisition software and stored 
in digital format offline for later analysis (Mullen et al., 1997). Brachial artery 
diameter was measured continuously for 1 minute at baseline, during 5 minutes 
of reduced blood flow (induced by inflation to 300 mm Hg of a pneumatic cuff 
placed at a site distal to the segment of artery being analysed), and for a further 5 
A B 
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minutes during reactive hyperaemia after cuff release. Brachial artery diameter 
(over 1-2 cm section) and brachial artery dilation expressed as percentage and 
absolute increase from baseline diameter and time to peak dilatation were 
determined using automatic edge-detection software (Vascular Research Tools, 
Medical Imaging Applications LLC Iowa City, USA). Furthermore, for each scan, 5 
analyses along the vessel length were made and the mean calculated for each of 
the parameters described above (i.e. baseline diameter, time to peak dilatation, 
percentage increase and absolute increase in diameter) to give the FMD response 
as a percentage (i.e. calculation of the change from the baseline diameter and 
expressed as a percentage) and this mean value was used as an n=1 (Figure 2.11). 
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Figure 2.10: Ultrasound Image of the brachial artery obtained during FMD examination. A 
typical image is shown above. The vessel edges and lumen of the brachial artery are clearly seen. 
The measurement cursor is placed in the centre of the vessel which acts as a marker for adjustment 
of the image if there is any distortion of the image following inflammation or deflation of the cuff. 
The ECG allows synchronisation (gating) of the image with the R-wave of the cardiac cycle, 
providing elimination of any distortion of the images due to the pulsation of the artery during the 
study.  
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Figure 2.11: Screenshot of the Vascular Research Tools Medical Imaging Application 
Software for analysis of the FMD from the brachial artery. There is a graphical analysis of the 
image recording over time. The x-axis has the number of frames (each frame lasting 3 seconds) 
and the y-axis is brachial artery lumen diameter in measured in millimetres. Following inflation of 
the cuff after 1 minutes (i.e. frame 20) of the baseline recording, there was induction of ischaemia, 
which was released at 5 minutes (i.e. frame 120). A peak response in dilatation of the artery is seen 
following cuff deflation within one minute of cuff deflation (i.e. within frames 120-130). This 
represents the FMD response following reactive hyperaemia. 
 
2.3.6 Measurement of antibody titre 
Plasma samples taken at baseline and at 32h post typhoid were analysed for 
antibody titre using a commercially available kit (Typhoid Vi IgM ELISA kit; Alpha 
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Diagnostic International, USA) as per the manufacturer’s instructions. Briefly, this 
Typhoid Vi IgG/IgM antibody test kit is based on the principle of indirect ELISA. 
Typhoid Vi antigen is bound on the surface of the microtiter strips. 100 µL of 
diluted sample (1:20 with distilled water) and 100 µL of pre-diluted supplied 
calibrators standards were pipetted into the wells of the microtiter plate. The 
wells were gently mixed by tapping against the palm for 5-10 seconds. The plate 
was then covered with aluminium foil and incubated at room temperature (25-28 
oC) for 60 mins. The contents of the wells were then aspirated and the plate was 
blotted on absorbent paper. The wells were then washed immediately 3 times 
with 300 µL of 1 x wash buffer. 100 µl of diluted anti-IgM-HRP conjugate was 
added to all the wells leaving one empty for the substrate blank. The plate was 
then mixed gently for 5-10 seconds. The plate was then covered and incubated for 
30 minutes at room temp (25-28 oC). Vi IgG/IgM antibodies bind to the 
immobilised Vi antigen. The wells were then washed again with 300 µL of 1 x wash 
buffer. 100 µl the substrate (TMB) solution is added to all the wells (including the 
substrate blank on this occasion). The plate is then mixed gently for 5-10 seconds. 
The plate was then covered and incubated for 15 minutes at room temp (25-28 
0C). Blue colour developed in positive controls and samples. The reaction was 
stopped by adding 100 µL of stop solution to all wells. The plate was then mixed 
gently for 5-10 seconds to have uniform colour distribution (blue colour turns 
yellow). The absorbance was measured at 450 nm and a reference filter 630nm 
using an ELISA reader within 15 minutes. 
 
175 
 
2.3.7 Inflammatory cell flow cytometry 
2.3.7.1 Basic principles of flow cytometry 
Flow cytometry is an analytical technique that utilises light to quantify and analyse 
the properties of individual cells in a heterogeneous sample (Herzenberg and De 
Rosa, 2000). The use of fluorophore-conjugated antibodies, highly specific for cell 
surface antigens, enables the identification and characterisation of specific cell 
subpopulations in a sample (Herzenberg and De Rosa, 2000). Cells are suspended 
in fluid and travel in a single file through the flow chamber. When the laser beam 
hits each cell, light is scattered in different directions, and emitted, upon excitation 
of the fluorophore, at different wavelengths. Light scatter is recorded as forward 
scatter (FSC) and side scatter (SSC), to identify the size, and granularity and 
internal complexity of the cell, respectively. Light scatter and fluorescence 
intensities are recorded as voltages and displayed using histograms or 2D/3D dot 
plots.  
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Figure 2.12. Picture of the flow cytometry apparatus (Cancer Research Institute. Queen's 
University at Kingston, 2016). A flow cytometer is comprised of a hydrodynamic focusing 
system, a laser beam, filters, light detectors, and a data analysis system. Cells in suspension pass 
through the flow chamber in a single file stream formed as a result of hydrodynamic focusing. The 
laser beam hits each cell as it passes through the path of the laser, and the light scatter is detected 
as FSC and SSC, by light detectors. Fluorophore conjugated to antibodies are excited by the laser 
and emit light at different wavelengths, detected by photomultiplier tubes (PMT). Dichroic mirrors 
and filters placed in front of PMTs transmit a specific range of wavelength to the detectors. Signals 
are then sent to the computer enabling tabulation and analysis of cell characteristics in the sample.  
 
A fluorophore molecule absorbs light over a range of wavelengths, and emits light 
at different, longer wavelengths (emission spectrum). As fluorphores emit light 
over a range of wavelengths, this may result in spectral overlap when using 
multiple fluorophores in an experiment. Spillover fluorescence emitted by one 
fluorophore can be detected by another channel for a different fluorophore. 
Spectral overlap can be corrected by manual fluorescence compensation, which is 
FSC 
SSC 
Laser 
Bandpass filter 
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crucial for accurate data analysis. Controls, comprising of an unstained and single 
stained samples with each individual fluorophore conjugated antibodies, were 
used to manually compensate for any spillover occurring at a channel (Perfetto et 
al., 2004). Samples were acquired and recorded on the LSR Fortessa II Cell 
Analyzer (BD Biosciences, San Jose, CA, USA) using BD FACSDiva Software (BD 
Biosciences, San Jose, CA, USA).   
 
2.3.7.2 Measurement of circulating cell populations and their activation 
state 
The systemic inflammatory response pre and post intervention was assessed 
using Fluorophore conjugated monoclonal antibodies specific for leucocyte 
subpopulations, including neutrophils, monocytes and lymphocytes, and 
expression markers, CD11b, CD162 and CD62L, were used for FACS analysis 
(listed in Table 2.2).  
 
 2.3.7.3 Preparation of samples for flow cytometry 
18 FACS tubes were labelled in numerical order and placed on ice. The volume of 
conjugated antibodies pipetted into each labelled FACS tube are found in 
Appendix 4. 50μL of blood was immediately added to each FACS tube and 
incubated on ice for 30 minutes. The samples were covered with aluminium foil to 
avoid photo bleaching of the flourophore-conjugated antibodies.  
 
During incubation, the immunolyse for whole blood lysing (Beckman Coulter Inc.) 
was prepared in a 15mL Falcon tube. A 1:24 dilution of immunolyse solution was 
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prepared using the following calculation: 380μL of immunolyse + 9120μL of PBS 
(4560μL x 2).  
 
To remove excess antibody, 2000μL of phosphate buffered saline (PBS) solution 
was added to each FACS tube. Each tube was then centrifuged on 400g for 5 
minutes at 4°C, and the supernatant was decanted and discarded appropriately. 
The next step involved heamolysis, with 500μL of the prepared immunolyse added 
to each FACS tube. The tubes were then vortexed thoroughly on a low setting, two 
at a time, whilst being incubated for 2 minutes. Samples were then fixed using 
125μL of fixative solution, containing formaldehyde. Each tube was washed again 
using 2000μL of PBS and then centrifuged. The supernatant was decanted 
appropriately to preserve the pellet, and the wash step was repeated once more. 
Finally, the pellet was re-suspended in 300μL of PBS and left incubated on ice 
pending FACS analysis. 
 
All samples were then analysed using BD LSR Fortessa Cell Analyser (BD; flow 
cytometer) and recorded with BD FACSDiva 6.0 software. 
 
2.3.7.4. Flow cytometry and analysis 
The principles of flow cytometry were described in section 2.3.7.1 and the same 
principles apply to the analysis of the cell types and activation markers. Combined 
with FSC and SSC data used to identify cell types (Figure 2.5) the staining pattern 
of each leukocyte was used to calculate the relative percentage of cells expressing 
each inflammatory marker. In addition, in each case the respective median 
fluorescence intensity (MFI) was determined and provides a measure of the 
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number of markers present on each cell type.  To ensure that the fluorescence 
recorded was due to specific primary antibody binding to the desired marker, and 
not due to non specific binding (i.e. Fc receptors), isotype-matched control 
antibodies were used.  MFIs were recorded in absolute values  
 
As mentioned previously, overlapping of emission spectra between 
fluorochromes can occur therefore when using multiple fluorochromes, the 
emitted light from the leading and trailing tails from a neighbouring fluorochrome 
is registered. Since 7 different fluorochromes were used for cell type and 
activation marker analysis, spectral overlap had to be accounted for by manual 
compensation to allow accurate data analysis.  In order to manually compensate, 
single staining of samples with each antibody conjugated fluorochrome was 
recorded on the flow cytometer. 
 
Cell populations within a heterogeneous sample can be selected or ‘gated’ in order 
to observe the characteristics of each population. Gating is a graphical boundary 
that enables the removal of debris and isolation of cell subpopulations within a 
sample. The light scatter (FSS v SSS) dot plot, seen in Figure 2.13, highlights 
isolated leucocyte subpopulations including granulocytes, monocytes and 
lymphocytes. Specific subpopulations can also be ‘gated’ and further analysed 
(Figure 2.13b).  The quadrant boundaries between cells that stained positive and 
negative for a particular leukocyte population was determined according to the 
fluorescence distribution of positively stained cell relative to the unstained 
sample. 
 
180 
 
Figure 2.13. Dot plot illustrating the FSS/SSC and fluorescence intensity of leucocyte 
subpopulations derived from whole blood. A) A P1 gate is used to select all leucocytes in the 
sample, excluding cell debris represented by black dots. The FSC/SSC plot enables the 
differentiation of leucocyte subtypes, according to their forward and side scatter characteristics. 
Lymphocytes (green) and monocytes (purple) are small in size with reduced granularity/internal 
complexity, whereas, granulocytes (orange) are large with increased granularity/internal 
complexity. B) Fluorescent intensity dot plot highlighting monocyte subpopulations: resident 
monocytes (RM), intermediate monocytes (Inter) and inflammatory monocytes (IM). Quadrant 
boundaries are used to identify positive and negative populations. These boundaries are placed 
according to an unstained control.  
  
A 
Granulocytes 
Monocytes 
Lymphocytes 
B 
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Antibody Function of surface marker Cell types Fluorophore Source Dilution 
CD14 Pattern recognition receptor that binds 
to bacterial lipopolysaccharide (LPS), 
mediating an innate immune response. 
Monocytes FITC Beckton, 
Dickinson 
& company, 
New Jersey, 
USA 
20μL 
CD16 Low affinity Fc receptor known as 
FcγRIIIa (CD16a) and FcγRIIIb 
(CD16b). Receptor binds to Fc region of 
IgG antibodies and mediates antibody 
dependent cell mediated cytotoxicity. 
Monocytes, 
Natural killer 
cells 
PE Beckton, 
Dickinson 
& company, 
New Jersey, 
USA 
2 μL 
CD16b FcγRIIIB binds to the Fc region of IgG 
antibodies. 
Neutrophils PE Beckton, 
Dickinson 
& company, 
New Jersey, 
USA 
20μL 
CD3 T cell co-receptor. Associated with T-
cell receptor and ζ-chain to form TCR 
complex. 
Lymphocytes 
(T cell co-
receptor) 
FITC eBioscience 
Inc, San 
Diego, USA 
2.5μL 
CD4 Membrane glycoprotein co-receptor for 
TCR. Binds to MHC class II on the 
surface of antigen presenting cell, and 
initiates T cell activation and 
differentiation into T helper cells. 
T cells, and 
also B cells, 
macrophages 
and 
granulocytes 
PEcy7 
eBioscience 
Inc, San 
Diego, USA 
2.5μL 
CD8 Transmembrane glycoprotein co-
receptor for TCR expressed on 
cytotoxic T cells. Binds to MHC class I. 
T cells PerCy5.5 eBioscience 
Inc, San 
Diego, USA 
2.5μL 
CD162 
(PSGL-1) 
P-selectin glycoprotein ligand 1. High 
affinity for P-selectin but also binds to 
E-selectin and L-selectin. Involved in 
tethering and rolling of leucocytes on 
the endothelium. 
Granulocytes, 
monocytes, T 
cells and B 
cells 
APC 
eBioscience 
Inc, San 
Diego, USA 
5μL 
CD62L 
(L-
selectin) 
Cell adhesion molecule expressed on 
leucocytes. Belongs to family of 
selectins, and mediates leucocyte-
leucocyte interactions (secondary 
tethering). Also, acts as a homing 
receptor for lymphocytes to enter 
secondary lymphoid tissues. 
Neutrophils, 
monocytes, 
lymphocytes 
APC 
eflour780 
eBioscience 
Inc, San 
Diego, USA 
5μL 
CD11b Integrin αM (ITGAM) subunit that 
forms αMβ2 (Mac1). Mediates the firm 
adhesion of leucocytes to endothelium. 
Activated 
lymphocytes, 
monocytes, 
neutrophils 
and natural 
killer cells 
Pacific Blue 
Beckton, 
Dickinson 
& company, 
New Jersey, 
USA 
10μL 
 
Table 2.2. The fluorochrome conjugated antibodies used for flow cytometry to identify 
specific cell surface markers 
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2.3.8 Platelet flow cytometry 
2.3.8.1 Flow cytometric assessment of platelet P- selectin expression 
Two-colour whole blood flow cytometry was used to measure platelet P-selectin 
using previously published protocols and recommendations (Knight et al., 1997; 
Ritchie et al., 2000; Sidhu et al., 2004). There were 3 control tubes as follows: 2 µL 
of P-selectin isotype control  in addition to 2 µL of CD42b were added to 41 µL of 
HEPES buffer (150 mM NaCl, 10 mM Hepes,  5 mM KCl, 1 mM MgSO4, 3 mM CaCl2, 
Sigma, made in MQ water). The second control tube had 2µL of CD42b and 43 µL 
of HEPES buffer. The third and final control tube comprised of 2 µL CD42b isotype 
control and 43 µL HEPES buffer.  5 µL of citrated whole blood was immediately 
added to each of the control tubes. For the samples in which P- selectin was to be 
measured,   2 µL anti-CD42b and anti-CD62 were added to 40 µL of HEPES buffer 
and finally 5 µL citrated whole blood was added immediately. These samples were 
then treated with one of the following agoinsts: ADP (10 µM or 3 uM), collagen  (3 
ug/ml or 1 ug/ml) or PBS control (Figure 2.14) and incubated for 20 min at room 
temperature (21-23 oC) after very gentle mixing and then fixed with 500 µL of 1 
% paraformaldehyde (Sigma, UK) and stored at 4oC and then analysed using a 
Becton Dickinson FACSCalibur flow cytometer (Becton Dickinson, San Jose, Calif.) 
on the same day. 
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Figure 2.14 Schematic of sample make-up for P-Selectin expression 
 
Lyophylised ADP (2.5 mg, Chrono-Par #384, Labmedics) was reconstituted in 
sterile saline to give a 1 mM stock. This stock solution was stored at -80 °C in 
aliquots and fresh aliquots used daily for each experiment/study. For each 
experiment, ADP was diluted in PBS to provide an end concentration of 10 µM and 
3 µM. These dilutions were kept on ice until use on the day of the experiment and 
discarded after use.  
 
Horm Collagen Suspension (Nycomed #1130630) was supplied as 1 mg/ml in 
isotonic glucose. This stock was stored at 4 °C and used as required to make fresh 
agonist diluted accordingly in isotonic glucose supplied by the manufacturer to 
provide a concentration of either 3 µg/mL or 1 µg/mL. Again, these dilutions were 
kept on ice the day of the experiment and discarded after use.  
 
For P-selectin expression identification in blood samples, platelet population was 
identified preliminarily based on forward and side scatter properties, then further 
delineated via labelling with CD 42b monoclonal antibody conjugated to 
allophycocyanin (APC), (Biolegend, UK) (Figure 2.15). Gates were used to isolate 
1:25 CD42b Ab 
1:25 Isotype  
         CD42P Ab 
1:25 CD42b Ab 1:25 CD42b    
Isotype Ab 
1:25 CD42b Ab    
1:25 CD62P Ab 
1:50 ADP (10 µM) 
1:25 CD42b Ab    
1:25 CD62P Ab 
1:50 ADP (3 µM) 
1:25 CD42b Ab    
1:25 CD62P Ab 
1:50 Collagen          
(3 µg/ml) 
1:25 CD42b Ab    
1:25 CD62P Ab 
1:50 Collagen          
(1 µg/ml) 
1:25 CD42b Ab    
1:25 CD62P Ab 
1:50 PBS 
1 2 3 4 5 6 8 7 
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this population and CD62 (P-selectin; 0.4 ng/µL) monoclonal antibody conjugated 
to fluorescein isothiocyanate (FITC) (ABD Serotec, UK) was used to determine P- 
selectin expression.  Populations were further confirmed by use of antibody 
negative isotypes to P- selectin and CD42b (1:25). 10,000 platelets were acquired 
in the CD42b region. Results were expressed as the percentage of platelets positive 
for P- selectin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15. Dot plot of flow cytometry assessment of P-selectin expression  
A. Platelets were first identified based on their forward and side-scatter properties (P1)  
B. Then further delineated via labelling with CD42b monoclonal antibody conjugated to 
allophycocyanin (APC) (P2)  
C. CD62 (P-selectin) monoclonal antibody was used to determine P-selectin expression (P3)  
CD42b 
CD62 
A B 
C 
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2.3.8.2 Flow cytometric assessment of platelet monocyte aggregate 
expression 
Platelet monocyte aggregates were measured using a modification of previously 
published protocols (Harding et al., 2007) with 2-colour lysed blood flow-
cyotometry. Initially, the monocyte population was identified based on forward 
and side scatter properties. This was then further delineated via labelling with 
CD14 monoclonal antibody (20 µL per test as per manufacturer’s instructions) 
conjugated to (fluoroscienisthiocyanate) FITC (BD Biosciences, UK). To isolate this 
population, gates were used and and CD42b monoclonal antibody (1:25) 
conjugated to APC (Biolegend, UK) was used to determine platelets bound to the 
monocyte population, hence platelet monocyte aggregates.  
 
Fluorescent antibodies selective for the platelet marker CD42b and CD14 
(dilutions stated above) were incubated with 100 µL whole blood samples in 5 ml 
polystyrene round bottom flow cytometry tubes (BD Falcon, UK) as per Figure 
below (Figure 2.16). 
 
 
 
                               
 
 
 
 
 
 
 
 
 
 
Figure 2.16: Schematic of the antibody combinations used for platelet monocyte aggregates. 
 
Unstained CD14 Ab CD42 Ab (1:25) Isotype CD14 Ab 
(1:25) 
CD14 Ab 
Isotype CD42 Ab 
(1:25) 
CD14 
CD42b (1:25) 
1 2 3 4 5 6 
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Subsequently, 4 ml of PBS was added to each sample and all 6 samples were 
centrifuged at 400 g for 5 min at 21 °C. The supernatant was then discarded and 
500 µL of Immunolyse solution (a whole blood lysing solution diluted in PBS 
(1:25)) was added to each sample. Each tube containing the samples were then 
vortexed twice with a 1 min interval. Following this, fixative solution was added 
(1:5) as supplied by the manufacturer and each sample vortexed again. Following 
this, 3 ml of PBS was added to each sample before centrifugation. Post 
centrifugation, the supernatant was discarded and 4 ml of PBS was added before 
a final centrifugation at 400 g for 5 min at 21°C. Finally, the supernatant was 
discarded and the sample was resuspended in 300 µL PBS before flow cytometry 
analysis. Samples were analysed immediately using a Becton Dickinson Fortessa 
flow cytometer (Becton Dickinson, San Jose, Calif.). Using BD-diva flow cytometry 
analysis software CD42b expression was measured as a percentage of the CD14+ 
population (see Figure 2.17). 
 
2.3.9 Platelet aggregation 
Blood was collected into citrated blood collection tubes (3.2 % sodium citrate) (BD 
Biosciences, UK). Platelet aggregation was assessed in whole blood in response to 
PBS, ADP and collagen using impedance aggregometry (MultiplateR analyzer, 
Dyabyte Medical, Germany).  
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Figure 2.17: Dot plot of typical gating of platelet population based on size and granularity 
(P1). P2 defines the CD14 positive population and P3 the CD42b positive subset of P2. 
 
2.3.9.1 Measurement of whole blood aggregometry 
Impedance aggregometry is based on the principle that platelets are non-
thrombogenic in their resting state, but expose receptors on their surface when 
they get activated which allow them to attach on vascular injuries and artificial 
surfaces. The device has five channels for parallel tests, and a single-use test cell 
with duplicate impedance sensors, each consisting of two straight silver coated 
electrode wires (blood contacting area: 3 mm length, 0.3 mm diameter for each 
CD14 
CD42b 
Monocytes 
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sensor wire). When platelets stick on the Multiplate® sensor wires, they enhance 
the electrical resistance (impedance) between the two electrodes, which is 
continuously recorded (Figure 2.18). This delivers automated quality control of 
measurements by comparison of the two simultaneously recorded single analyses. 
The method has been described previously (Tóth et al., 2006).  
 
In the test cuvette, whole blood (300 μL) is diluted, 1:1, with 0.9% NaCL with 3 
mmol/L CaCL2 (Sigma, UK) solution maintained at 37°C for 3 minutes. At the end 
of this time, 12µl of agonist was added to give end concentrations of ADP of 10 µM 
or 3 µM (ChronoLog, Havertown, PA) and 3 µg/ml or 1 µg/ml of collagen 
(Nycomed, Munich, Germany). The ADP and collagen were made up as previously 
described in section 2.3.8.1. Phosphate buffered saline (PBS) was added to one 
test-cell as a control. The increase of impedance due to the attachment of platelets 
to the electrodes was detected for each sensor unit separately and transformed to 
arbitrary aggregation units (AU) that were plotted against time (AU*min). The 
aggregation measured with this device was quantified as area under the curve 
(AUC) of AU*min. (Figure 2.18) 
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Figure 2.18: Screenshot of typical aggregation data. Whole blood is incubated with PBS in 
channel 1, with ADP and collagen in channels 2-5 respectively. 
 
2.3.10 Lipid Mediator Profiling 
Blister exudates or plasma samples were added to 2 volumes of ice cold MeOH 
containing deuterated internal standards (d4-LTB4, d8-5S-HETE, d4-PGE2, d5-LXA4 
and d5-RvD2, 500pg each). These were then kept at -20 oC for 45 minutes to allow 
for protein precipitation and subjected to solid phase extraction as per previous 
publication (Colas et al., 2014). Methyl formate fractions were then brought to 
dryness using a TurboVap LP (Biotage) and products suspended in water-
methanol (50:50 vol:vol) for LC-MS-MS. A Shimadzu LC-20AD HPLC and a 
Shimadzu SIL-20AC autoinjector (Shimadzu, Kyoto, Japan), paired with a QTrap 
5500 (ABSciex, Warrington, UK) were utilised and operated as described (Colas et 
al., 2014). To monitor each lipid mediator and respective pathways, a Multiple 
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Reaction Monitoring (MRM) method was developed with diagnostic ion fragments 
and identification using recently published criteria (Colas et al., 2014), including 
matching retention time (RT) to synthetic and authentic materials and at least six 
diagnostic ions for each lipid mediator. Calibration curves were obtained for each 
using authentic compound mixtures and deuterium labelled lipid mediator at 0.78, 
1.56, 3.12, 6.25, 12.5, 25, 50, 100, and 200 pg. Linear calibration curves were 
obtained for each lipid mediator, which gave r2 values of 0.98 – 0.99. All analyses 
were conducted blind and conducted by the BartsLipidomic Unit led by Dr. 
Jesmond Dalli. 
 
2.3.11 Cytokine/Chemokine analysis  
Cytokine/chemokine expression profiles were analysed from 50 µL of blister fluid 
and plasma using a IDEXX ProCyte Dx® Haematology Analyser. This is a tool that 
utilises laser based flow cytometry, optical fluorescence and measurement of 
impedance to laminar flow to produce a readout of relative numbers and 
percentages of IL-6, IL-8, IL-10, CXCL1, CXCL2, CCL5 and CCL2.  All analyses were 
conducted blind and were analysed by Labospace in Italy. 
 
2.3.12.1 Measurement of nitrate and nitrite levels in plasma, saliva and 
urine samples [Ozone chemiluminescence] 
 
Following collection into EDTA tubes as described in section 2.3.1, blood samples 
were centrifuged immediately (1300g, 4oC, 10 min) and the supernatant then 
deproteinated. Deproteination was achieved by means of filtering through 
Microcon® Ultracel YM\3 (3kDa) (Millipore Corporation, Billerica, USA) filters via 
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centrifugation at 15000g for 60 min at 4°C. Prior to deproteination, the filters were 
washed twice with NO3-- and NO₂--free water to remove any possible NO3-/NO2- 
contamination. Deproteinated samples were then snap frozen until analysis using 
ozone chemiluminescence. 
 
[NOx] of urine, saliva and deproteinated plasma samples was determined using 
ozone-based chemiluminescence as described previously (Ignarro et al., 1993b). 
 
Ozone chemiluminescence is a highly sensitive and reproducible method of 
quantifying nanomolar quantities of NO and NO related species in biological fluids. 
The carrier gas, nitrogen, was bubbled through the sample where NO production 
was occurring. This was then passed on to the reaction cell and was quantified 
using the NO analyser, Sievers Nitric Oxide Analyser 280. In the reaction cell, NO 
reacted with ozone (O3), which generated nitrogen dioxide (NO2.) in an excited 
state (1). When nitrogen dioxide relaxes back to the ground state (NO2), a photon 
of a specific wavelength was emitted (2). The emitted light then goes through a 
filter and is intensified in a photomultiplier tube and quantified in the analyser. 
The intensity of the light emitted correlates to the amount of NO present initially 
in the reaction. Thus, using appropriate reducing agents nitrate and nitrite species 
can be reduced to NO and quantified. To ensure that standard curves generated 
were precise, with minimal variability between different days, control standards 
were run. 
 
NO + O3 → NO2. + O2                                                                              (1) 
Equation 2.1: Reaction of NO with O3 to produce excited nitrogen dioxide (NO2.). 
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NO2. → NO2 + hv                                                                               (2) 
Equation 2.2: Stabilisation of excited nitrogen dioxide. 
 
2.3.12.1.1 Determination of nitrite levels 
NO can be formed via the reduction of nitrite. When NO is then reacted with O3, 
NO2. is formed which can be quantified based on the intensity of light signal 
released when the excited species returns to ground state. The reducing agent 
used to measure nitrite levels in samples is 1% potassium iodide (KI, Sigma 
Aldrich, UK) in glacial acetic acid (C2H4O2, AnalaR NORMAPUR, VWR, UK). 10ml of 
this reducing agent was injected into the purge chamber and bubbled with 
nitrogen for 20 minutes to eliminate any oxygen present in the vessel and for the 
baseline to stabilize, before standard and sample injections (Figure 2.19). Nitrite 
molecules available in samples react with the reducing agent to form NO (3).  
 
I- + NO2- + 2H+ → NO + ½ I2 + H2O                                                                (3) 
 
Equation 2.3:  The overall reduction reaction of NO2- to NO in the presence of iodide (I-) 
 
Calibration curves, using known standards of sodium nitrite, were constructed 
every day. This was done by dissolving 0.069g of sodium nitrite (NaNO2, Sigma 
Aldrich) in 1L of MQ water, which forms 1mM of stock solution. The stock solution 
was used to prepare dilutions of 10µl, 1µl and 0.1µl. Three MQ water samples of 
25µl were injected first to ensure a baseline reading with no peaks. The nitrite 
standards were then run in order of the most diluted 0.1µl followed by 1µl and 
193 
 
10µl. Volumes of 20µl, 40µl and 50µl were used for each of the dilutions and a 
sodium nitrite calibration curve was created, as shown in Figure 2.20 & Figure 
2.21. Table 2.3, summarises the dilutions of each of the samples as well as volume 
injected. Samples were injected in duplicates to obtain mean concentrations for 
each sample.  
 
Sample Dilution Volume 
Plasma No 
Dilution 
25µl 
Urine No 
Dilution 
30µl 
Saliva 1:100 10µl 
 
Table 2.3: Dilutions and volumes injected of the different sample types injected into the 
purge vessel to measure nitrite levels.  
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Figure 2.19: Photograph of the ozone chemiluminescence setup for NO2- measurement. To 
determine the NO2- concentration, samples were added to 0.09 M potassium iodide (KI) in glacial 
acetic acid refluxing under N2 at room temperature (equation 2.3). Initially a calibration curve is 
made based on the final dilutions from a stock solution of sodium nitrite (NaNO2). Refer to figure 
2.15 for an example trace obtained from different injection volumes and concentrations of 
standards and figure 2.16 for a calibration curve after integration of each peak to the correct 
standard (NO2-=nitrite; KI=potassium iodide; NaNO2=sodium nitrite). 
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Figure 2.20: Graph of the generation of the NaNO2 calibration curve. The peaks represent the 
different volumes and concentrations of NaNO2 standards, for which the area under the each peak 
is determined. 
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Figure 2.21: Graph of a typical standard curve produced prior to the measurement of NO2- 
in liquid samples (slope=7.1; intercept=1.2; R2=0.9999) (NO2-=nitrite). 
 
2.3.12.1.2 Determination of nitrate levels 
The reducing agent used in determining nitrate levels is a 0.1M solution of 
vanadium chloride (VCl3, Sigma Aldrich, UK) dissolved in 1M hydrochloric acid 
(HCl, Sigma Aldrich, UK). 6ml of the solution was dispensed into the purge vessel 
at 95oC and nitrogen was bubbled through. This is a stronger reducing agent and 
reduces both nitrite and nitrate molecules present in a sample, collectively known 
as NOx. A gas bubbler filled with 8ml of 1M sodium hydroxide (NaOH, Sigma 
Aldrich, UK), was connected between the purge vessel and NO analyser (NOA 
280A, Sievers), to prevent the HCl vapour from damaging the analyser (Figure 
2.22).  
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0.085g of NaNO3 (Sigma Aldrich, UK) was dissolved in 1L of MQ water to prepare 
1mM of stock solution. The stock solution was used to prepare the dilutions of 
100µM, 10µM and 1µM. For the NOX calibration curve to be created the following 
injections of standards were made: 20µl, 40µl and 50µl of the 1µM, 20µl, 40µl, 50µl 
and 70µl of the 10µM and 10µl of the 100µM dilution; as shown in Figures 2.23 & 
Figure 24. Vanadium reacts with the nitrate available in the sample to form NO 
(4). As this setup determines the NOX levels in samples, by subtracting the NO2- 
levels obtained from the previous step, the amount of NO3- in each sample can be 
calculated (5).  
 
2NO3- + 3V3 + 2H2O → 2NO + 3VO2 + 4H+                                                                                            (4)  
 
Equation 2.4 Reduction of NO3- by vanadium (III) chloride to produce NO. 
 
[NOx] – [NO2-] = [NO3-]                                                                             (5) 
 
Equation 2.5:  Subtracting the NO2- measurement from the NOx value gives a measure of the 
NO3-. 
 
Table 2.4, summarises the dilutions of each of the samples as well as volume 
injected. Samples were injected in duplicates to obtain mean concentrations for 
each sample. 
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Sample 
Dilution Volume 
Plasma 1:10 10 µl 
Urine 1:100 20 µl 
Saliva 1:100 10 µl 
 
 
Table 2.4: Dilutions and volumes injected of the different sample types injected into the 
purge vessel to measure NOx levels.  
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Figure 2.22: Photograph of the ozone chemiluminescence setup for NOx determination. A 
gas bubbler containing 1 M sodium hydroxide (NaOH) was installed between the purge vessel and 
the NOA to prevent HCl vapour damaging the NOA (NOA=nitric oxide analyser; HCl=hydrochloric 
acid; NaOH=sodium hydroxide). 
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Figure 2.23: Graph of the generation of the NaNO3 calibration curve. The peaks represent the 
different volumes and concentrations of NaNO3 standards, for which the area under the each peak 
is determined. 
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Figure 2.24: Graph of the NaNO3 Calibration curve. The calibration curve was generated from 
known NaNO3 standard solutions. 
 
2.3.13 Measurement of plasma [cyclic GMP] 
For the majority of the physiological functions that occurs due to NO, cGMP plays 
an important role as a second messenger. Therefore, by determining the levels of 
cGMP in plasma samples collected at visit 2, baseline values can be established, 
which theoretically should be similar in both groups. cGMP levels measured at the 
6 months can then be compared to the baseline values. Thus, any changes in these 
levels would be due to the treatment. It is also worth noting that cGMP acts as a 
second messenger for atrial natriuretic factor. However, since the intervention in 
the study is NO3- (and hence NO), we can assume that the levels of atrial natriuretic 
factor will remain constant between the groups. 
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Blood was collected into tubes containing the non-competitive non-selective 
phosphodiesterase (PDE) inhibitor, 3-isobutyl-1-methylxanthine (IBMX, 100 µM) 
prior to centrifugation at 14,000 g for 10 min. Plasma was then collected and 
immediately snap frozen and stored at -80°C pending measurement.  
 
2.3.13.1 cGMP assay 
The ELISA kit (cGMP enzymeimmunoassay Biotrak system RPN226, GE 
Healthcare, Little Chalfont, UK) was used to measure plasma cGMP levels and 
protocol followed was from the data sheet (www.gelifesciences.com, GE 
Healthcare, Little Chalfont, UK). Competitive enzymeimmunoassay is a 
biochemical test used in determining the concentration of specific 
macromolecules in a sample. In this highly specific and sensitive assay, the antigen 
in the sample competes for a limited antigen binding site on the anti-cGMP 
antibody (Figure 2.25). The unlabelled cGMP from the unknown sample or 
standard competes with fixed quantities of labelled horse raddish peroxidase 
conjugated cGMP. Thus, the samples with high levels of cGMP result in higher 
levels of unlabelled cGMP being bound to the anti-cGMP antibody, compared with 
the conjugated cGMP. The tetramethylbenzidine substrate added will then only 
bind to the labelled cGMP, developing a blue colour. Therefore, there is an inverse 
correlation between the intensity of the blue colour formed, after the addition of 
the chromogenic substrate, and the concentration of unlabelled cGMP in the 
sample or standard. This relationship can be used to plot a standard curve and 
extrapolate unknown cGMP concentrations from samples.  
203 
 
 
Figure 2.25: Schematic of the principle of the cGMP competitive enzymeimmunoassay 
system. 
 
2.3.13.2 Determination of plasma cGMP levels 
A 1:2 dilution of acetylation standards were prepared. The unknown plasma 
samples where then diluted 1:20 with assay buffer (25µl plasma and 475µl assay 
buffer). The assay buffer consisted of 0.05M sodium acetate buffer pH 6.0 
containing 0.002% (w/v) bovine serum albumin and 0.01% (w/v) preservative. 
50µl of acetylating reagent (2:1 of triethylamine and acetic acid) was added to 
each of the diluted plasma samples and standards and vortexed immediately. 
100µl of antiserum (cGMP antibody) was dispensed into all wells in a 96-well plate 
(which had all been pre-coated with donkey anti-rabbit IgG) except blank and non-
specific binding (NSB). 50µl of all the standards and unknown samples where 
dispensed into their appropriate wells, in duplicates. 150µl of assay buffer was 
dispensed into the NSB well. The plate was then covered, gently mixed and 
incubated at 4oC for 2hr. After incubation, 100µl of diluted conjugate of lyophilized 
Donkey anti-Rabbit IgG 
coated microplate 
Rabbit anti-cGMP 
antibody 
Unlabelled 
cGMP 
cGMP- Horse raddish 
peroxidase conjugate 
Tetramethylbenzidine substrate 
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cGMP conjugated to horseradish peroxidase was added into all wells except blank. 
The plate was then covered again and incubated at 4oC for 1hr. The plate was then 
washed 4 times with wash buffer (0.01 M phosphate buffer pH 7.5 containing 
0.05% (v/v) Tween™ 20) and 200ul of enzyme substrate (3,3’,5’5’- 
tetramethylbenzidine (TMB)) was added to all wells. The plate was incubated for 
30 minutes at room temperature. The colourless substrate TMB is converted into 
blue by the peroxidase. Using a spectrophotometric plate reader (MRX-TC 
Revelation, Dynex Technologies, UK), the plate was read at λ=450nm after the 
addition of 100µl 1M of sulphuric acid into all wells (which turns the blue colour 
into yellow). The colour change depends on the amount of enzyme linked to the 
well and is inversely proportional to the cGMP concentration.  Each sample and 
standard were analysed in duplicate.  
 
As shown in Figure 2.26, the standard curve was then plotted and the 
concentration of cGMP of unknown samples was calculated.         
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Figure 2.26: Typical standard curve generated from known standards. 
2.3.14 Met haemoglobin measurement 
A finger probe pulse oximeter (Massimo Signal Extraction technology) was used 
to measure Sp Met Hb level in all participants during each study visit. Pulse 
oximetry is based upon two physical principles. The light absorbance of 
oxygenated haemoglobin is different from that of reduced haemoglobin, at the 
oximeter’s two wavelengths, which include red and near infrared light; and the 
absorbance of both wavelengths has a pulsatile component, which is due to the 
fluctuations in the volume of arterial blood between the source and the detector. 
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2.4 Clinical study design and execution 
In terms of overall design and execution of these studies, I helped to design the 
two healthy volunteer studies as well as the phase II clinical trial. I developed the 
protocol and applied for ethical approval. I recruited patients for all three studies 
and carried out the clinical and biochemical measurements. 
 
The measurement and analysis of the lipid mediators were performed by Dr. 
Jesmond Dalli’s lab at the William Harvey Research Institute. The cytokine and 
chemokine measurements were performed and analysed by Labospace in Italy 
and I am grateful to both labs for their help and guidance. 
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3.0 Investigating the influence of sex on inflammation-induced endothelial 
dysfunction in healthy volunteers 
 
3.1 Acute low grade systemic induced-inflammation to assess endothelium 
dependent dilatation 
Observational as well as epidemiological studies have suggested an association 
between infection or inflammation and risk of CVD (Liuzzo et al., 1994; Maseri, 
1997; Quartin et al., 1997; Ridker et al., 1997; 1998a; Ridker et al., 1998b; Tillett 
et al., 1983; Valtonen et al., 1993). Two patterns of association have emerged: an 
association between an acute systemic inflammatory response and a transiently 
increased risk of an acute cardiovascular event (Liuzzo et al., 1994; Quartin et al., 
1997; Tillett et al., 1983; Valtonen et al., 1993)  and a link between chronic low-
grade inflammation/infection and the slow process of atherogenesis (Ridker et al., 
1997; 1998a; Ridker et al., 1998b).  
 
3.1.1 To investigate these associations 
Previously, to initiate a systemic inflammatory response, studies have used an 
intramuscular injection of the capsular polysaccharide typhoid vaccine Typhim Vi 
(Cooper et al., 1992; Plotkin and Bouveret-Le Cam, 1995). In the 8 hours after 
vaccination, the vaccine produced a mild leukocytosis without changes in BP or 
heart rate. In addition, there was an increase in IL-6 (a proinflammatory cytokine) 
(Hingorani et al., 2000a). In addition to the pro-inflammatory cytokine response, 
these studies have also demonstrated that inflammation caused by typhoid 
vaccination causes an increased oxidant stress and impairs forearm arterial 
endothelium dependent dilatation, suggesting that even a relatively mild systemic 
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inflammatory response is associated with significant alteration in endothelial 
function of a type commonly thought to be associated with increased 
cardiovascular risk (Calver et al., 1992; Chowienczyk et al., 1992; Gerhard et al., 
1996; Panza et al., 1990). If this model accurately reflects the pathology of 
systemic inflammation, then this may indicate a mechanism by which 
inflammatory events may lead to a transient rise in the incidence of cardiovascular 
events. 
 
Systemic inflammation that is far more severe and long-lasting than the insult 
produced by vaccination occurs in a wide variety of infective disorders and after 
iatrogenic procedures such as major abdominal surgery. There is growing 
evidence that acute systemic inflammation is associated with an increase in the 
risk of cardiovascular events that may persist for days or weeks (Meier et al., 1998; 
Tillett et al., 1983). There is also evidence that unstable angina is associated with 
inflammation (Liuzzo et al., 1994), which might precede the onset of the 
syndrome.  
 
We therefore decided to use the typhoid-induced model of systemic inflammation 
to further interrogate the changes in endothelial regulation of vascular tone in the 
arterial circulation but also to determine whether this model might be useful 
ultimately in interrogating the potential beneficial effects of inorganic NO3- upon 
inflammation. Although atherosclerosis is predominantly a disease of chronic 
inflammation, we tested the hypothesis that endothelial dysfunction underlies the 
association between an acute inflammatory episode and the transiently increased 
risk of a cardiovascular event by examining the effects of an acute experimental 
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inflammatory stimulus (using the typhoid vaccine) on endothelium-dependent 
vasodilation as utilised previously (Hingorani et al., 2000a). To test these 
methodologies, we carried out studies by assessing differences between the sexes 
in the first place to establish the model in our laboratory I investigated the 
responses to typhoid in both men and women to determine whether the response 
to systemic inflammation is different between the sexes. 
 
As discussed above, systemic inflammation plays a critical role in the progression 
of cardiovascular disease and since inflammation plays a key role in the process of 
restenosis, we initially developed a systemic assay of inflammatory mediators to 
assess endothelial function. Furthermore, to test these methodologies, we carried 
out studies by assessing differences between the sexes.  
 
3.3 Results 
3.3.1 Baseline demographics 
Healthy volunteers were recruited between 2013 to 2015. Baseline data for the 24 
healthy volunteers recruited into the typhoid study demonstrates that the 
volunteers were well matched in terms of age. Expected differences between the 
sexes were observed in BMI, SBP and DBP (Table 3.1). For examples, whilst the 
volunteers had similar age, the men ha higher BMI and higher BPs. This is typical 
of a healthy volunteer cohort and has been well documented. 
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Table 3.1. Demographics of healthy volunteers in the typhoid study. Data are shown as mean  
s.e.mean with statistical significance determined using Student’s unpaired t-test. 
 
  Typhoid Study 
  Male Female P Value 
Volunteers (n) 12 12  
Age (years) 26.0 ± 5.7 24.7 ± 6.8 0.59 
BMI (Kg/m2) 24.8 ± 3.2 21.8 ± 2.9 0.021 
Baseline SBP (mmHg) 119.5 ± 1.8 107.5 ± 2.4 0.0005 
Baseline DBP (mmHg) 65.6 ± 3.0 67.6 ± 1.2 0.55 
Heart rate (bpm) 69.4 ± 2.8 65.7 ± 2.6 0.36 
Oral contraceptive - 4   
3.3.2 Typhoid vaccine induces a low grade systemic inflammation in both 
males and females 
Typhoid vaccination resulted in a rise in circulating leucocyte numbers in both 
sexes due almost entirely to a neutrophilia (Table 3.2), as per previous reports 
(Hingorani et al., 2000b).  
 
Table 3.2. Body temperature, blood differentials and CRP levels in male and female healthy 
volunteers at baseline and at 8 and 24 hours post typhoid vaccination. Data are shown as mean  
s.e.mean with statistical significance determined using using two-way ANOVA with post-hoc 
Sidak’s tests shown as * for P<0.05 and ** for P<0.01 for male versus female and §§ for P<0.01, §§§ 
for P<0.001 and §§§§P<0.0001  for within group versus baseline comparison.   
Sex Time-point 
Temp 
Hb (g/dL) 
Platelets 
(x109/L) 
WBC 
(x1011/L) 
Neutrophils 
(x109/L) 
Lymphocytes 
(x109/L) 
Monocyte
s (x109/L) 
CRP 
(mg/L) 0C 
Male 
Baseline 36.0 ± 0.1** 14.8 ± 0.3** 223.4 ± 14.8 5.5 ± 0.2 2.9 ± 0.7 1.9 ± 0.4 0.5 ± 0.2 <5 
8 hours 35.9 ± 0.1* 14.5 ± 0.4* 223.6 ± 14.9 8.0 ± 0.5§§§§ 5.2 ± 1.5§§§ 2.1 ± 0.4 0.6 ± 0.2 <5 
32 hours  35.9 ± 0.1** 14.7 ± 0.4** 235.0 ± 15.0 5.5 ± 0.3 3.0 ± 1.1 1.9 ± 0.4 0.4 ± 0.2 <5 
  
 
       
Female 
Baseline 36.2 ± 0.1 13.3 ± 0.3 251.3 ± 12.0 6.7 ± 0.4 4.3 ± 1.3 2.2 ±0.4 0.4 ±0.1 <5 
8 hours  36.1 ± 0.1 13.1 ± 0.2 255.8 ± 11.2 9.2 ± 0.6§§§ 6.5 ± 2.0§§ 2.2 ± 0.4 0.6 ± 0.2 <5 
32 hours  36.2 ± 0.1 13.0 ± 0.2 249.0 ± 12.1 6.3 ± 0.3 3.7 ± 1.0 2.2 ± 0.4 0.5 ± 0.2 <5 
 
         
  Sex comparison 0.0073 <0.0001 0.031 0.0024 0.0005 0.024 0.864 - 
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Interestingly, at baseline it is notable that in females the numbers of white blood 
cells trend to higher values vs males. The differential counts demonstrate that this 
difference is due to greater numbers of neutrophils in females (P<0.05); all other 
circulating cell numbers at baseline were similar between the sexes. Use of flow 
cytometry to assess the relative activation state of the circulating cells 
demonstrated that at baseline the expression of key adhesion molecules involved 
in inflammatory cell recruitment (CD11b, CD162 and CD62L) were largely similar 
between the sexes except for an elevation in expression of activation markers on 
circulating monocytes in females (Figure 3.1, Figure 3.2 and Figure 3.3), 
possibly suggesting that these markers are good markers of basal activation.   
 
Following typhoid vaccine the activation state of circulating neutrophils relative 
to baseline was enhanced in males but not females. Specifically with elevations of 
CD162 and CD62L (Figure 3.4) were seen, both cellular adhesion molecules that 
play a pivotal role in cell homing, rolling and adhesion in an inflammatory scenario 
(Pillay et al.; Xu et al., 2008). The effect upon CD162 and CD62L was only  evident 
on neutrophils and not on any other cell types interrogated (Figure 3.1, Figure 
3.2 and Figure 3.3). There were no measureable changes from baseline in platelet 
reactivity in either sex and at all the time-points tested (Table 3.3).   
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Figure 3.1: Changes in expression of CD11b, CD62L and CD162 on monocytes, in male and female healthy volunteers measured at baseline, 8 hours and 32 hours 
following typhoid vaccine. Data expressed as mean ± s.e.mean for n=12 for each sex. Statistical significance determined using two-way ANOVA with Sidak’s post-hoc 
analysis. MFI = Median fluorescence intensity. 
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Figure 3.2: Changes in expression of CD11b, CD62L and CD162 on CD4+ lymphocytes in male and female healthy volunteers measured at baseline, 8 hours and 
32 hours following typhoid vaccine. Data expressed as mean ± s.e.mean for n=12 for each sex. Statistical significance determined using two-way ANOVA with Sidak’s post-
hoc analysis. MFI = Median fluorescence intensity. 
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Figure 3.3: Changes in expression of CD11b, CD62L and CD162 on CD8+ lymphocytes in male and female healthy volunteers measured at baseline, 8 hours and 
32 hours following typhoid vaccine. Data expressed as mean ± s.e.mean for n=12 for each sex. Statistical significance determined using two-way ANOVA with Sidak’s post-
hoc analysis. MFI = Median fluorescence intensity. 
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Figure 3.4: Low grade systemic inflammation induced by typhoid vaccination enhances neutrophil activation state in healthy male but not female volunteers. 
Changes in expression of (A) CD11b (B) CD162 and (C) CD62L on neutrophils in male and female healthy volunteers at baseline, 8 hours and 32 hours following typhoid 
vaccine. Changes in expression of (D) CD11b, (E) CD162 and (F) CD62L from baseline in male and female healthy volunteers at 8  hours and 32 hours following typhoid 
vaccine. Data expressed as mean ± s.e.mean of n=12 male and female volunteers. Statistical significance determined using two-way ANOVA with Sidak’s post-hoc analysis 
shown as * for P<0.05.
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Table 3.3. The effect of typhoid on the expression of platelet activation markers and platelet 
activity in healthy volunteers. Data are shown for % P-selectin expression in males and females 
following PBS treatment and in response to ADP (3 and 10 µM) or collagen (3 and 10 µg/ml) at 
baseline, 8 hours and 32 hours post vaccine. For % platelet monocyte aggregates levels were 
measured at baseline, 8 hours and 32 hours post-vaccine. Data are shown as mean  s.e.mean and 
statistical analysis conducted using two-way ANOVA to determine the influence of sex differences 
for n=10 male and n=12 female volunteers (2 samples lost due to technical difficulties). Statistical 
significance was tested using two-way ANOVA with Sidak's post-hoc analysis. 
 
  Males   Females Sex 
comparison 
  Baseline 8 hours 32 hours   Baseline 8 hours 32 hours P Value 
% P-Selectin expression 
        
 PBS 2.3 ± 1.4 0.7 ± 0.2 2.2 ± 1.2 
 
1.0 ± 0.2 0.5 ± 0.1 0.8 ± 0.3 0.517 
     Collagen 1 µg/ml 2.2 ± 0.7 1.3 ± 0.3 2.6 ± 1.1 
 
2.3 ± 0.7 1.1 ± 0.2 1.2 ± 0.2 0.567 
     Collagen 3 µg/ml 3.7 ± 0.9 3.2 ± 0.8 4.2 ± 1.6 
 
3.8 ± 1.3 2.7 ± 0.6 2.2 ±0.4 0.448 
     ADP 3 µM 9.1 ± 2.6 6.8 ± 1.3 4.2 ± 1.6 
 
8.9 ± 2.1 12.3 ± 3.7 10.8 ± 3.3 0.723 
     ADP 10 µM 10.9 ± 3.3 7.1 ± 1.8 12.5 ± 3.3 
 
12.0 ± 2.5 12.9 ± 3.0 13.8 ± 3.6 0.587 
         
% PMA expression 31.5 ± 4.2 34.2 ± 6.4 26.8 ± 4.3 
 
27.8 ± 5.4 34.4 ± 6.0 33.1 ± 4.7 0.611 
         
Platelet Aggregation 
(AU) 
        
 PBS 7.2 ± 2.1 8.8 ± 3.0 8.2 ± 2.3 
 
9.2 ± 2.0 13.5 ± 2.5 8.1 ± 2.3 0.268 
     Collagen 1 µg/ml 59.5 ± 3.4 61.6 ± 5.2 54.8 ± 4.0 
 
60.2 ± 5.3 74.6 ± 5.1 61.3 ± 5.2 0.086 
     Collagen 3 µg/ml 78.9 ± 3.7 91.5 ± 4.9 75.1 ± 3.9 
 
83.8 ± 5.9 99.6 ± 5.9 76.8 ± 6.5 0.245 
     ADP 3 µM 35.1 ± 4.1 37.8 ± 4.1 37.7 ± 5.4 
 
46.3 ± 5.8 54.4 ± 5.1 43.2 ± 5.5 0.008 
     ADP 10 µM 47.8 ± 4.1 49.9 ± 4.3 43.9 ± 3.7 
 
57.0 ± 4.4 68.6 ± 3.5 56.9 ± 4.8 0.0002 
 
 
Neither circulating levels of CRP or body temperature were altered by typhoid 
vaccine (Table 2). Furthermore, the differences seen between the sexes was not 
due to differences in dosing since typhoid (IgM) antibody titres at 32 hours 
following vaccination were similar (Male: 10.4 ± 1.8 n=11 and female: 11.4 6 ± 1.6 
n=10 U/ml). These observations suggest that the differences in systemic 
inflammation relate to biological differences between the sexes in the response to 
an inflammatory stress and not difference in dose delivered. 
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3.3.3 Sex differences in the vascular response to typhoid vaccination 
Baseline ultrasound FMD responses were similar between the sexes, however, 
whilst typhoid vaccine tended to decrease the FMD response in males, in females 
the response actually increased at the 8 hour period.  This profile of FMD response 
was significantly different between the sexes, with the greatest difference evident 
at the 8-hour time-point (P<0.01; Figure 3.6 A-B). These differences were evident 
despite no change over time in baseline diameter or in the time taken to reach 
peak diameter following release of the cuff (Table 3.4).  
Table 3.4. Vascular measures at baseline and at 8 and 32 hours following typhoid vaccination. Data 
are shown as mean  SD with statistical significance determined using using two-way ANOVA with 
post-hoc Sidak’s tests shown as * for P<0.05, **P <0.01, ***P <0.001, ****P <0.0001   for comparison 
of time-points between the sexes and no significant differences for within group comparisons to 
baseline.  
  
  Males (n=12)   Females (n=12) 
  Baseline 8 hours 32 hours  Baseline 8 hours 32 hours 
Sex 
comparison 
Ultrasound         
 Baseline brachial   
     artery diameter, mm 3.8 ± 0.5*** 3.8 ± 0.5**** 3.8 ± 0.4**  3.1 ± 0.3 3.1 ± 0.4 3.2 ± 0.4 <0.0001 
 Time to peak     
     diameter, min 6.7 ± 0.5 6.7 ± 0.7 6.7 ± 0.8  6.7 ± 0.2 6.8 ± 0.2 6.8 ± 0.2 0.492 
         
PWA         
     Augmentation index, % 13.3 ± 1.9 13.8 ± 1.2 13.5 ± 1.7*  12.1 ± 1.4 11.6 ± 2.2 11.9 ± 1.9 0.24 
 PWV, m/s 6.7 ± 0.1 6.7 ± 0.1 6.7 ± 0.2*  6.3 ± 0.1 6.2 ± 0.2 6.2 ± 0.1 <0.0001 
 
Evidence suggests that the FMD response is due predominantly to triggering of 
endothelium-dependent NO generation.  To assess whether this might underlie 
differences in the sexes we measured nitrite and nitrate (NOx) levels. We found no 
significant differences in circulating NOx levels between the time-points, however 
interestingly post-hoc correlation analyses demonstrated that circulating nitrite 
concentrations correlate directly to the magnitude of the FMD response in females 
but not males (Figure 3.5). This suggests the possibility that circulating total 
plasma NOx levels could be reflective of localised NO production.   
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Figure 3.5: Correlations between FMD responses in healthy volunteers and levels of plasma NO metabolites NO2-, NO3- and NOX in females (A-C) and males (D-F). 
Data from pre-vaccine baseline and 8 and 32 hours post-vaccine are collated. All graphs show Pearson linear regression, and statistical significance of r-value.  
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Figure 3.6: Low grade systemic inflammation induced by typhoid vaccination does not cause 
endothelial dysfunction in healthy female volunteers. The effect of typhoid vaccination on (A) 
Flow mediated dilatation (FMD) measured at baseline and 8 and 32 hours following typhoid 
vaccination. (B) The effect of sex differences upon the change in FMD at 8 hours following typhoid 
vaccination from baseline.  All data expressed as mean ± s.e.mean of N = 12 for each sex. Statistical 
significance determined using (A) two-way ANOVA with Sidak’s post-hoc analysis shown as ** for 
p<0.01 and (B) Student’s unpaired test.  
 
In contrast to FMD, typhoid vaccination did not alter the vasodilation response to 
sublingual GTN in either sex (Figure 3.7 C-D), and did not influence PWV or 
augmentation index through PWA. Since the PWV and PWA are measures of 
arterial compliance determined predominantly by smooth muscle function (Table 
3.4), the data collectively suggest that the differences seen in the FMD response to 
typhoid vaccination were not due to underlying changes in smooth muscle 
reactivity.  
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Figure 3.7: Brachial artery responses secondary to GTN in healthy volunteers. Maximal 
dilatation of the brachial artery in response GTN in (A) male and (B) female healthy volunteers 
measured at baseline and 8 and 32 hours following typhoid vaccination. Data expressed as mean 
± s.e.mean of N=8. Statistical significance determined using one-way ANOVA with Sidak’s post-hoc 
analysis.  
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3.4 Summary 
 
• As expected, typhoid vaccination caused an expected low grade systemic 
inflammation that was reflected by a neutrophilia. 
• The neutrophilia response to typhoid was equally evident in both men and 
women. 
• As expected, brachial artery size was greater in men than women and this was 
associated with a slight lower baseline FMD and lower PWV.  
• Females exhibit a significantly increased FMD response compared to baseline 8 
hours following typhoid vaccination, whilst in contrast, the FMD response in men 
showed a trend towards a worse FMD at 8 hours post-vaccine. 
• Ozone chemiluminescence reveals a trend towards sex differences in plasma  
[NO2-], [NO3-] and [NOX] profiles following typhoid vaccination. 
• Females exhibit positive correlation between FMD and plasma [NO2-]. However, 
no such correlation is observed in males. 
• These results suggest that female sex protects against endothelial dysfunction 
induced by acute inflammation. Moreover, our data suggest such sex differences 
may, at least in part, reflect better utilisation of nitrite by females to improve 
endothelial function. 
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4.0 Accelerated resolution of inflammation underlies sex differences in the 
inflammatory response and inflammation-induced vascular dysfunction in 
humans 
 
4.1 Assessment of the acute and resolution phases of inflammation in 
humans using the cantharidin blister model 
As already discussed in section 1.11, cardiovascular disorders are characterised 
by an underlying vascular inflammation that is considered to play a major 
causative role in pathogenesis (Willerson and Ridker, 2004). We used the typhoid-
induced systemic inflammation model to assess whether endothelium dysfunction 
is different between the sexes. As shown in Chapter 3, our results indicated a 
resistance to the effects of typhoid in females. To study the inflammatory response 
in humans more closely, we explored whether a suitable model of innate 
inflammation might be available.  There have been a number of human in vivo 
models of acute inflammation that have been developed over the last two decades. 
These include the negative pressure-induced skin blister model (Follin, 1999), the 
systemic inflammatory reaction following endotoxin inhalation (Michel et al., 
1997) and the cantharidin-induced skin blister model (Day et al., 2001a). Out of 
all of these models, the cantharidin skin blister is relatively non-invasive, has few 
side-effects, and has low within-subject variability. In addition, the blisters 
provide immediate access to cells and supernatant to study the response more 
closely as well as a collection process that minimises alteration in phenotype 
arising from ex vivo processing.  In addition, the blister can be maintained for 
several days to characterise both the immediate response and resolution of the 
innate inflammatory response. Following topical administration to the skin, 
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cantharidin (a protein phosphatase inhibitor), induces atraumatic acantholysis 
and blister formation (Day et al., 2001a). This is associated with an infiltration of 
CD16+ neutrophils into the fluid space in the first 24 hours, and CD14+ 
monocyte/macrophages from 24 to 72 hours (Morris et al., 2010). 
 
Since this model of acute, localised inflammation has low within person variability 
(Dinh et al., 2011), we decided to use this model to characterise the leukocytes, 
chemokines, cytokines and resolution factors generated during an inflammatory 
response and to determine whether any of these may be altered between the 
sexes.  
 
4.2 Results 
4.2.1 Baseline demographics 
Volunteers were recruited from 2015 to 2016. Baseline data demonstrates that 
the volunteers were well matched in terms of age. Expected differences were 
observed in BMI, SBP and DBP (Table 4.1). These profile of the demographics are 
very similar to those of the typhoid study indicating close similarities between the 
two cohort of participants. 
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Table 4.1. Demographics of healthy volunteers in the cantharidin study. Data are shown as mean 
 s.e.mean with statistical significance determined using Student’s unpaired t-test. 
 
  Cantharidin Study 
  Male Female P Value 
Volunteers (n) 16 16  
Age (years) 27.4 ± 1.1 26.8 ± 1.1 0.68 
BMI (Kg/m2) 24.6 ± 0.7 22.4 ± 0.6 0.019 
Baseline SBP (mmHg) 115.7 ± 2.0 104.1 ± 1.7 0.0001 
Baseline DBP (mmHg) 68.3 ± 1.7 64.6 ± 1.5 0.12 
Heart rate (bpm) 64.1 ± 2.3 68.4 ± 1.7 0.15 
Oral contraceptive - 6   
 
4.2.2 Sex differences in cantharidin-induced inflammation  
Cantharidin application at the time-points assessed was not associated with a 
systemic inflammatory response in either sex as reflected by no change from 
baseline at 72 hours after cantharidin application in peripheral blood markers of 
systemic inflammation such as CRP, leucocyte count, and leucocyte differential 
(Table 4.2).  
 
Table 4.2. Blood differentials and CRP levels in male and female healthy volunteers at baseline and 
post cantharidin-induced blister harvest. Data are shown as mean  SD with statistical significance 
determined using using two-way ANOVA with post-hoc Sidak’s tests (note there were no 
significant differences between the sexes or on the effects of cantharidin on circulating markers or 
within sex).  
    Hb 
(g/dL) 
Platelet 
count 
(x109/L) 
WBC 
(x1011/L) 
Neutrophils 
(x109/L) 
Lymphocytes 
(x109/L) 
Monocytes 
(x109/L) 
CRP 
(mg/L) 
Male Baseline 15.0 ± 0.3 234.7 ± 15.2 5.4 ± 0.3 3.0 ± 0.3 1.8 ± 0.1 0.4 ± 0.04 <5 
Post-blister 15.0 ± 0.3 242.2 ± 12.9 5.6 ± 0.4 3.2 ± 0.3 1.8 ± 0.1 0.4 ± 0.04 <5 
Female Baseline 13.1 ± 0.3 258.0 ± 12.0 6.3 ± 0.5 3.8 ± 0.4 1.9 ± 0.1 0.4 ± 0.02 <5 
Post-blister 12.7 ± 0.2 259.9 ± 12.2 6.0 ± 0.3 3.3 ± 0.2 2.0 ± 0.1 0.4 ± 0.02 <5 
         
  Sex 
Comparison 
 
<0.0001 
 
0.123 
 
0.109 
 
0.133 
 
0.133 
 
0.859 
 
0 
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All volunteers reported that the typhoid vaccine caused minimal discomfort 
beyond the injection and that the cantharidin blisters were pain free other than an 
itching and/or tingling sensation a few hours after cantharidin application as the 
blisters formed. These observations are in line with other published studies 
(Brunner et al., 1998; Day et al., 2001b; Jenner et al., 2014), providing evidence 
that this is indeed a safe, reliable and reproducible technique to study acute 
inflammation.  
 
Within the cantharidin-induced blister, I found significantly less oedema in terms 
of volume collected in females compared to males (Figure 4.2).  More 
interestingly, whilst some blisters unfortunately popped prior to collection, the 
majority of the 72 hour blisters in the women but not the men had resolved (Table 
4.3). 
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Figure 4.1: Representative dot plots to identify leucocyte sub-populations collected in 
cantharidin induced blister fluid in healthy volunteers: A-B) Characteristic FSC/SSC dot plot 
from a 24hrs and 72hrs blister fluid respectively; C) Density dot plot of neutrophils (yellow-gated 
cells) confirmed by anti-CD16b+ binding; D) Density dot plot of monocytes showing presence of 
CD14+/CD16- classical inflammatory (IM) monocytes (green-gated), CD14+/CD16+ intermediate 
monocytes (blue-gated) and a fraction of CD14lo/CD16++ resident (RM) monocytes confirmed by 
appropriate binding patterns with anti-CD14 and/or anti-CD16; E) Density dot plot of lymphocytes 
(red-gated cells) confirmed by anti-CD3 binding and F) Density dot plot showing T-cell sub-types 
with anti-CD4+ (orange-gated cells) and anti-CD8+ (blue-gated cells) binding
A B 
C D 
E F 
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Figure 4.2: Reduced oedema response to cantharidin in female compared to male healthy 
volunteers. The total volume of fluid at 24 hours and 72 hours following application of cantharidin 
to the volar aspect of the forearm.  Data is shown as mean ± s.e.mean of n=16 of each sex. Statistical 
analysis was determined using two-way ANOVA followed by Sidak’s post-tests shown as ## p 
<0.01.  
 
Indeed, at the 72 hour time-point blisters had completely resolved in 11 females 
(70%) in comparison to only 5 males (using a 4 by 2 contingency table the chi-
square test demonstrated a significant difference between the sexes, p<0.0019) 
(Table 4.3).  
 
Table 4.3. Number of resolved blisters at 72 hrs post-cantharadin. Statistical analysis performed 
using chi-squared test. 
72 hr Blisters 
 
Blister formed 
and present 
Resolved Popped Total 
Male 12 0 4 16 
Female 5 9 2 16 
    p=0.0019 
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There was no significant difference (albeit a trend) in the total number of cells 
collected within the blisters between the sexes. Of all the cell types present, the 
neutrophil numbers were at least ten times higher than any other cell type. 
However, there were no differences in the number of neutrophils recruited into 
the blisters between the sexes (Figure 4.3 A and B). Whilst the percentage of cells 
were not different between the sexes (Figure 4.4), the assessment of levels of 
other key inflammatory cell types and cell activation state exposed a prominent 
difference between the sexes (see Figure 4.1 for typical scatter plots). 
 
Figure 4.3: Total number of cells and neutrophil response at 24 hours and 72 hours post 
application of cantharidin in female compared to male healthy volunteers. The total number 
of cells at 24 hours and 72 hours (A) and neutrophil response (B) following application of 
cantharidin to the volar aspect of the forearm.  Data is shown as mean ± s.e.mean of n=16 of each 
sex. Statistical analysis was determined using two-way ANOVA followed by Sidak’s post-tests.  
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Figure 4.4: Total percentage of all cell types at 24 hours and 72 hours post application of cantharidin in female compared to male healthy volunteers. The 
total percentage of all cell type at 24 hours (A) and 72 hours (B) following application of cantharidin to the volar aspect of the forearm.  Data is shown as mean ± 
s.e.mean of n=16 of each sex. Statistical analysis was determined using two-way ANOVA followed by Sidak’s post-tests.  
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Figure 4.5: Reduced inflammatory monocyte response to cantharidin in female compared 
to male healthy volunteers. The Inflammatory Monocyte count at 24 hours and 72 hours 
following application of cantharidin to the volar aspect of the forearm.  Data is shown as mean ± 
s.e.mean of n=16 of each sex. Statistical analysis was determined using two-way ANOVA followed 
by Sidak’s post-tests shown as # p <0.05.  
 
 
 
 
Figure 4.6: Intermediate Monocyte count in cantharidin-induced blister fluid at 24 hours 
and 72 hours post application in healthy volunteers (male n=13-15, female n=14-16). Data 
shown as mean ± s.e.mean with statistical significance determined using two-way ANOVA to 
compare between sexes on each day; not significant. 
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Figure 4.7 – Resident Monocyte in cantharidin-induced blister fluid at 24 hours and 72 
hours post application in healthy volunteers (male n=13-15, female n=14-16). Data shown as 
mean ± s.e.mean with statistical significance determined using two-way ANOVA to compare 
between sexes on each day; not significant. 
 
 
 
Figure 4.8: Reduced CD4+ and CD8+ T-cell count response to cantharidin in female 
compared to male healthy volunteers. The CD4+ (A) and CD8+ (B) T-cell count at 24 hours and 
72 hours following application of cantharidin to the volar aspect of the forearm.  Data is shown as 
mean ± s.e.mean of n=16 of each sex. Statistical analysis was determined using two-way ANOVA 
followed by Sidak’s post-tests shown as ## p <0.01.  
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In addition, the proportions and total numbers of inflammatory monocytes in 
blisters were significantly reduced in females compared to male volunteers 
particularly at 72 hours (Figure 4.5). Of note, there were also significantly lower 
levels of CD4+ and CD8+ T-cells in females when compared to males at both the 
24 and 72 hour time-points (Figure 4.8 A and B). There were no differences in 
the numbers of either the intermediate (inter) monocyte or the resident monocyte 
subtype (See Figure 4.6 and 4.7).  
 
Interestingly, as shown in Figure 4.9, irrespective of whether there were 
differences in the absolute numbers of specific cell subtypes between the sexes, all 
cell types showed a substantially and significantly reduced expression of all 3 
activation markers in females compared to males. In 24 hour blister samples, 
using a cytokine/chemokine bead array, we identified no differences between the 
sexes in the levels of the pro-inflammatory cytokines/chemokines that included 
IL-6, the neutrophil chemokines CCL5 and CXCL1 or the monocyte chemokine 
CCL-2. Interestingly, we found higher levels of IL-8 in the blisters from female 
volunteers compared to males and importantly a trend for higher expression of 
the anti-inflammatory cytokine IL-10 in females (Table 4.4). 
 
 
 
 
 
 
 
235 
 
Table 4.4. Cytokine/chemokine array of 24 hour cantharidin-induced blister supernatants in male 
and female healthy volunteers. Data are shown as mean  SD with statistical significance 
determined using using two-way ANOVA with post-hoc Sidak’s tests shown as ** for P <0.01 for 
comparison of time-points between the sexes and no significant differences for within group 
comparisons to baseline.  
 
  IL-6 (pg/ml) 
IL-10 
(pg/ml) 
CCL-5 
(pg/ml) 
CXCL-1 
(pg/ml) 
IL-8 (pg/ml) 
MCP-1 
(pg/ml) 
Male 
24 h 4361 ± 1182 6.6 ± 2.3 11.5 ± 1.8 1046 ± 606.6 5716 ± 1453 6139 ± 2141 
72 h 3250 ± 1178 48.1 ± 26.7 38.5 ± 26.0 224.5 ± 36.0 3675 ± 563.8 224.4 ± 26.86         
Female 
24 h 5087 ± 1697 18.0 ± 7.3 15.5 ± 2.7 4224 ± 1809 
13383 ± 
2771** 
9658 ± 3113 
72 h 5240 ± 3007 30.6 ± 0.0 10.7 ± 0 380.4 ± 124.3 5511 ± 9376 302.6 ± 93.2         
 
Sex 
comparison 
P value 
0.452 0.653 0.375 0.221 0.0484 0.527 
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Figure 4.9: Reduced inflammatory cell activation state in cantharidin –induced blister 
exudates in female compared to male healthy volunteers. Mean Fluorescence Intensity (MFI) 
of the expression molecules CD162, CD62L and CD11b on (A) neutrophils, (B) inflammatory (IM) 
monocytes and (C) CD4+ and CD8+ T-cells in healthy male (n=16) and female (n=16) volunteers. 
Data shown as mean ± s.e.mean Statistical significances determined using two-way ANOVA shown 
as ** p < 0.01, ***p<0.001 and **** p<0.0001 followed by Sidak’s post-tests shown as # p < 0.05, 
## p < 0.01 and #### P < 0.0001 comparing between the sexes at each time-point. 
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4.2.3 Elevated levels of resolving mediators in female blister exudates 
Since lipid mediators play an important role in both the initiation and the 
termination of acute inflammation (Serhan, 2014; Serhan et al., 2015) we next 
profiled lipid mediator levels in 24 hour blister exudates to investigate whether 
mediator levels from the three major bioactive metabolomes were differentially 
regulated between males and females. Using LC-MS/MS we identified mediators 
from the arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) bioactive metabolomes including Leukotriene (LT) B4, Prostaglandin 
(PG) E2, Resolvin (Rv) D1, RvD2, RvD3 and Protectin (PD) 1. These molecules were 
identified in accordance with published criteria (Colas et al., 2014) including 
matching retention times and > 6 diagnostic ions in the MS-MS to authentic or 
synthetic standards (Figure 4.10 A). Multiple reaction monitoring (MRM) was 
used to quantify mediators in these blister exudates. Using orthogonal-partial 
least squares discriminant analysis (OPLS-DA) distinct clusters for lipid mediator 
profiles in the exudates were evident between male and females (Figure 4.10 B, 
Table 4.5).  
 
Assessment of overall levels of each of the lipid mediator families demonstrated 
that the specialised pro-resolving mediators (SPM) levels were elevated in female 
blister exudates when compared to those obtained from males (sum of all of the 
SPMs significantly greater in females (17.2 7.4 pg/50l) (SD)) versus males (10.5 
6.3 pg/50l, P=0.015), with particularly the D-series resolvin levels collectively 
demonstrating a significant increase in females compared to males (Figure 4.11 
A). In these exudates we also found significantly higher levels of the potent 
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leucocyte chemoattractant LTB4 in male exudates when compared to female 
exudates (Figure 4.11 B), thus indicating that female-derived exudates gave an 
overall pro-resolving lipid mediator profile when compared to male exudates 
(Figure 4.11 C). To determine whether similar differences were evident in 
volunteers subjected to typhoid vaccination we assessed the levels of lipid 
mediators in the plasma from volunteers 8 h following vaccination, the time-point 
at which the differences in endothelial function were most evident (Chapter 3.0, 
Figure 3.6 A). In plasma from these patients we identified lipid mediators from 
all three major bioactive metabolomes in accordance with published criteria 
(Colas et al., 2014). Multivariate analysis of Lipid mediator profiles obtained using 
MRM gave two distinct clusters. Assessment of mediators that were associated 
with either of the clusters demonstrated that LTB4 was associated with the male 
cluster with a Variable in Importance Score >1, whereas RvE1 and RvE3 were 
found to associate with the female clusters. Statistical analysis of each of the 
bioactive mediator families demonstrated that in females there was a significant 
decrease in the LTB4 metabolome and a significant upregulation of the E-series 
resolvins specifically, RvE1 and RvE3. (see Figure 4.12, Figure 4.13 and  Table 
4.6). 
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Figure 4.10: Female blister exudates display a pro-resolving mediator profile. Lipid mediators from exudates were extracted using C18 SPE and profiled using 
LC-MS-MS based lipid mediator profiling. (A) Representative multiple reaction monitoring chromatograms for identified lipid mediators and pathway markers from 
the three major bioactive metabolomes (left panel) and MS-MS spectra employed for their identification (Right panel). (B) Partial least square discriminant analysis 
of exudate lipid mediator profiles (top panel) 2-D score plot (bottom panel) corresponding 2-D loading plot. Results shown are mean ± s.e.mean of n= 11 females and 
n=13 males. Statistical significance determined using Students unpaired t-test and shown as * p <0.05.  
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Figure 4.11: Female blister exudates display a pro-resolving mediator profile. Lipid mediators from exudates were extracted using C18 SPE and profiled using 
LC-MS-MS based lipid mediator profiling. (A-D) Cumulative levels for the lipid mediator from the (A) docosahexaenoic acid (B) eicosapentaenoic acid and (C) 
arachidonic acid SPM and Arachidonic acid-derived LTB4 (D) Ratio of SPM to LTB4. Results shown are mean ± s.e.mean of n= 11 females and n=13 males. Statistical 
significance determined using Students unpaired t-test and shown as * p <0.05. 
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Table 4.5. Blister exudate LM-SPM profiles. Exudates were collected from male (n=13) and female 
volunteers (n=11) 24h after cantharidin application and supernatants were profiling using LC-
MS/MS based profiling.  Results are mean  s.e.mean with statistical significance determined using 
Student’s unpaired t-test. - = below limit, limit ≈ 0.1 pg. 
 
 
 
   
Lipid mediators levels (pg/50μL) 
 
   
DHA bioactive 
metabolome 
Q1 Q3 Female Male p value 
RvD1 375 215 1.6 ± 1.1 1.4 ± 0.8 0.317 
RvD2 375 215 0.4 ± 0.7 0.1 ± 0.3 0.120 
RvD3 375 147 0.0 ± 0.1  -  0.143 
RvD4 375 101  -   -   
RvD5 359 199 0.3 ± 0.3 0.5 ± 0.5 0.176 
RvD6 359 159  -   -   
17R-RvD1 375 215 1.8 ± 1.7 0.8 ± 0.9 0.051 
17R-RvD3 375 147 0.0 ± 0.1 0.1 ± 0.1 0.246 
          
PD1 359 153 0.3 ± 0.6  -  0.046 
10S,17S-diHDHA (PDX) 359 153 0.7 ± 0.6 0.8 ± 0.9 0.463 
          
MaR1 359 250 2.5 
± 
6.4 0.9 
± 
1.7 
0.195 
7S,14S-diHDHA 359 221 0.1 ± 0.3 0.3 ± 0.7 0.201 
          
17-HDHA 343 245 22.7 ± 17.5 242.6 ± 589.5 0.115 
14-HDHA 343 205 194.2 ± 108.2 163.8 ± 120.4 0.263 
7-HDHA 343 141 2.7 ± 1.6 3.2 ± 2.7 0.282 
4-HDHA 343 101 3.6 ± 1.7 4.6 ± 4.8 0.264 
          
DHA 327 283 3031.3 ± 1309.2 2789.6 ± 1334.4 0.33 
          
EPA bioactive metabolome          
RvE1 349 161 0.4 ± 1.0 0.4 ± 0.6 0.403 
RvE2 333 199 1.0 ± 1.1 0.8 ± 1.2 0.344 
RvE3 333 245 4.0 ± 6.6 1.6 ± 3.1 0.125 
          
18-HEPE 317 259 2.1 ± 4.8 4.0 ± 9.6 0.288 
15-HEPE 317 219 7.9 ± 11.3 101.7 ± 227.7 0.094 
12-HEPE 317 179 20.1 ± 52.2 27.3 ± 70.8 0.390 
5-HEPE 317 115 0.4 ± 1.2 1.6 ± 4.9 0.23.2 
          
EPA 301 257 975.5 ± 622.1 1231.0 ± 857.7 0.210 
          
AA  bioactive metabolome          
LXA4 351 115  -   -   
LXB4 351 221 5.4 ± 3.6 3.5 ± 2.0 0.062 
5S,15S-diHETE 335 115 15.0 ± 19.6 9.9 ± 6.6 0.193 
AT-LXA4 351 115 0.2 ± 0.3 0.2 ± 0.3 0.493 
AT-LXB4 351 221 0.6 ± 1.2 0.3 ± 0.5 0.198 
          
LTB4 335 195 0.6 ± 0.3 1.2 ± 1.0 0.037 
          
PGD2 351 189 16.2 ± 12.9 8.9 ± 4.0 0.032 
PGE2 351 189 228.1 ± 205.6 134.9 ± 72.2 0.070 
PGF2α 353 193 1116.6 ± 550.0 808.9 ± 468.2 0.076 
TxB2 369 169 805.2 ± 796.4 426.8 ± 559.6 0.093 
          
20-HETE 319 301 15.5 ± 11.9 19.9 ± 17.8 0.246 
15-HETE 319 219 144.8 ± 211.0 848.2 ± 1605.3 0.082 
12-HETE 319 179 551.2 ± 223.4 514.5 ± 311.8 0.374 
5-HETE 319 115 9.3 ± 5.3 13.3 ± 8.6 0.098 
          
AA 303 259 4320.9 ± 1980.6 4714.8 ± 2041.8 0.319 
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Table 4.6. Lipid mediator profiles in plasma from male or female volunteers following 
typhoid vaccination Plasma was collected and LM levels were assessed using LM-profiling. 
Results are expressed as pg/mL; mean ± s.e.mean; n = 4 volunteers per group. - = below limit, 
limit ≈ 0.1 pg. 
  
   
Lipid mediators levels (pg/mL) 
 
   
DHA bioactive 
metabolome 
Q1 Q3 Male Female p value 
RvD1 375 233 0.1 ± 0.0 0.1 ± 0.0 0.280 
RvD2 375 141 0.3 ± 0.1 0.4 ± 0.2 0.312 
RvD3 375 147 0.2 ± 0.1 0.1 ± 0.0 0.187 
RvD4 375 101 0.5 ± 0.5 0.1 ± 0.1 0.230 
RvD5 359 199 1.2 ± 0.2 2.0 ± 0.7 0.152 
RvD6 359 101 0.3 ± 0.1 0.2 ± 0.1 0.340 
17R-RvD1 375 141 0.1 ± 0.0 0.1 ± 0.1 0.312 
17R-RvD3 375 147 0.2 ± 0.1 0.1 ± 0.0 0.187 
          
PD1 359 153 0.2 ± 0.0 0.2 ± 0.1 0.296 
17R-PD1 359 153 0.2 ± 0.1 0.1 ± 0.1 0.329 
22-OH-PD1 375 153 0.4 ± 0.4 0.7 ± 0.7 0.343 
10S,17S-diHDHA (PDX) 359 153 0.6 ± 0.0 0.9 ± 0.3 0.098 
          
MaR1 359 221  -   -   
MaR2 359 191 2.9 ± 1.3 2.5 ± 1.0 0.395 
22-OH-MaR1 375 221 0.4 ± 0.4 0.1 ± 0.2 0.247 
7S,14S-diHDHA 359 221  -   -  0.232 
4S,14S-diHDHA 359 101 0.3 ± 0.3 0.1 ± 0.1 0.178 
          
EPA bioactive 
metabolome 
   
 
  
 
 
 
RvE1 349 161 0.2 ± 0.1 0.4 ± 0.1 0.118 
RvE2 333 159 0.1 ± 0.1  -  0.369 
RvE3 333 201 0.4 ± 0.2 0.9 ± 0.4 0.094 
          
AA  bioactive 
metabolome 
   
 
  
 
 
 
LXA4 351 217 0.1 ± 0.0 0.1 ± 0.0 0.298 
LXB4 351 221 5.2 ± 2.6  -  0.028 
5S,15S-diHETE 335 235 4.9 ± 2.6 1.1 ± 0.8 0.082 
AT-LXA4 351 217 0.2 ± 0.2 0.1 ± 0.1 0.317 
AT-LXB4 351 221 1.1 ± 0.6 1.2 ± 0.8 0.440 
          
LTB4 335 195 0.6 ± 0.0 0.5 ± 0.0 0.006 
6-trans- LTB4 335 195 0.1 ± 0.0  -  0.168 
12-epi-6-trans- LTB4 335 195 0.2 ± 0.1  -  0.099 
5S,12S-diHETE 335 195 0.1 ± 0.0 0.1 ± 0.0 0.414 
20-OH-LTB4 351 195 0.1 ± 0.0  -  0.085 
          
PGD2 351 189 3.5 ± 1.8 4.4 ± 2.6 0.382 
PGE2 351 189 5.7 ± 2.4 6.9 ± 3.7 0.379 
PGF2α 353 193 3.8 ± 1.0 6.0 ± 3.0 0.220 
TxB2 369 169 97.8 ± 36.3 108.7 ± 52.7 0.426 
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Figure 4.12: Distinct plasma LM-SPM profiles in males and females following typhoid vaccination. Plasma was collected for healthy volunteers following 
typhoid vaccine administration and LM levels were assessed using LM-profiling (see methods for details). (A) left panel Representative Multiple Reaction Monitoring 
chromatograms for identified mediators. a=Δ6-trans-LTB4, b=12-epi, Δ6-trans-LTB4. right panel   MS-MS fragmentation and diagnostic ions employed for LXB4 and 
RvE1 identification. m/z, mass-to-charge ratio; M-H, molecular ion. (B) top panel 2-dimentional score plot of human plasma LM-SPM profiles. Bottom panel 2-
dimentional loading plot. Grey ellipse in the score plot denotes 95% confidence regions. Results are representative n=4 male and n=4 female healthy volunteers. 
Results are mean±s.e.mean n=4 volunteers per group. * p<0.05 vs Male volunteer plasma values.  
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Figure 4.13: Distinct plasma LM-SPM profiles in males and females following typhoid vaccination. Plasma was collected for healthy volunteers following 
typhoid vaccine administration and LM levels were assessed using LM-profiling (see methods for details). (A-B) Cumulative levels for each of the bioactive LM families 
identified. Results are mean±s.e.mean n=4 volunteers per group. * p<0.05 vs Male volunteer plasma values.   
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4.3 Summary 
• Cantharidin application to the skin induced blister formation in both sexes. Whilst 
the exudate volume generated at 24 hrs was similar between the sexes, at 72 hrs 
the volume was substantially less in females compared to males.  
• The total number of cells recruited into blisters showed a trend for reduction in 
females – although this did not reach statistical significance.  
• After 72 hrs, blisters had resolved in 56% of females and 0% in male volunteers, 
suggesting a faster rate of resolution in females. 
• Flow cytometry analysis exposed a prominent sex difference in the proportions of 
leucocyte subsets recruited into blisters, with significantly reduced numbers of 
monocytes and lymphocytes in females compared to males. 
• There was a generalised reduction in the activation state of all major leucocytes 
populations as demonstrated by reduced fluorescence intensity of activation 
markers in females compared to males. 
• Lipid mediator profiling exposed a prominent sex difference with a pronounced 
shift in balance towards a pro-resolving profile in females compared to males. 
• Our findings suggest that differences in female sex either suppresses 
inflammatory leucocyte recruitment in inflammation or promotes leucocyte exit 
from blisters, with reduced numbers of both inflammatory monocytes and 
lymphocytes and a reduced activation state of all leucocyte subsets. This 
difference is associated with a lipid mediator profile indicating that the reduction 
in cell recruitment in females is likely due to a more efficient resolution of the 
inflammatory response.  
• Both the cantharidin and typhoid vaccine (described in Chapter 3.0) models of 
inflammation in healthy volunteers enabled us to establish cell assessing 
techniques in our laboratory and use similar techniques for larger phase II clinical 
trials such as the NITRATE-OCT study. 
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5.0 A randomised, double-blind, placebo-controlled study investigating the 
effects of inorganic nitrate on vascular function, platelet reactivity and 
restenosis in stable angina: Protocol of the NITRATE-OCT study 
 
5.1 Introduction to NITRATE-OCT 
The mainstay treatment for reducing the symptoms of angina and long-term risk 
of heart attacks in patients with heart disease is stent implantation in the diseased 
coronary artery. Whilst this procedure has revolutionised treatment the incidence 
of secondary events remains a concern. These repeat events are thought to be due, 
in part, to continued enhanced platelet reactivity, endothelial dysfunction and 
ultimately restenosis of the stented artery. The NITRATE-OCT trial is investigating 
whether a once a day inorganic nitrate (NO3-) administration might favourably 
modulate platelet reactivity and endothelial function leading to a decrease in 
restenosis. This is a double-blind, randomised, single-centre, placebo-controlled 
phase II trial that aims to enrol 246 patients with stable angina due to have elective 
PCI procedure with stent implantation. Patients are randomised to receive 6 
months of a once a day dose of either NO3--rich beetroot juice or NO3--deplete 
beetroot juice (placebo) starting up to one week before their procedure (Figure 
5.1). As recruitment for this is still ongoing, the results in this chapter contains the 
baseline data for 200 participants that have been recruited upto 30th of April 2018. 
 
5.1.1 Introduction to the effect of inorganic nitrate on the inflammatory 
response following PCI 
Inorganic NO3-, when converted to NO2- via the enterosalivary circuit, has been 
shown to reduce smooth muscle cell proliferation and promote endothelial cell 
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growth in our laboratory. This study contains a sub-analysis of our large Phase II 
double blinded randomised controlled trial (NITRATE-OCT) that is investigating 
whether there is a reduction in the growth of smooth muscle cells (preventing 
restenosis within the stent), following ingestion of inorganic NO3- in patients 
undergoing percutaneous coronary intervention (PCI) with stent implantation for 
stable angina. If this hypothesis is found to be correct, then the exact mechanisms 
by which this benefit might be occurring are not yet clear.  
 
The aim of this part of the thesis was to explore the possibility that the beneficial 
effects of inorganic NO3- with regards to reducing restenosis in stable angina 
patients might relate to effects on inflammation, by assessing the levels of specific 
pro-inflammatory components and circulating cell subtypes as exploratory 
endpoints in the NITRITE-OCT cohort. 
 
To ensure that the trial remained blinded from the investigators of the trial, the 
samples have been grouped as the ‘whole cohort’ at baseline compared to 6 
months post  intervention. We analysed peripheral blood leukocyte subsets 
including markers of activation and the release kinetics of high-sensitivity CRP 
(hs-CRP), and the neutrophil chemokines CX3CL-1 and CCL-2 in patients who 
received either inorganic NO3- in the form of beetroot juice containing 4-5 mmol 
of inorganic nitrate (N = 78 in total). Blood samples were collected at baseline and 
at 6 months following ingestion of the juice.  
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5.2 Aims 
The primary aim of this study is to test whether dietary NO3- ingestion in addition 
to conventional therapy has beneficial effects in patients with stable angina. To 
date, I have recruited 200 patients with 130 patients who have completed their 
primary endpoint. In this chapter, I will present all the baseline data so far. 
 
Specific aims are: 
1) To determine whether it is safe to deliver dietary NO3- in patient 
undergoing PCI and stent implantation and whether the randomisation is 
effective. 
2) To determine whether dietary NO3- ingestion exerts anti-platelet effects or 
improvement of endothelial function and the mechanisms involved in this effect. 
 
5.3 Methods 
The study was carried out according to the detailed methods described in 
Chapter 2 section 2.2 and the flow chart shown in Figure 5.1. 
 
5.3.1 Sample size calculation 
Sample size was determined for a total of 246 patients for a two treatment 
parallel-design study. We calculated that with a probability of 80 percent we are 
able to detect a treatment difference at a two sided 5% significance level, if the 
true difference in late loss between the treatments is 0.22 mm (i.e. ~50% of the 
effect size seen with PDE inhibition which resulted in a 35% reduction in late loss) 
(Mauri et al., 2005). This absolute difference is calculated from a mean late loss of 
1.27mm with a standard deviation of the response variable of 0.550. These values 
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being the mean and average of the standard deviations of 22 trials measuring late 
loss in trials of both drug eluting and bare metal stents described in the review by 
Mauri et al (Mauri et al., 2005). The recruitment of 246 also takes into account an 
additional 10% for drop-out or withdrawal/non-compliance. This value is based 
upon previous experience in our unit.  All sample calculations were done using 
G*Power 3.0 TM.   
 
In addition, the sample size of 246 enables sufficient power for secondary outcome 
measure of estimation of the hard endpoint of MACE at 6 months. The number is 
based on a study, in stable angina patients who underwent elective angioplasty 
and a remote ischaemic preconditioning intervention which resulted in a 
significant reduction in MACE at 6 months with 4/110 (3.6%) in the treatment 
group versus 13/104 (12.5%) in the control group (Davies et al., 2013). Using 
these data as a basis for power calculations, a total number of 230 patients are 
needed for 80% power using one-tailed analysis. Thus, to account for potential 
loss to follow-up 246 patients will be recruited in total. The data will be analysed 
on an intention to treat basis.  In addition, further per protocol analyses and a 
subgroup analysis of patients on organic nitrates as part of their routine therapy 
and a comparison of DES (drug-eluting stents) versus BMS (bare-metal stents) will 
be conducted. 
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Figure 5.1: Flow diagram of Study design  
hsCRP: high sensitivity C-Reactive Protein, IL-6: Interlukin 6, MACE: Major Adverse Cardiac Events, 
OCT: Optical Coherence Tomography, TVR: Target Vessel Revascularisation, XOR: Xanthine 
Oxidoreductase. 
 
 
Patients with stable angina 
identified 
Consent for study 
Randomisation 
Intervention: 70 ml of beetroot 
juice concentrate (containing 4-5 
mmol nitrate) from one day prior 
to PCI up to 6 months  
 
Control: 70 ml of nitrate 
deplete placebo juice 
concentrate from one day 
prior to PCI up to 6 months 
 
Secondary end point at 6 months: Flow-mediated dilatation at 6 months post PCI.  Markers of 
inflammation: plasma and erythrocyte nitrite reductase and XO activity, hsCRP and IL-6.  Platelet 
activation (P-Selectin and platelet-monocyte aggregates) and aggregation ex vivo (ADP, collagen, 
arachidonic acid). Reduction in TVR and MACE. 
 
Primary end point: Assessment of 
in-stent late loss using angiogram 
and OCT at 6 months ± 1 month 
 
Baseline measurements: Flow-mediated dilatation.  Markers of inflammation: plasma and erythrocyte 
nitrite reductase and XO activity, hsCRP and IL-6. Platelet activation (P-Selectin and platelet-
monocyte aggregates) and aggregation ex vivo (ADP, collagen, arachidonic acid) measured. 
 
Secondary end point at 12 months: Markers of inflammation: plasma and erythrocyte nitrite 
reductase and XO activity, hsCRP and IL-6.  Platelet activation (P-Selectin and platelet-monocyte 
aggregates) and aggregation ex vivo (ADP, collagen, arachidonic acid). Reduction in TVR and 
MACE. 
 
Secondary end point at 24 months: Reduction in TVR and MACE. 
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5.4 Data analysis 
The data analysis plan for this study is as detailed in the methods (sections 2.2.2.5 
and 2.2.2.6). However, since the study is still underway, for this thesis all available 
baseline data is shown according to the randomisation group. The study has been 
maintained blind by an unrelated individual dividing the patients recruited into 
gamma and delta groups. For all analysis comparing baseline with completed, the 
two groups are combined and an overall assessment of baseline with 6 months 
conducted for only those patients that have completed the primary outcome at 6 
months. For the sake of this thesis, paired analysis has been conducted. 
 
The data are shown for 200 patients for demographics, 200 patients for discharge 
and 130 patients have reached the primary end point. For the biochemical 
analysis, there is data available for 83 plasma NO3-/NO2- analysis, 74 saliva NO3-
/NO2- analysis and 66 urine NO3-/NO2- analysis. With regards cGMP measurement, 
we have analysed 77 paired samples to date. For the inflammation sub-group 
analysis, we have 78 paired data for total leukocyte and urate levels, 66 paired 
analysis for the activations markers from flow cytometry and 78 paired data for 
the cytokine and chemokine analysis. Table 5.1 describes this attrition and 
reasons in more detail. 
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 Total Number so far Target  Reasons 
Data collected (n=200)    
Demographics 200 (100.0%) 246  Study is ongoing collecting data 
Discharge data 200 (100.0%) 246  Study is ongoing collecting data 
Primary end point 130 (65.0%) 220  Study is ongoing collecting data 
Biochemical Analysis     
    Plasma NO3-/NO2- 83 (41.0%) 246  Study is ongoing collecting data 
    Saliva NO3-/NO2- 74 (37.0%) 246  Study is ongoing collecting data 
    Urine NO3-/NO2- 66 (33.0%) 246  Study is ongoing collecting data 
    cGMP 77 (38.5%) 246  Study is ongoing collecting data 
   Inflammation Sub-group     
 Total leukocyte 78 (39.0%) 80  Loss of data due to drop-outs 
    Urate levels 78 (39.0%) 80  Loss of data due to drop-outs 
    Activation marker data 66 (33.0%) 80  Loss of data due to drop-outs 
 Chemokine/cytokine data 78 (39.0%) 80  Loss of data due to drop-outs 
 
Table 5.1. Attrition rate of data from the NITRATE-OCT Study. Values shown as number (%) 
unless otherwise stated. 
 
5.5 Clinical Trial Results 
5.5.1 Clinical Trial recruitment to date 
200 patients have been recruited to date (from the 10th of November 2015 to the 
30th of April 2018) and 130 have completed the primary endpoint as of 30th April 
2018, (Figure 5.2). 
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Figure 5.2: Recruitment to NITRATE-OCT (As of 30th April 2018) 
 
Between November 2015 and April 2018, 3190 patients were admitted for an 
elective angioplasty and stent insertion for symptoms of stable angina at The Barts 
Health Heart Attack Centre. Of these patients 466 were eligible for this study and 
2724 were excluded for not meeting study criteria. Among these 466 patients, 266 
(57.1%) were excluded for the following reasons: 175 (37.6%) patients declined 
to have the second procedure in the study, 49 (10.5%) patients declined to take 
part in any research, 15 (3.2%) patients did not like the taste of beetroot juice (the 
intervention), 14 (3.0%) patients did not meet the inclusion/exclusion criteria and 
13 (2.8%) patients could not commit to the study visits involved in the study. This 
left 200 patients suitable who were randomised. In the unit, many studies in both 
healthy volunteers and CVD patients have been conducted and this is the first that 
we have witnessed taste as a criteria for refusal to participate. The 3% rate 
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suggests that whilst this is more than previous, this would still not be a major 
determent for therapeutics. Nevertheless, this data suggests that large-scale trials 
are needed to discern the true potential of this dietary approach in terms of 
compliance. Certainly, this represents the largest and longest trial to date of such 
a dietary intervention, with previous studies lasting no more than 6 months and 
at most in 126 patients (Mills et al., 2016). From the patients recruited so far, 
baseline data is available for 200 patients in total (100 patients in both groups). 
Furthermore, we have data collected for the primary endpoint for 130 (Figure 
5.3). 
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Figure 5.3: Consort diagram.  
 
 
 
  
Assessed for eligibility 
n=3190 
2724 Excluded for not meeting 
study criteria 
Eligible patients 
Screened 
n=466 
Randomised 
n=200 
266 Excluded  
175 Declined the second procedure 
  49 Declined all research 
  15 Did not like the intervention (juice)  
  14 Did not meet the inclusion/exclusion criteria    
  13 Could not commit to the study visits 
100 randomised to nitrate-
rich or nitrate-deplete 
beetroot juice (placebo) 
100 in the gamma group 
100 randomised to nitrate-rich 
or nitrate-deplete beetroot juice 
(placebo) 
100 in the delta group 
65 included in clinical endpoint 
at 6 months (ongoing) 
65 included in clinical endpoint 
at 6 months (ongoing) 
12 Lost to follow-up 
9 No primary end-point (1 died) 
14 Lost to follow-up 
13 No primary end-point 
8 included in clinical endpoint 
at 1 year (ongoing) 
8 included in clinical endpoint at 
1 year (ongoing) 
1 Lost to follow-up (died) 2 Lost to follow-up (died) 
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5.5.3 General characteristics of Study population 
As the NITRATE-OCT study is still ongoing, the treatment given to each group 
remains blinded to avoid bias in analysis. The groups have been labelled gamma 
and delta to ensure that the trial remains blinded from the investigators.  
 
This study is a randomised trial and as such the baseline characteristics 
demonstrate good matching of the groups. All baseline characteristics were 
similar between the treatment groups (Table 5.2) except for mean baseline heart 
rate (HR), which was higher in the gamma group compared to the delta group 
(69.85±17.00 bpm vs 64.93±12.71 minutes). This difference in HR in 1 in 30 of the 
different baseline characteristics is likely to be reflective of a chance observation. 
The mean age of the trial participants was 62 years, with 83.5% male. This split is 
typical of such cohorts and reflects the prevalence as discussed previously of 
increased rates of coronary artery disease in men versus women. In general, rates 
of coronary artery disease in women catch up to those in men post 65 years (Maas 
and Appelman, 2010). The two study groups were similar with respect to NYHA 
and CCS classification of angina and Previous MI/PCI/CABG (Table 5.2).  
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Table 5.2. Baseline characteristics of patients in NITRATE-OCT by blinded treatment 
group.  
Values shown as number (%) unless otherwise stated. (PCI, percutaneous coronary 
intervention; TIMI, Thrombolysis in myocardial infarction; DES drug-eluting stent; MI, 
myocardial infarction; BPM, beats per minute; BP, blood pressure; CCS, Canadian 
classification system; NYHA, New York Heart Failure Association Classification; CABG, 
Coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease).  
a The body-mass index is the weight in kilograms divided by the square of the height in metres.  
 Gamma (n=100) Delta (n=100) P Value 
Age (yr) (Mean±SD) 61.5±9.1 63.1±9.6 0.257 
Sex (M/F) 84 (84.0) 82 (82.0) 0.981 
Ethnicity 
 Caucasian 84 (84.0%) 82 (82.0%) 
 
1.000 
 Afro-Caribbean 3 (3.0%) 5 (5.0%) 0.444 
 Asian 10 (10.0%) 10 (10.0%) 1.000 
 East Asian 3 (3.0%) 3 (3.0%) 1.000 
Diabetes mellitus  26 (26.0%)  26 (26.0%) 1.000 
 Type I 4 (4.0%) 4 (4.0%) 1.000 
 Type II 22 (22.0%) 22 (22.0%) 1.000 
Body-mass index (kg/m2) (Mean±SD)a 28.8±4.3 29.7±5.2 0.185 
Hypertension  75 (75.0%) 75 (75.0%) 1.000 
Hypercholesterolaemia  73 (73.0%) 84 (84.0%) 0.106 
Previous MI 20 (20.0%) 22 (22.0%) 0.855 
Previous PCI 28 (28.0%) 34 (34.01%) 0.422 
Previous CABG 3 (3.0%) 3 (3.0%) 1.000 
Previous Smoker 62 (62.0%) 64 (64.0%) 0.878 
PVD 7 (7.0%) 11 (11.0%) 0.433 
CVA/TIA 3 (3.0%) 6 (6.0%) 0.720 
NYHA    
 Class I 3 (3.0%) 6 (6.0%) 0.720 
 Class II 3 (3.0%) 4 (4.0%) 0.541 
CCS    
 CCS I 15 (15.0%) 20 (20.0%) 0.442 
 CCS II 42 (42.0%) 33 (33.0%) 0.283 
 CCS III 42 (42.0%) 46 (46.0%) 0.654 
Asthma 9 (9.0%) 9 (9.0%) 1.000 
COPD 11 (11.0%) 5 (5.5%) 0.281 
Previous History of CAD 47 (47.%) 53 (58.2%) 0.181 
    
Heart rate (BPM) (Mean±SD) 69.9±17.0 64.9±12.7 0.030 
Systolic BP (mmHg) (Mean±SD) 135.3±18.0 136.5±16.2 0.652 
Diastolic BP (mmHg) (Mean±SD) 76.9±8.8 75.8±10.5 0.745 
    
Culprit Vessel    
Left main stem 1 (1.0%) 0 (0.0%) 1.000 
Left anterior descending 33 (33.0%) 39(39.0%) 0.536 
Circumflex  21 (21.0%) 17 (17.0%) 0.569 
Right coronary  34 (34.0%) 30 (30%) 0.633 
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There were no differences in the type of stent deployed, length of stent or diameter 
of stent between the two groups. Use of drug-eluting stents and anti-platelet 
therapy were similar between the 2 groups (Table  5.3).  
 
There were three main types of drug eluting stents used over the period of 
recruitment. These included Xience (Everolimus-eluting stent), Promus 
(Everolimus-eluting stent) and Resolute Integrity (Zotarolimus-eluting). Overall, 
majority of the patients had a Xience stent implanted mainly based on the operator 
preference. Since there were a number of patients who did not undergo a stent 
implantation during the procedure, which was a decision made by the cardiologist 
at the time, the sum of all the stents do not add up to 100%. This was documented 
as a protocol deviation for the study. 
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Table 5.3. Procedural characteristics by treatment group. Values shown as number (%) unless 
otherwise stated. (DES; Drug-eluting stent) 
 
 
5.5.4 Primary End-point 
Out of all patients recruited to date, 130 have achieved the primary endpoint of 
Angiography and for QCA analysis and OCT. An example of the angiogram (at 
baseline and 6 month) for patient 040 is shown in Figure 5.4 and Figure 5.5.  
 Gamma (n=100) Delta (n=100) P value 
Access site    
    Radial 76 (76.0%) 76 (76.0%) 1.000 
    
DES use 87 (87.0%) 88 (88.0%) 0.778 
Number of stents used (Mean±SD) 1.51±0.82 1.56±0.75 0.847 
Stent Type    
 Xience 74 (74.0%) 76 (76.0%) 0.865 
 Resolute Integrity 6 (6.0%) 3 (3.0%) 0.598 
 Promus Premier 2 (2.0%) 4 (4.0%) 0.368 
 Biofreedom 0 (0%) 1 (1.0%) 1.000 
Stent length (Mean±SD)    
 First Stent 25.2±9.1 25.24±8.7 0.983 
 Second Stent 23.1±8.2 22.06±9.6 0.662 
 Third Stent 20.0±5.8 20.25±8.1 0.945 
 Fourth Stent 26.5±16.3 23.00±13.4 0.781 
Stent diameter (Mean±SD)    
 First Stent 3.1±0.5 3.0±0.5 0.145 
 Second Stent 3.2±0.6 3.0±0.5 0.119 
 Third Stent 3.0±0.6 2.9±0.4 0.815 
 Fourth Stent 3.0±0.7 3.5±0.8 0.458 
Treatment at time of PCI    
 Verapamil 43 (46.0%) 43 (43.0%) 0.842 
 Heparin 100 (100%) 100 (100%) 1.000 
 Heparin Dose (Mean±SD) 8926.5±2770.1 9198.5±3126.9 0.698 
 Aspirin 100 (100%) 100 (100%) 1.000 
 Clopiodgrel/Ticagrelor 100 (100%) 100 (100%) 1.000 
    
Procedural Success  100 (100%) 100 (100%) 1.000 
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Figure 5.4: Angiogram images of the LAD (indicated by the white arrow) at A) baseline 
before the stent was implanted, B) at baseline after the stent and C) at 6 months after the 
stent.  
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Figure 5.5: Representative images of: A) An angiogram of the LAD artery, B) OCT imaging of 
the proximal LAD stent showing moderate to severe in-stent restenosis and C) OCT imaging 
of the distal LAD stent showing normal endothelialisaton and virtually no in-stent 
restenosis. 
 
Panel A demonstrates an angiogram of the LAD in the RAO Cranial view. There is 
moderate to severe stenosis within the proximal portion of the stent. Panel B 
shows moderate to severe ISR (represented by the green *). Panel C shows normal 
endothelialisation within the stent (represented by the yellow *). The red arrow 
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shows the stent strut and there is drop-out of light behind the stent strut. The blue 
is showing the lumen of the LAD artery. The white # is showing the OCT catheter 
and the white * represents the guide wire, again there is drop-out of light behind 
the wire due to wire artefact. 
 
5.5.5 Acute safety and tolerability of nitrate across the whole cohort 
There were no significant differences between the groups regarding heart rate, 
systolic BP or diastolic BP at 6 months compared to baseline (Table 5.4).  
 
 
Table 5.4. Baseline and 6 month blood pressure, heart rate and methamaglobinaemia levels 
are shown (BP, blood pressure; BPM, beats per minute). 
 
Assessment of the change in each parameter over the 6 month indicated an overall 
reduction in SBP at 6 months compared to baseline of -4.50 mmHg (IQR: -14.00 – 
6.00)  and an overall reduction in DBP at 6 months compared to baseline of -10.00 
mmHg (IQR: -19.00 – 0.00). In contrast, there does not appear to be any significant 
change in heart rate at 6 months compared to baseline (1.00 BPM (IQR: -4.50 – 
4.50) (Figure 5.6). 
 
Met-Hb levels were measured to assess the possibility that raising circulating NO2- 
levels may result in complications with oxygen delivery due to the interaction of 
NO2- with oxy-Hb (Greer and Shannon, 2005). Overall, there appears to be no 
Baseline Baseline (n=130) 6 months (n=130) P value 
   
Heart rate (BPM) (Mean±SD) 67.38±15.16 66.71±16.48 
 
0.276 
Systolic BP (mmHg) (Mean±SD) 135.91±17.05 129.78±21.00 0.385 
Diastolic BP (mmHg) (Mean±SD) 76.316±9.67 73.68±10.11 0.686 
Methaemaglobinanemia level (Mean±SD) 0.41±0.27 0.54±0.31 0.839 
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clinically significant rise in met-Hb levels at 6 months compared to baseline 
(median 0.10 IQR: -0.10 - 0.30). (Figure 5.7). 
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Figure 5.6: Assessment of the effect of beetroot juice (both inorganic nitrate and placebo) 
on systolic blood pressure, diastolic blood pressure and heart rate.  
The change in BP (A & B) and heart rate (C) following 6 months of the intervention compared to 
baseline is shown.  
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Figure 5.7: Assessment of the effect of beetroot juice (both inorganic nitrate and placebo) 
on methaemaglobinaemia levels. 
Overall change in methaemaglobinaemia levels at 6 months compared to baseline in (n=130) are 
shown. This suggests no significant change in methaemaglobin levels. 
 
5.5.6 Medication 
Data was available on prescribed medication for 100% of patients at discharge 
following the angioplasty. Overall the majority of both patient groups were 
optimised on medical therapy at discharge (dual anti-platelet agents, statin, beta-
blocker and angiotensin-receptor blocking drugs). (Table 5.5).  
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 Gamma  Delta P value 
Medication at discharge (n=100)  (n=100)  
ACE inhibitor 55 (55.0%)  45 (45.0%) 0.307 
ARB 11 (11.0%)  17 (17.0%) 0.195 
Diuretic 9 (9.0%)  12 (12.0%) 0.626 
Amlodipine 23 (23.0%)  19 (19.0%) 0.585 
   β Blocker 63 (63.0%)  74 (74.0% 0.152 
   Statin 95 (95.0%)  92 (92.0%) 0.767 
   Aspirin 100 (100%)  100 (100%) 1.000 
   Clopidogrel 78 (78.0%)  75 (75.0%) 0.621 
   Ticagrelor 22 (22.0%)  25 (25.0%) 0.725 
   Nicorandil 9 (9.0%)  13 (13.0%) 0.478 
   Organic Nitrate 23 (23.0%)  20 (20.0%) 0.718 
   GTN 55 (55.0%)  66 (66.0%) 0.172 
   Ranolazine 2 (2.0%)  2 (2.0%) 1.000 
   Warfarin 1 (1.0%)  3 (3.0%) 0.621 
   NOAC 5 (5.0%)  5 (5.0%) 1.000 
 
Table 5.5. Prescribed drugs at baseline Values shown as number (%) unless otherwise stated. 
Abbreviations: ACEi: Angiotension-converting enzyme; ARB: Angiotensin receptor blocker.   
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5.5.7 Serious adverse events and adverse events 
Of the 200 patients recruited, all of the patients were discharged successfully 
following their procedures with no events during their stay. On average, the stay 
duration was 1.3±0.6 days. There were no differences between the groups in the 
length of stay. There have been 15 serious adverse events (SAE) (4 deaths – (1 
following mitral valve surgery 5 month following the index procedure, 3 further 
deaths beyond 1 year from recruitment, which means they were 6 months 
following their end of the intervention), 3 re-hospitalisations for myocardial 
infarction (2 NSTEMIs and 1 STEMI), 2 re-hospitalisations (1 for right sided chest 
pain following a mechanical fall), 1 prolonged hospitalisation for left ventricular 
failure, 6 patients underwent target vessel revascularisation at their 6 month 
angiogram and 1 patient was diagnosed with prostate carcinoma. There have been 
37 adverse events (16 patients had gastrointestinal upset resulting in 13 patients 
withdrawing from the study, 1 patient had light-headedness at 5.5 months into the 
study, 1 patient had light-headedness 3 months into the study, 1 patient had an 
unplanned diagnostic angiogram due to shortness of breath – angiogram was 
unremarkable, 1 patient had PCI to by-standing disease in another vessel due to 
angina, 1 patient was diagnosed with leukaemia but is not life-threatening, 2 
patients had high blood sugars which was managed by increasing the doses of 
diabetic medications and 1 patient broke their ankle at work (mechanical in 
nature). There have been no suspected, unexpected serious adverse reactions. All 
four deaths in the study have been reviewed by the Chief Investigator and 
Principal Investigator of the study and we have concluded that this unfortunate 
event was not related to the intervention and therefore the study was not 
unblinded at the time.  
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5.5.8 Major adverse cardiac events 
MACE is a powered secondary endpoint in this study. The events shown have been 
recorded but not unblinded. Overall, at a 2 year time-point after being recruited 
into the study, 13 patients have suffered MACE (4 deaths, 3 recurrent myocardial 
infarction and 6 unscheduled revascularizations) (Figure 5.8).  
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Figure 5.8: Kaplan Meier curve. Survival curve showing cumulative probability of major 
adverse cardiac events (MACE) after PCI for stable angina in the overall population.  
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5.6 Comparison of baseline and 6 month plasma [cGMP] and 
plasma/urine/saliva [NO2-] and [NO3-] in patients with stable angina 
 
5.6.1 Effect of 6 month intervention on [NO3-] and [NO2-] in plasma samples 
from patients with angina  
There was a significant increase in the plasma [NO3-] concentration from baseline 
of approximately 3.7 - fold (Figure 5.9A). In contrast, there was a trend towards 
an increase approximately 0.6 - fold in plasma [NO2-] concentration but this did 
not reach significance when comparing 6 months to baseline (Figure 5.9B).  
 
  
 
 
 
 
270 
 
B a s e lin e 6  m o n th s
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
P
la
s
m
a
 [
N
it
ra
te
] 
( 
m
o
l/
L
)
(A )
**
B a s e lin e 6  m o n th s
B a s e lin e 6  m o n th s
0
1
2
3
P
la
s
m
a
 [
N
it
ri
te
] 
(
m
o
l/
L
)
(C )
B a s e lin e 6  m o n th s B a s e lin e 6  m o n th s
0
1
2
3
P
la
s
m
a
 [
N
it
ri
te
] 
(
m
o
l/
L
)
(D )
B a s e lin e 6  m o n th s
B a s e lin e 6  m o n th s
0
1 0 0
2 0 0
3 0 0
4 0 0
P
la
s
m
a
 [
N
it
ra
te
] 
(
m
o
l/
L
)
(B )
B a s e lin e 6  m o n th s
 
 
Figure 5.9: Plasma (A) and (B) [NO3-] and (C) and (D) [NO2-] of all recruited patients that had 
completed the study, at baseline and after 6 months of treatment. The treatment was with 
either dietary nitrate (nitrate-rich juice 70 mL daily) or placebo (nitrate-depleted juice 70 mL 
daily), in patients with stable angina. Data expressed as mean ± SEM. n = 83. Statistical analysis 
was performed using paired t-test. **P = 0.0087. 
 
5.6.2 Effect of 6 month intervention on [NO3-] and [NO2-] in saliva samples 
from patients with angina 
There was a significant increase in the saliva [NO3-] concentration at 6 months 
compared to baseline of approximately 2.5 - fold (Figure 5.10A). There was also 
a trend towards an increase in the saliva [NO2-] concentration at 6 months 
compared to baseline of approximately 1.5 – fold but this did not reach statistical 
significance (Figure 5.10B).  
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Figure 5.10: Saliva (A) and (B) [NO3-] and (C) and (D) [NO2-] of all recruited patients that had 
completed the study, at baseline and after 6 months of treatment. The treatment was with 
either dietary nitrate (nitrate-rich juice 70 mL daily) or placebo (nitrate-depleted juice 70 mL 
daily), in patients with stable angina. Data expressed as mean ± SEM. n = 74. Statistical analysis 
was performed using paired t-test. *P = 0.0120. 
 
5.6.3 Effect of 6 month intervention on [NO3-] and [NO2-] in urine samples 
from patients with angina 
There was a significant increase in the urine [NO3-] concentration at 6 months 
compared to baseline of approximately 2.5 - fold (Figure 5.11A). Similarly, there 
was a significant increase in the urine [NO2-] concentration at 6 months compared 
to baseline of approximately 2.1 - fold (Figure 5.11B).  
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Figure 5.11: Urine (A) and (B) [NO3-] and (C) and (D) [NO2-] of all recruited patients that had 
completed the study, at baseline and after 6 months of treatment. The treatment was with 
either dietary nitrate (nitrate-rich juice 70 mL daily) or placebo (nitrate-depleted juice 70 mL 
daily), in patients with stable angina. Data expressed as mean ± SEM. n = 77. Statistical analysis 
was performed using paired t-test. ***P = 0.0012; ***P = 0.0007.  
 
5.6.4 Plasma [cGMP] in patients with angina 
Overall, after being treated for 6 months, plasma [cGMP] was significantly 
increased 1.15-fold (Figure 5.9).    
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Figure 5.12: Plasma (A) and (B) [cGMP] of all recruited patients that had completed the 
study, at baseline and after 6 months of treatment. The treatment was with either dietary 
nitrate (nitrate-rich juice 70 mL daily) or placebo (nitrate-depleted juice 70 mL daily). Data 
expressed as mean ± SEM. n= 77 in the whole cohort. Statistical analysis was performed using 
paired t-test. ** P = 0.0027.  
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5.7 Exploratory investigations of the effect of inorganic nitrate on the 
inflammatory response following primary percutaneous coronary 
intervention for stable angina 
 
5.7.1 Effect of nitrate on the systemic inflammatory response in patients 
with stable angina 
 
5.7.1.1 General characteristics of inflammation study subpopulation 
Looking at the subpopulation of patients from the NITRATE-OCT study where we 
have inflammation data, the treatment given to each group was still kept blind to 
avoid bias in analysis. The groups have again been labelled gamma and delta to 
ensure that the trial remains blinded from the investigators. Again, the baseline 
characteristics demonstrate good matching of the groups. All baseline 
characteristics were similar between the treatment groups in this sub-analysis 
(Table 5.6). 
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Table 5.6. Baseline characteristics of inflammation sub-study patients in NITRATE-
OCT by blinded treatment group.  
Values shown as number (%) unless otherwise stated. (PCI, percutaneous coronary 
intervention; TIMI, Thrombolysis in myocardial infarction; DES drug-eluting stent; MI, 
myocardial infarction; BPM, beats per minute; BP, blood pressure; CCS, Canadian 
classification system; NYHA, New York Heart Failure Association Classification; CABG, 
Coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease).  
a The body-mass index is the weight in kilograms divided by the square of the height in metres.  
 Gamma (n=40) Delta (n=40) P Value 
Age (yr) (Mean±SD) 61.7±8.8 62.1±10.1 0.421 
Sex (M/F) 31 (77.5%) 37 (92.5%) 0.115 
Ethnicity 
 Caucasian 
 
33 (82.5%) 29 (72.5%) 
 
0.211 
 Afro-Caribbean 1 (2.5%) 3 (7.5%) 0.615 
 Asian 5 (12.5%) 7 (17.5%) 0.378 
 East Asian 0 (0.0%) 1 (2.5%) 1.000 
Diabetes mellitus  9 (22.5%) 9 (22.5%) 1.000 
 Type I 1 (2.5%) 1 (2.5%) 1.000 
 Type II 8 (20.0%) 8 (20.0%) 1.000 
Body-mass index (kg/m2) (Mean±SD)a 28.8±4.5 29.0±4.7 0.889 
Hypertension  32 (80.0%) 32 (80.0%) 1.000 
Hypercholesterolaemia  27 (67.5%) 35 (87.5%) 0.059 
Previous MI 6 (15.0%) 4 (10.0%) 0.737 
Previous PCI 8 (20.0%) 9 (22.5%) 1.000 
Previous CABG 2 (5.0%) 2 (5.0%) 1.000 
Previous Smoker 24 (60.0%) 27 (67.5%) 0.642 
PVD 2 (5.0%) 4 (10.0%) 0.675 
CVA/TIA 0 (0.0%) 0 (0.0%) - 
NYHA    
 Class I 3 (7.5%) 1 (2.5%) 0.842 
 Class II 2 (5.0%) 1 (2.5%) 0.958 
CCS    
 CCS I 9 (22.5%) 11 (27.5%) 0.797 
 CCS II 13 (32.5%) 14 (35.0%) 1.000 
 CCS III 17 (42.5%) 14 (35.0%) 0.647 
Asthma 4 (10.0%) 3 (7.5%) 1.000 
COPD 5 (12.5%) 1 (2.5%) 0.201 
Previous History of CAD 18 (45.0%) 23 (57.5%) 0.371 
    
Heart rate (BPM) (Mean±SD) 68.3±19.7 61.9±10.7 0.279 
Systolic BP (mmHg) (Mean±SD) 132.4±20.7 135.0±16.5 0.388 
Diastolic BP (mmHg) (Mean±SD) 75.4±8.3 76.0±11.4 0.084 
    
Culprit Vessel    
Left main stem 1 (1.0%) 0 (1.0%) 1.000 
Left anterior descending 13 (32.5%) 15(37.5%) 0.815 
Circumflex  13 (32.5%) 9 (22.5%) 0.453 
Right coronary  9 (22.5%) 12 (30%) 0.612 
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Again, there were no differences in the type of stent deployed, length of stent or 
diameter of stent between the two sub-groups. Use of drug-eluting stents and anti-
platelet therapy were similar between the 2 groups (Table  5.7).  There were three 
main types of drug eluting stents used over the period of recruitment. These 
included Xience (Everolimus-eluting stent), Promus (Everolimus-eluting stent) 
and Resolute Integrity (Zotarolimus-eluting). Overall, the majority of patients had 
a Xience stent implanted mainly based on the operator preference. Again, since 
there were a number of patients who did not undergo a stent implantation during 
the procedure, which was a decision made by the cardiologist at the time, the sum 
of all the stents do not add up to 100%. This was documented as a protocol 
deviation for the study. 
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Table 5.7. Procedural characteristics of the inflammation sub-study by treatment group. 
Values shown as number (%) unless otherwise stated. (DES, Drug-eluting stent) 
 
5.7.1.2 Total leukocyte cell count 
Total circulating leukocyte cell counts were measured at baseline and 6 months 
after PCI in all patients. Total leukocyte cell counts were similar between the two 
timepoints at 6 months compared to baseline (P = 0.822) (Figure 5.13).     
 Gamma (n=40) Delta (n=40) P value 
Access site    
    Radial 32 (80.0%) 31 (77.5%) 1.000 
    
DES use 37 (92.5%) 35 (87.5%) 0.712 
Number of stents used (Mean±SD) 1.52±0.83 1.58±0.81 0.910 
Stent Type    
 Xience 31 (77.5%) 29 (72.5%) 0.782 
 Resolute Integrity 5 (12.5%) 3 (7.5%) 0.677 
 Promus Premier 4 (10.0%) 8 (20.0%) 0.348 
 Biofreedom 0 (0%) 0 (0%) - 
Stent length (Mean±SD)    
 First Stent 23.1±9.5 25.0±8.8 0.643 
 Second Stent 22.0±8.1 27.6±9.4 0.553 
 Third Stent 23.0±5.7 20.8±11.8 0.240 
Stent diameter (Mean±SD)    
 First Stent 3.0±0.5 2.9±0.4 0.122 
 Second Stent 3.3±0.6 3.2±0.6 0.726 
 Third Stent 2.9±0.5 2.9±0.5 0.877 
Treatment at time of PCI    
 Verapamil 14 (35.0%) 12 (30.0%) 0.691 
 Heparin 100 (100%) 100 (100%) 1.000 
 Heparin Dose (Mean±SD) 8166.7±2301.9 8285.7±2212.9 0.919 
 Aspirin 100 (100%) 100 (100%) 1.000 
 Clopiodgrel/Ticagrelor 100 (100%) 100 (100%) 1.000 
    
Procedural Success  100 (100%) 100 (100%) 1.000 
278 
 
B a s e lin e 6  M o n th s
0
2
4
6
8
1 0
T
o
ta
l 
W
h
it
e
 B
lo
o
d
 C
e
ll
 C
o
u
n
t 
(x
 1
0
9
/L
)
B a s e lin e
6  M o n th s
T im e
 
Figure 5.13: Total leukocyte count pre and post PCI. Total leukocyte count was measured at 
baseline and 6 months after PCI. Leukocyte count assessed over time (n=78). Data expressed as 
mean ± SEM. Statistical analysis was performed using paired t-test. 
 
5.7.1.3 Leukocyte inflammatory marker expression  
Inflammatory marker expression (CD11b, CD62L and CD162) on each leukocyte 
population: neutrophils, monocytes (inflammatory, intermediate and resident), 
and T lymphocytes (CD4+ and CD8+) were measured. Measurements were made 
at baseline and 6 months post-PCI in 66 patients in total (33 patients in each 
group).  
 
5.7.1.4 Neutrophil activation marker expression  
Neutrophil CD11b, CD62L and CD162 changed from baseline to 6 months but not 
this did not reach statistical significance. (Figure 5.14 A, C and D).  
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Figure 5.14: Neutrophil Median Fluorescence Intensity. Median Fluorescence Intensity (MFI) 
for CD11b/CD62L/CD162 was measured at baseline and 6 months after PCI as shown in panels 
A-C in 66 patients. Panel A shows CD11b MFI assessed over time. Panel B shows CD162 MFI over 
time. CD62L MFI was assessed over time as shown in panel C.  Data expressed as mean ± SEM.  
Statistical analysis was performed using paired t-test. 
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5.7.1.5 T Lymphocytes 
5.7.1.5.1 CD4+ T lymphocytes 
Expression levels of CD11b and CD62L on CD4+ lymphocytes did not change from 
baseline to 6 months (Figure 5.15 A and C). There was a trend towards an 
increase in expression levels of CD162 at 6 months compared to baseline, however 
this did not reach statistical significance (p=0.0501, Figure 5.15B). 
 
5.7.1.5.2 CD8+ T lymphocytes 
CD8+ T lymphocyte CD11b, CD162 and CD62L levels did not change from baseline 
to 6 months. (Figure 5.16 A, B and C).  
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Figure 5.15: CD4+ T Lymphocyte CD11b/CD62L/162 Median Fluorescence Intensity. Median 
Fluorescence Intensity (MFI) for CD11b/CD62L/CD162 was measured at baseline and 6 months 
after PCI as shown in panels A-C in 66 patients. Panel A shows CD11b MFI assessed over time. Panel 
B shows CD162 MFI over time. CD62L MFI was assessed over time as shown in panel C.  Data 
expressed as mean ± SEM.  Statistical analysis was performed using paired t-test. 
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Figure 5.16: CD8+ T lymphocyte Median Fluorescence Intensity. Median Fluorescence 
Intensity (MFI) for CD11b/CD62L/CD162 was measured at baseline and 6 months after PCI as 
shown in panels A-C in 66 patients. Panel A shows CD11b MFI assessed over time. Panel B shows 
CD162 MFI over time. CD62L MFI was assessed over time as shown in panel C.  Data expressed as 
mean ± SEM.  Statistical analysis was performed using paired t-test. 
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5.7.1.6 Monocytes 
Monocytes were split into inflammatory (classical) monocytes (CD14+/CD16-), 
intermediate monocytes (CD14+/CD16+) and non-classical/resident monocytes 
(CD14+/CD16++) (Passlick et al., 1989; Ziegler-Heitbrock et al., 2010; Rogacev et 
al., 2012) 
 
5.7.1.6.1 Inflammatory monocytes (CD14+/CD16-) 
Inflammatory monocyte CD11b and CD62L did not change from baseline to 6 
months (Figures 5.17 A and C). However, CD162 expression increased from 
baseline to 6 months but this did not reach statistical significance. (Figure 5.17B).  
 
5.7.1.6.2 Intermediate monocytes (CD14+/CD16+) 
Intermediate monocyte CD11b, CD162L and CD62L expression did not change 
from baseline to 6 months (Figures 5.18 A, B and C). 
 
5.7.1.6.3 Resident monocytes (CD14+/CD16+)  
Resident monocyte CD11b and CD162 expression increased from baseline to 6 
months but this did not reach statistical significance (Figure 5.19 A and B). 
CD162 expression did not change over the time period (Figure 5.19C). 
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Figure 5.17: Inflammatory monocyte Median Fluorescence Intensity. Median Fluorescence 
Intensity (MFI) for CD11b/CD62L/CD162 was measured at baseline and 6 months after PCI as 
shown in panels A-C in 66 patients. Panel A shows CD11b MFI assessed over time. Panel B shows 
CD162 MFI over time. CD62L MFI was assessed over time as shown in panel C.  Data expressed as 
mean ± SEM.  Statistical analysis was performed using paired t-test. 
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Figure 5.18: Intermediate monocyte Median Fluorescence Intensity. Median Fluorescence 
Intensity (MFI) for CD11b/CD62L/CD162 was measured at baseline and 6 months after PCI as 
shown in panels A-C in 66 patients. Panel A shows CD11b MFI assessed over time. Panel B shows 
CD162 MFI over time. CD62L MFI was assessed over time as shown in panel C.  Data expressed as 
mean ± SEM.  Statistical analysis was performed using paired t-test. 
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Figure 5.19: Resident monocyte Median Fluorescence Intensity. Median Fluorescence 
Intensity (MFI) for CD11b/CD62L/CD162 was measured at baseline and 6 months after PCI as 
shown in panels A-C in 66 patients. Panel A shows CD11b MFI assessed over time. Panel B shows 
CD162 MFI over time. CD62L MFI was assessed over time as shown in panel C.  Data expressed as 
mean ± SEM. Statistical analysis was performed using paired t-test. 
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5.7.2 Effect of nitrate on the inflammatory mediators in patients with stable 
angina 
Plasma levels of high-sensitivity C-reactive (hs-CRP) protein, urate, interleukin-1β 
(IL-1β), interleukin-6 (IL-6) and tumor necrosis factor α (TNFα) were measured 
at baseline and  6 months post-PCI.  
 
5.7.2.1 High-sensitivity C-reactive protein 
Overall, plasma hs-CRP levels showed a trend towards a reduction at 6 months 
compared to baseline (Figure 5.20A, p=0.1780). After measuring changes from 
baseline, there was an overall reduction in hs-CRP level compared to baseline 
(Figure 5.20B).  
 
5.7.2.2 Interleukin1-β (IL-1β), Interleukin-6 (IL-6) and Tumor necrosis 
factor α (TNFα) 
Overall, plasma TNFα showed a trend towards a reduction at 6 months compared 
to baseline (Figure 5.21A). IL-1β levels were not statistically different at 6 months 
compared to baseline (Figure 5.21B). However, IL-6 levels were statistically 
significantly lower at 6 months compared to baseline (Figure 5.21C) (p=0.0106).  
 
5.7.2.3 Plasma Urate levels 
Plasma urate did not change significantly from baseline at 6 months. (Figure 5.22, 
p=0.854).  
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Figure 5.20: Effect of time and treatment on plasma hs-CRP. High-sensitivity C-reactive 
protein (hs-CRP) was measured at baseline and 6 months after PCI in the whole cohort (n=78) 
(panel A). Panel B shows the change in hs-CRP at 6 months compared to baseline in the whole 
cohort. Data expressed as mean ± SEM.  Comparison performed using paired t-test for panel A. 
(Hs-CRP= High-sensitivity C-reactive protein). 
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Figure 5.21: Effect of time and treatment on plasma TNFα, IL-1β and IL-6. Plasma levels of 
tumor necrosis factor α (TNFα), interleukin-1β (IL-1β) and interleukin-6 (IL-6) were measured at 
baseline and 6 months post-PCI shown in panel A, B and C, respectively in 78 patients.  Data 
expressed as mean ± SEM.  Comparison performed using paired t-test. 
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Figure 5.22: Serum urate levels pre and post PCI. Plasma urate levels were measured at 
baseline and 6 months after PCI in the whole cohort (n=78) (panel A). Data expressed as mean ± 
SEM. Statistical analysis was performed using paired t-test for both panels. 
 
5.7.2.4 Neutrophil chemokines 
We investigated the levels of CXCL-1, CXCL-5, CXCL-8, CXCL-2 and CXCL-12 
measured in 78 patients at baseline and 6 months post-PCI.  
 
5.7.2.4.1 CXCL-1, CXCL-5, CXCL-8, CXCL-2 and CXCL-12 
Plasma CXCL-1 levels were significantly lower at 6 months compared to baseline 
(Figure 4.11A) (p=0.0120). CXCL-5 levels were significantly lower at 6 months 
compared to baseline (Figure 5.23B) (p=0.0017). CXCL-8 levels were significantly 
lower at 6 months compared to baseline (Figure 5.23C) (p=0.0087). CXCL-2 were 
significantly lower at 6 months compared to baseline (Figure 5.23D) (p=0.0121). 
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However, CXCL-12 levels were comparable in the two groups at baseline and at 6 
months (Figure 5.23E) (p=0.1312). 
 
Figure 5.23: Effect of time and treatment on plasma CXCL-1 CXCL-5, CXCL-8, CXCL-2 and 
CXCL-12. Plasma levels of CXCL-1 (panel A), CXCL-5 (panel B), CXCL-8 (panel C), CXCL-2 (panel D) 
and CXCL-12 (panel E) were measured at baseline and 6 months post-PCI over time in 78 patients.  
Data expressed as mean ± SEM.  Comparison performed using paired t-test. 
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5.7.2.5 Monocyte chemokines 
We also measured levels of CCL-2 and CX3CL-1 in 78 patients at baseline and 6 
months post-PCI.  
 
5.7.2.5.1 CCL-2 and CX3CL-1 
Plasma CCL-2 levels were significantly lower at 6 months compared to baseline 
(Figure 5.24A, p=0.0034). CX3CL-1 levels were significantly lower at 6 months 
compared to baseline (Figure 5.24B, p=0.0499).  
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Figure 5.24: Effect of time and treatment on plasma CCL-2 and CX3CL-1. Plasma levels of 
CCL-2 and CXCL-1 were measured at baseline and  6 months post-PCI. CCL-2 as shown in panel A 
and CX3CL-1 (panel B) were assessed over time in 78 patients. Data expressed as mean ± SEM.  
Comparison performed using paired t-test. 
 
5.7.2.6 IL-10, anti-inflammatory mediator 
Overall, there was a trend towards a reduction in IL-10 at 6 months compared to 
baseline (Figure 5.25, p=0.1664).  
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Figure 5.25: Effect of time and treatment on plasma IL-10. IL-10 levels were measured at 
baseline and 6 months after PCI (N = 78). Data expressed as mean ± SEM.  Comparison performed 
using a paired t-test. (IL-10=interlukin-10). 
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5.8 Summary 
 
1. For the 200 patients recruited, baseline characteristics were similar indicating 
adequate randomisation of the study so far. 
2. To date, no safely issues with respect to the placebo or active juice have been 
identified.  
3. In the whole cohort, total circulating WCC numbers and hs-CRP did not change 
significantly, however, there was reduction in IL-6 levels at 6 months compared 
to baseline.  
4. There was an overall combined reduction in the levels of neutrophil specific 
chemokines (CXCL-1, CXCL-5, CXCL-8 and CXCL-2) at 6 months compared to 
baseline. 
5. There was also an overall combined reduction in the levels of the monocyte 
specific chemokines (CX3CL-1 and CCL-2) at 6 months compared to baseline. 
6. There were no differences in the number of other leukocyte populations 
(neutrophils, inflammatory monocytes and lymphocytes) or activation markers 
expressed by these cells.  
7. These results suggest an increase in NOX metabolite and a reduction in systemic 
inflammatory marker over time. Whether this is due to nitrate is currently 
unknown and will become clear following unblinding at the end of the trial. 
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6.0 Discussion 
Despite significant advances in the management of CVD, CHD still represents an 
enormous burden in terms of morbidity and mortality and there is no doubt that 
further improvement in treatment is needed in this field particularly in the 
management of stable angina.  PCI is a procedure that is used to ‘re-open’ patients’ 
narrowed coronary arteries with the view to reduce or completely relieve the 
patients’ angina symptoms.  Since the birth of PCI in 1977, there has been 
significant growth in stent technology, however, one of the main issues 
surrounding both BMS and DES is the accelerated neo-intimal proliferation at the 
site of the stent placement, resulting in luminal restenosis. Currently there is a 
growth of evidence suggesting that inflammation may play an important role in 
restenosis (Libby et al., 2003; Toutouzas et al., 2004), raising the possibility that 
measurement of inflammation may improve our ability to predict those at 
increased risk. 
 
It is thought that systemic inflammation is a key driver of CVD and particularly 
atherosclerosis and CHD.  This view has recently been corroborated with the 
outcome of the CANTOS trial.  In CANTOS, Ridker and colleagues assessed whether 
targeting inflammation might reduce CVD in patients at risk of events following 
the use of canakinumab, a therapeutic monoclonal antibody targeting IL-1β. The 
study recruited 10,061 patients with previous MI and a hsCRP level of  2 mg/litre. 
The study found that anti-inflammatory therapy targeting the IL-1β innate 
immunity pathway resulted in a significantly lower rate of recurrent 
cardiovascular events than placebo, which was independent of lipid-level 
lowering (Ridker et al., 2017). This confirms that targeting inflammation provides 
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options for therapeutics in CVD and CHD.  The work in this thesis has been carried 
out to assess whether inflammation is the target for NO2-/NO3- and whether the 
effects are sufficient to lead to benefit  
 
However, here are many issues surrounding the use of biologics including cost of 
development (which results in high marketing costs), route of administration 
(often requiring hospital admission due to need for intravenous administration), 
side effects (including immunosuppression) and lack of long-term data in terms of 
efficacy and safety. In addition, one of the issues with the approach taken in 
CANTOS is that biologics are expensive and so identifying perhaps easier to deliver 
therapeutics that overcome the issues with biologics is desirable. One such 
possibility of course is inorganic NO3-, the testing of which has been a key aim in 
this thesis and discussed in the latter sections of this discussion.  In addition, the 
fact that altering inflammation impacts upon CVD raises the question of whether 
differences in inflammatory responses between distinct groups of individuals 
might also underlie differences in CVD susceptibility.  Of particular relevance to 
this PhD is the question of whether differences in inflammation between the sexes 
might relate to differences in response to inflammatory stressors.  Chapters 3 and 
4 of this thesis focused upon testing whether this might be the case. 
 
6.1 Differences in responses to inflammatory stimuli between the sexes 
could underlie differences in CVD pathogenesis 
It is accepted that pre-menopausal women have reduced levels of CVD compared 
to their age-matched male counterparts (Lerner and Kannel, 1986).  The exact 
mechanisms involved in mediating this protection are uncertain but have been 
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attributed to an effect of female sex hormones (Mendelsohn and Karas, 2005). 
Separately we know that whilst women tend to experience increased autoimmune 
disease, they have lower rates of inflammation in the context of chronic disease 
such as CVD and infection (Beagley and Gockel, 2003; Gubbels Bupp, 2015). Since 
good evidence links innate immune responses with CVD (Ross, 1999b) and 
inflammation is particularly thought to be causative in endothelial dysfunction (a 
critical pathogenic step in CVD progression) we speculated that reduced acute 
inflammatory responses in females may contribute to the protection of women 
against endothelial dysfunction and ultimately CVD development.  Using 
experimental models in healthy volunteers, we have shown that female sex 
protects against the endothelial dysfunction induced by a mild systemic 
inflammatory response and that this protection likely relates to an enhanced 
leucocyte surveillance in the female circulation and an accelerated resolution of 
inflammation. We speculate that this enhanced capacity to deal with and then 
recover from an inflammatory stress likely plays a crucial role in the reduced rates 
of inflammatory CVD in premenopausal females.  
 
6.1.1 Low grade systematic inflammation results in transient endothelial 
dysfunction in males but not females 
Administration of typhoid vaccine to healthy volunteers causes a transient 
endothelial dysfunction reflected by a reduced response to reactive hyperaemia 
(Hingorani et al., 2000b). In Chapter 3.0, I have shown that the FMD response was 
reduced following typhoid vaccination in males but, if anything, in females FMD 
was greater following vaccine administration. Comparison of the change in FMD 
from baseline between the sexes (the primary outcome of this study) 
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demonstrates a clear protection in females from the damaging effects of systemic 
inflammation induced by typhoid vaccination. Since I also demonstrated that the 
responses to the endothelium-independent vasodilator, GTN, in both sexes were 
unchanged over the course of the study and neither were there any changes in 
arterial stiffness measures of PWV and PWA, my findings suggest that protection 
against the damaging effects of typhoid vaccination evident in females, relates to 
alterations in endothelial function and not changes in smooth muscle reactivity. 
This latter observation agrees with previous findings demonstrating no effect of 
typhoid vaccination upon NO donor-induced brachial artery dilator response 
either to sublingual GTN (Hingorani et al., 2000b) or intra-arterial infusions of 
sodium nitroprusside (Chia et al., 2003). It is worth noting that although previous 
studies have demonstrated a significant reduction in FMD in healthy male 
volunteers following the administration of the typhoid vaccine, I only 
demonstrated a trend. One possible explanation for this finding could be that in 
our group, the absolute FMD measurements have been much lower (Ranging 
between 5-8% in healthy participants compared to that published in the literature 
(ranging between 10-15%) (Nowicki et al., 2018; Peretz et al., 2007). Hence, the 
relative change is much smaller., which would mean we would require a larger 
sample size to see a significant reduction in FMD following administration of the 
typhoid vaccine. 
 
Plasma NO2- levels are thought to reflect endothelial NO generation, and NO is 
considered to mediate at least part of the shear stress-induced FMD response 
(Kleinbongard et al., 2003; Lauer et al., 2001; Mullen et al., 2001; Mullen et al., 
1997). Post-hoc correlation analyses show that whilst FMD responses in females 
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correlated directly with circulating NO2- levels there was no such relationship in 
males. The primary pathway implicated in upregulation of beneficial NO levels in 
health is phosphorylation of endothelial nitric oxide synthase (eNOS), and perhaps 
in particular  via an AKT-dependent pathway (Figure 6.1); and importantly this 
pathway also underlies oestrogen-induced enhanced NO bioavailability (Garcia-
Cardena et al., 1998; Russell et al., 2000). It is likely that this pathway is 
responsible for the enhanced FMD responses in this study too. In pre-clinical 
studies oestrogen-induced upregulation of the AKT-eNOS phosphorylation 
pathway in blood vessels in females is resistant to repression by pathological 
stimuli that cause profound endothelial dysfunction in males (Taguchi et al., 
2012). Additionally, stimuli activating the AKT pathway procure greater activation 
of this pathway in females compared to males (Kane et al., 2009). Of relevance to 
this study acute low grade inflammation whilst activating pro-inflammatory 
pathways also triggers reflex protective effects particularly through upregulating 
AKT phosphorylation (Ha et al., 2008; Jones and Bolli, 2006). These observations 
together support the view that the enhanced FMD response in females following 
typhoid is likely secondary to a phosphorylation of eNOS resulting in greater 
shear-stress induced NO generation.  
 
The lack of a correlation between plasma NO2- levels and FMD in males suggests 
that the FMD response in males is not entirely dependent upon NO (Green et al., 
2014). This view is supported by a recent meta-analysis of studies assessing the 
contribution of NO in mediating FMD, where it was estimated that 47-67% of the 
dilator response to flow could be attributed to NO. The wide range possibly being 
due to differences in the methodology used(Green et al., 2014) but also possibly 
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due to the high inter-individual variability that exists in the FMD response (Parker 
et al., 2011), but also now our data suggest that this variability may also be a 
reflection of the influence of sex differences. 
 
 
Figure 6.1 The role of kinases and phosphatases in the activation of eNOS by multi-site 
phosphorylation. Activation of NO synthesis by eNOS involves multiple and coordinated 
phosphorylation events and protein–protein interactions. Important activators of eNOS include 
bradykinin, vascular endothelial growth factor (VEGF), shear stress and pharmacological stimuli 
such as statins. Numerous kinases and phosphatases contribute to the regulation of eNOS 
phosphorylation, although the specific kinases and phosphatases involved can vary depending on 
either the activating stimulus or the tissue bed. + indicates kinase-mediated phosphorylation. − 
indicates phosphatase-mediated dephosphorylation. Adapted from Mount et al. (Mount et al., 
2007). 
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As expected a number of demographic variables were distinct between the sexes 
despite being age-matched and healthy (Vitale et al., 2009).  These include BMI 
and BP but also WCC. The elevated WCC at baseline in females has been attributed 
to higher neutrophil numbers (Bain and England, 1975a) and indeed in my study 
different neutrophil numbers accounted for the differences in WCC between men 
and women. Importantly, all women recruited into these studies attended 
experimental days at the mid-point of their menstrual cycles when oestrogen 
levels are generally at their highest and so also are the leucocyte and neutrophil 
counts (Bain and England, 1975b). This raised WCC/neutrophil number in females 
may be due to oestrogen-induced margination of neutrophils from the bone 
marrow. In healthy women asked to conduct controlled exercise, as a trigger for 
changes in granulocyte distribution, the response remained unchanged at 
different stages of the menstrual cycle(Bain and England, 1975b). However, 
studies in mice suggest that low dose oestrogen inhibits rather than triggers bone 
marrow margination (Josefsson et al., 1992). Exactly why these diametrically 
opposing results occur is uncertain but may simply reflect important species 
differences.  
 
Interestingly, whilst we saw no significant differences in monocyte numbers at 
baseline my data suggest a generalised raised activation state of circulating 
neutrophils and monocytes in females compared to males. In particular, we saw 
enhanced expression of both CD162 and CD62L adhesion molecules on these cell 
types in men at 8h, with recovery of baseline expression levels by 32h following 
typhoid vaccine, but no significant changes in expression levels in women. If 
anything, there was some suggestion of a slight but non-significant decrease in 
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females in the expression of the adhesion molecules relative to baseline.  With 
respect to CD62L it is possible that this reflects the shedding of CD62L which 
occurs during inflammatory responses and is thought to enhance leukocyte 
transmigration (Hafezi-Moghadam et al., 2001), however further experiments 
powered against CD62L levels are needed to investigate this.  Both cellular CD162 
and CD62L have been identified as critical mediators of the homing, rolling and 
adhesion of both neutrophils and monocytes to sites of inflammation through 
interaction with the endothelium and thus the enhanced cell expression in the 
males is likely to reflect an increased cell activation (Pillay et al.; Xu et al., 2008).  
 
6.1.2 Acute localised inflammatory response is reduced in females 
compared to males 
Irrespective of which mechanisms might underlie the sex differences in cell 
numbers and activation state, the outcome of such a response would be to reduce 
exposure of the vasculature to the potentially long-term detrimental effects of a 
sustained inflammatory response, and offers possible explanations for the 
absence of vascular dysfunction in the female sex. Interestingly, recent evidence 
suggests that the sex differences in leucocyte count and activation state evident in 
healthy volunteers are lost in individuals with raised CVD risk. Although it is worth 
noting that the average age of the women in this particular study was 62, an age 
when the majority of the women must have been post-menopausal (although 
whether this was the case or not is unclear) (Gomez-Sanchez et al., 2015). Our 
observations in typhoid-induced systemic inflammation suggest that there is an 
enhanced surveillance and readiness to deal with inflammatory stimuli in women 
resulting, probably, in a reduced detrimental impact upon the vasculature. In 
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order to probe the possible mechanisms further we assessed acute inflammatory 
responses using the cantharidin based model of innate inflammatory response 
(Day et al., 2001b).  
 
Cantharidin is a protein phosphatase 1 and 2 alpha inhibitor (Honkanen, 1993). 
When applied to the skin it results in acantholysis and blister formation which has 
been characterised as the detachment of tonofilaments from desmosomes 
(Bertaux et al., 1988).  This in turn causes leucocyte extravasation, cytokine 
release and clinical inflammation. During inflammation leucocytes and proteins 
traverse the blood vessel into the extravascaular space. Recruitment of cells to 
inflammatory sites is dependent on the release of vasoactive and chemotactic 
factors that increase regional blood flow, increase microvascular permeability and 
promote the exudation of leucocytes from the circulation into the tissues 
(Suffredini et al., 1999).  Cantharidin was used in this study to trigger this response 
to enable quantification of and, therefore, comparison between the sexes of this 
inflammatory response. This was achieved through assessment of the volume of 
fluid collecting into the blister as well as characterising the number and types of 
inflammatory cell collecting within the exudate. In this study, cantharidin elicited 
a similar magnitude of blister response, in terms of oedema (i.e. volume) and total 
number of cells,  in males and females; and a response that was similar in 
magnitude to that reported previously, (Jenner et al., 2014). Indeed, at the 24 hour 
time-point the number of neutrophils, the first cell recruited to a site of 
inflammation, was very similar between the sexes suggesting that female sex does 
not suppress the capacity to respond to an inflammatory stimulus per se. 
Assessment of the pro-inflammatory cytokine/chemokine profile in the main 
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supports this view. Our analyses suggest no differences between the sexes of some 
of the key mediators previously implicated in the cantharidin blister response in 
humans, including IL-6 (Jenner et al., 2014), neutrophil CXCL1, CCL5 and 
monocyte chemokines (CCL2) (Viola and Luster, 2008).  However, at 72 hours 
there was a pronounced reduction in the blister volume with a slight trend for 
reduced cell numbers in females; a reduction accounted for by a pronounced and 
significant reduction in inflammatory monocyte numbers. Importantly, in many of 
the women (~70% vs 30% in men) the blisters had resolved by 72 hours resulting 
in no volume collection at all. Since the immediate (24 hour) response was similar 
between the sexes, we speculated that the reduced cell number and volume at 72 
hours likely reflects an enhanced rate of resolution of inflammation.  
 
This suggestion of enhanced resolution is in line with recent evidence 
demonstrating the key role of resolvins in clearing oedema following an 
inflammatory insult, where oedema in the lung induced in mice with hydrochloric 
acid was reduced in mice treated with aspirin-trigged RvD3 (Colby et al., 2016). 
To explore this possibility further we assessed the level of IL-10, a pivotal cytokine 
released during the resolution stage of an inflammatory response that is derived 
from the anti-inflammatory intermediate (M2) monocyte (Chinetti-Gbaguidi et al., 
2015). We did observe a trend for enhanced IL-10 in the blisters of females at 24 
hours, however this did not reach statistical significance, likely due to the fact that 
the study was not powered for this measurement. However, it is thought that IL-
10 represses further cell recruitment in part by down-regulating inflammatory 
cell activation. Indeed, the levels of CD62L, CD11b and CD162 expression, were all 
substantially reduced supporting the view that whilst the response to the 
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inflammatory stimulus was similar between the sexes that in females this 
inflammatory response was likely cleared and ‘resolved’ at a much faster rate.  
 
6.1.3 Elevated pro-resolving lipid mediator profile in blister exudates from 
females 
It is now accepted that the resolution of acute inflammation is an active process 
that is initiated when the very first leucocytes arrive at the inflammatory site. This 
process of resolution is triggered by the recruited cells themselves and is mediated 
by a switch in the local production of lipid mediators from the pro-inflammatory 
eicosanoids, including prostaglandins and leukotrienes, to the pro-resolving and 
tissue reparative SPM including the lipoxins and resolvins (Serhan, 2014). Using 
targeted lipid mediator profiling we found a 1.4- to 2-fold higher level for each 
class of SPM in females. In addition, SPM amounts relative to those of the pro-
inflammatory/chemotactic lipid mediator LTB4 exposed a 3 times higher ratio of 
SPMs to LTB4 in the females compared to the males, suggesting that the balance of 
pro-resolving to pro-inflammatory lipid mediators was tipped in favour of 
resolution in females.  
 
SPMs share a number of key defining bioactions including their ability to limit 
neutrophil recruitment to a site of inflammation, counterregulate the production 
and actions of pro-inflammatory mediators and promote macrophage 
phagocytosis of cellular debris and apoptotic cells. In addition, each SPM displays 
unique biological action. For example MaR1 is produced in the later stages of the 
resolution phase and promotes tissue repair as well as displays potent 
antinociceptive actions (Dalli and Serhan, 2016). RvD1, RvD5 and PD1 are 
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produced during self-limited infections and promote the clearance of bacterial 
infections (Chiang et al., 2012), while Resolvin D2 potently regulates endothelial 
NO production (Spite et al., 2009).  In the present study, we found a statistically 
significant reduction both in neutrophil and monocyte/macrophage activation 
state in females compared to males.  This is in line with recent findings 
demonstrating that RvD1 potently regulates neutrophil recruitment and adhesion 
molecule expression (Norling et al., 2012) as well as with the findings that RvD1 
regulates LTB4 formation by regulating 5-lipoxygenase phosphorylation and 
translocation to the nuclear membrane (Fredman et al., 2014). This balance in 
favour of the resolving SPMs in the blisters of females compared to males was also 
evident in the plasma of females 8 h following typhoid vaccine. This observation 
supports the view that active resolution may also underlie the protection against 
vascular dysfunction in females. In line with such a proposal are my findings  that 
in plasma samples collected from volunteers at 8 h post-typhoid vaccination we 
found an upregulation in the  women compared to the men of molecules from the 
E-series resolvins that carry potent cardiovascular protective actions (Dona et al., 
2008). The differential regulation of EPA vs DHA derived resolvins in plasma and 
inflammatory exudates may reflect the activation of different biosynthetic 
pathways by the different stimuli in line with published findings (Dalli and Serhan, 
2012), as well as a differential utilisation of precursor fatty acids in plasma versus 
tissues (Colas et al., 2014; Kasuga et al., 2008). 
 
Interestingly, alterations in pathways influencing SPM levels has also been 
proposed to be a target for sex steroid activity. Studies in vitro using whole blood 
and isolated neutrophils collected from healthy male and female volunteers 
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demonstrated that following stimulation with a pro-inflammatory stimulus 
(lipopolysaccharide plus N-formyl-methionyl-leucyl-phenylalanine or with Ca2+-
ionophore A23187) the levels of the 5-lipoxygenase products, including LTB4, 
were reduced in males compared to females. Moreoever,  this study suggested that 
this effect was related to activity of testosterone and the inhibition of nuclear 
localisation of 5-lipoxygenase (Pergola et al., 2008).  Indeed, treatment of 
neutrophils, collected from healthy women, with 5--dihydrotesterone lowered 
the levels of 5-lipoxygenase products produced following stimulation compared 
to those evident in the cells isolated from males (Pergola et al., 2008). Of note, 
treatment of neutrophils from either males or females with female sex hormones, 
17-oestradiol or progesterone, did not alter the levels of the pro-inflammatory 
lipid mediators. However, it is worth noting that for the female cells the additional 
female sex hormones may not have been effective since the cells will have been 
exposed to physiological levels in vivo, and in males the lower levels of the 5-
lipoxygenase-derived mediators per se may have meant further inhibition 
unlikely. Treatment with additional 5--dihydrotesterone had no further effect in 
cells isolated from males suggesting this possibility likely. 
 
Exactly why in our studies we see higher SPM:LTB4 ratios in females whilst in the 
study mentioned above higher ratios were evident in males is uncertain. An 
important difference between the study by Pergola et al and our work, is that 
whilst in our study all assessments reflect the in vivo setting, in the work of 
Pergola all hormone treatments were conducted in vitro. Thus the differences may 
simply reflect the difference between in vivo and in vitro assessment.  To tease 
apart these issues is difficult until the field matures further and drugs that target 
309 
 
the molecular SPM synthetic pathways are developed. Further studies exploring 
the regulation of SPM receptors on inflammatory cells themselves, the impact of 
inhibiting SPM formation on resolution of inflammatory responses, as well as 
studies assessing the impact of raising SPM levels will be important to confirm the 
sexual dimorphism described and awaits the further delineation of the molecular 
pathways and receptor targets of the SPMs. Development of selective drug tools 
but also pharmacological approaches to ascertain whether delivery of SPMs, for 
example through dietary provision of substrate (Buckley et al., 2014; Serhan et al., 
2015), will be important to determine whether targeting the SPMs might offer  a 
therapeutic approach that could be useful in limiting inflammatory responses.   
 
6.1.4 Limitations of inflammatory models in humans 
There are a number of limitations of this work in healthy volunteers. Firstly, both 
models of inflammation provide an approximation of the systemic and local 
inflammatory scenarios. It is possible that the specific cellular profile induced by 
typhoid or cantharidin are not the same as those induced in a CVD scenario.  
 
Since a large number of female blisters had resolved at the 72 hour time-point, a 
full profile of the resolution time-course was not possible. Future experiments 
including time-points mid-way between 24 and 72 hours might provide a more 
detailed window on the time-course of the resolution between the sexes, although 
this may prove difficult and may offer only limited advances if the volumes of fluid 
are small.  In addition, recording of the time of resolution in males would also 
provide an improved comparison of the time scale between the sexes but the 
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difficulties with this relate to needing the blister to remain open and uncovered 
for assessment and thus possibly prone to rupture.  
 
6.1.5 Inflammatory experimental models in humans as tools to study the 
impact of dietary nitrate interventions 
These studies in healthy volunteers demonstrate that the damaging effects of 
systemic inflammatory stimuli on the vasculature are supressed in females 
compared to males, and that this is likely due to a more rapid resolution of the 
local inflammatory response. In this era of growing research in translational 
medicine, and particularly relevant for this thesis, the evidence demonstrating the 
critical role of immune responses and inflammation in CVD, identifying useful  
experimental models that enable testing of new therapeutic approaches that 
might dampen inflammation, are of major value.  My experiments have shown that  
the skin blister represents a reproducible model to tease out the processes that 
drive immune responses in humans and thus may also provide a useful model to 
use to ask whether defective pathways in the evolution of the response or its 
resolution contribute to the aetiology of chronic inflammatory conditions such as 
CVD. I have also re-confirmed that that the low-grade inflammation caused by 
typhoid vaccination causes a pro-inflammatory cytokine response that impairs 
forearm arterial endothelium-dependent dilatation in male volunteers but 
interestingly not in females.  By demonstrating that the same resolution pathways 
are altered between the sexes, my data indicates that combining studies using the 
blister model with typhoid vaccination to interrogate potential anti-inflammatory 
agents for assessing potential in CVD is feasible. Indeed, these studies have 
provided a framework with which experiments assessing the impact of dietary 
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NO3- on inflammation have been structured. As a result of my work we have 
designed and are mid-way through assessment of the impact of dietary NO3- on 
cantharidin-induced inflammation and typhoid-induced  endothelial dysfunction.  
 
We have initiated a double-blinded randomised, placebo- controlled parallel study 
to investigate the effect of dietary NO3- on vascular dysfunction and inflammation 
in healthy volunteers. This study aims to assess whether dietary NO3- (in the form 
of beetroot juice) can reduce systemic inflammation and endothelial dysfunction 
that arises following administration of typhoid vaccine. The principal research 
objective in this study is to determine whether circulating plasma NO2- levels can 
be raised sufficiently to prevent the systemic inflammation that underlies typhoid 
vaccine-induced endothelial dysfunction. The study aims to recruit 31 participants 
in each arm of the study (i.e. placebo and intervention). We are comparing FMD 
measurements between the intervention and placebo groups in healthy 
volunteers who have the typhoid vaccine. The study involves healthy participants 
attending for measurements of PWV/PWA, FMD, BP and collection of blood, urine 
and saliva samples. They then undergo randomisation to receive ether 8 mmol of 
NO3- - rich beetroot juice or NO3- - deplete beetroot juice (placebo). They then 
attend 4 days later at 8 am to receive the typhoid vaccine and then on the same 
day, attend 8 hours later to undergo the same measurements as those performed 
at baseline on day 1. Finally, they attend on Day 5 to undergo the same 
measurements as the previous day to assess recovery allowing measurements of 
the resolution phase of inflammation. A key component of the design of this study, 
based upon my observations, is that assessment of dietary NO3- is conducted in 
males only, since inflammation in females resolves rapidly. To assess whether 
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dietary nitrate alters resolution we will be assessing resolving lipid mediators 
using LC/MS-MS as described in section  2.3.10. Importantly our recent studies in 
animal models of atherosclerosis suggests that dietary NO3- treatment raises IL-
10 levels (Khambata et al., 2017).  As mentioned there is a close link between this 
cytokine and the SPMs. Studies have shown that resolvin E2 displays proresolving 
actions. It does this by potently enhancing nonphlogistic phagocytosis as well as 
promoting increased IL-10 production by macrophages. Therefore, these studies 
indicate that RvE2 has proresolving actions in accordance with and characteristic 
of the SPMs (Oh et al., 2012). 
 
Simultaneously we have embarked upon a second study using the cantharididn 
model of inflammation. This study is also a double-blind, randomised, placebo- 
controlled parallel study assessing the influence of dietary NO3- on skin 
inflammation in healthy volunteers. Here we aim to assess whether dietary NO3- 
might reduce localised recruitment of leucocytes and/or the activation state of 
leucocytes or perhaps alter the processes of resolution using the cantharidin 
model of inflammation. The principal research objective similarly to the typhoid 
study is to determine whether inorganic NO3- in the form of beetroot juice 
compared to placebo controls can raise circulating plasma NO2- levels sufficiently 
to modulate the inflammatory response. The study aims to recruit 12 healthy 
volunteers in each arm of the study (i.e. placebo and intervention and thus a total 
of 24 volunteers).  Again, due to the findings in my previous study, the rapid 
resolution of inflammation in females compared to males has driven our decision 
to conduct this study in males participants only. Within this study, we are 
comparing the mechanisms of resolution in localised inflammation induced by 
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cantharidin using flow cytometry. In addition, we will also measure both the 
cytokines and chemokines involved in this form of inflammation, such as IL-6, IL-
8, IL-10, CXCL1, CXCL2, CCL5 and CCL2. The reasons for selecting this group of 
cytokines and chemokines is that we have already observed a rise in levels during 
our first study as described in Chapter 3. . Again, we will assess the impact of 
dietary NO3- on the resolution phase of localised inflammation using LC/MS-MS to 
measure SPMs in order to investigate the relative levels of the various lipids so 
that an estimation of the resolving power can be made. Our hypothesis is that the 
male participants who are taking the NO3-- rich juice are more likely to have a 
faster resolution of inflammation compared to the males participants on the 
placebo.  
 
6.2 Effect of dietary nitrate on the enterosalivary circuit in patients with 
stable angina 
Studies have shown that dietary NO3- has positive effects upon vascular function; 
including reduction of BP, leukocyte activation and platelet reactivity as well as 
improvement of endothelial dysfunction (Kapil et al., 2015; Velmurugan et al., 
2016). Given the importance of NO in vascular function and its anti-inflammatory 
actions, it is logical to hypothesise that enhancing NO bioavailability might prove 
to be an effective strategy in improving vascular function, platelet reactivity and 
restenosis in patients with stable angina after PCI particularly since inflammatory 
pathways play a key role in progression of pathology. 
 
As the NITRATE-OCT study is still ongoing, the treatment given to each group has 
remained blinded, which is key to avoid bias in the final analysis. The groups have 
314 
 
been labelled gamma and delta for the baseline demographic data analysis to 
enable determination of whether the randomisation has been effective but the 
blinding has remained since the study has not yet completed recruitment of the 
target number of 246. Therefore, to avoid the introduction of selection bias and 
analysis bias the investigators in the study have remained blinded and will do so 
until the primary endpoint has been completed.   
 
With regards to the baseline demographics, there were no significant differences 
between the two groups in the study, except for mean baseline HR, which was 
higher in the gamma group compared to the delta group. This difference in HR in 
1 of 30 of the different baseline characteristics is likely to be reflective of a chance 
observation. Overall, the similarities between the two groups suggests good 
matching. Furthermore, there were no differences between the two groups with 
regards to procedural characteristics, particularly the type of stent used, and 
medications at discharge. This means that any differences that we see in the rates 
of restenosis between the two groups are likely to be due to the intervention. In 
addition, patients will be stratified according to the type of stent BMS or DES as 
both these groups have differing characteristics resulting in differing rates of 
restenosis. Finally, since patients with diabetes are at high risk of developing 
restenosis, these patients are included in this study with stratification in both 
groups to ensure even number of diabetic patients in both groups.  
 
When comparing the concentrations of NO2- and NO3- at baseline particularly in 
plasma, between the patients with stable angina with previous observations in 
healthy volunteers published in the literature my results suggest some potentially 
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important differences. The overall mean baseline plasma NO2- concentrations at 
baseline was 1.58 µmol/L, which is approximately 4 times higher than the baseline 
levels measured in healthy volunteers (Bahra et al., 2012). Previous studies by 
Lauer et al have suggested that plasma levels of NO2- are a mode sensitive indicator 
of in vivo NO production.  The raised level in this study suggests that in the patients 
with angina, NO levels may have been elevated even before treatment with dietary 
NO3- (Lauer et al., 2001). This result is consistent with the theory that perhaps in 
these patients with angina there is an enhanced inflammatory state that has led to 
the expression of iNOS,  iNOS is not normally expressed in health but can be 
rapidly induced in response to inflammation and cytokine production (Libby, 
2005). A related point to consider is that, NO produced by iNOS is not region 
specific, hence the increased and widespread production of NO reacts with 
superoxide and produces higher levels of peroxynitrite. This contributes to further 
deterioration of endothelial function despite the paradoxical high levels of NO2- 
that would be expected after treatment (Ridker et al., 2002). Furthermore, iNOS is 
mostly expressed in macrophages (Kajita et al., 2011; Panaro et al., 2003) and 
vascular smooth muscle cells (Fries et al., 2003; Ginnan et al., 2008) rather than 
the endothelial cell, although there is also some evidence suggesting that iNOS is 
present in endothelial cells (Binion et al., 1998; Leifeld et al., 2002; Yu et al., 2004) 
which can all account for the elevation of NO in patients with stable angina. This 
NO results in continuously elevated NO generation which is not stimulus specific 
and not requiring rises in intracellular calcium. 
 
Based on the results of the whole cohort it is clear that after 6 months there is on 
average a significant increase in the concentrations of cGMP, NO2- and NO3- in the 
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whole group in the different compartments measured. This supports the 
assumption that at least some of patients received a daily dietary NO3- treatment. 
If one looks at the paired data it is clear that the patients separate in to two groups 
and this likely reflects the difference in the NO3- content of the 2 interventions.  
This will be confirmed upon unblinding. 
    
The discovery of the NO3--NO2--NO pathway, which relies on an intact 
enterosalivary circuit, has provided scope for the development of novel disease 
prevention strategies through dietary NO3- supplementation. Results from this 
project suggest that perhaps a once daily ingestion of 70ml of NO3- rich beetroot 
juice increases the conversion of NO3- to NO and increases the levels of cGMP in 
patients with stable angina. This highlights the possibility that the enterosalivary 
circuit is intact in these patients and that the disease per se does not interfere with 
the functioning of this circuit.  
 
Overall, providing 4-5mmol daily of dietary NO3- for 6 months increased plasma 
NO3- concentrations by 3.7-fold. This is a similar peak fold increase to those 
achieved in previous studies (Velmurugan et al., 2016). The increase from baseline 
in NO2- plasma concentration after 6 months was of approximately 1.2-fold. This 
lower fold increase in NO2- concentrations, compared to NO3-, highlights the fact 
that this step relies on the bioconversion of NO3- to NO2- by oral bacteria (Salvatore 
Davide Tomasello, 2011). Inorganic NO3- from the diet is extracted from the blood 
after absorption by the salivary glands and enters the saliva where it is 
concentrated approximately 10-fold. NO3- is reduced to NO2- by the commensal 
bacteria in the oral cavity when it is secreted into saliva (Webb et al., 2008). The 
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levels of NO3- and NO2- in the saliva of the patients with stable angina increased by 
2.5-fold and 1.5-fold respectively. Since we know that at least half of the subjects 
received the placebo and thus assume that upon unblinding the groups would be 
separated, this theoretically should result in a doubling of these values in the 
dietary NO3- limb compared the placebo. This finding is in line with the results in 
healthy volunteers who were administered once daily doses of NO3- 
supplementation (Velmurugan et al., 2013). This further confirms the hypothesis 
that the enterosalivary circuit is intact in patients with stable angina and remains 
functional over the 6 months of once daily NO3--treatment. Furthermore, the 
baseline NO3- levels were ~27-fold higher in the saliva compared to plasma at 
baseline. This finding suggests that patients with stable angina could either have 
greater capacity to extract NO3- from the blood or have better ability to 
concentrate the NO3- in saliva compared to healthy volunteers. 
 
The ratio of NO2- to NO3- in saliva samples of healthy volunteers is approximately 
0.3 (Efsa, 2008; Velmurugan et al., 2016). In this project, the NO2-:NO3- after 6 
months was 0.5 and at baseline was 0.6. Hence, this finding perhaps suggests that 
in patients with stable angina, there is a baseline increased capacity to reduce NO3- 
and it is possible that this is sustained with the increased uptake of inorganic NO3- 
for a long duration. Again, once the groups are separated after unblinding it is 
possible that the ratio will be different between the groups and possibly even 
higher than 0.5 in the NO3- limb.  This observation would be in agreement with 
recent findings by our lab that have demonstrated that following 6 weeks of NO3- 
rich beetroot juice intake, alterations in the oral microbial community occurred 
with a significant shift in the structure of the bacterial community after dietary 
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NO3- intake that was not evident in the placebo group (Velmurugan et al., 2016). 
Therefore, it will be of value to analyse the salivary microbiome and assess for any 
changes after 6 months of treatment.  
 
 
Inorganic NO3- has been considered as a prodrug for the production of NO2-. with 
advantages to the use of NO3- over NO2- for treatment. For instance, NO3- has a 
longer half-life in plasma of about 6h, whereas the half-life of NO2- is 20-40min 
(Bhatt and Topol, 2003). Moreover, the relative rapid time to peak plasma NO3- 
concentration is between 1-3 hours after ingestion. The plasma NO3- then 
recirculates contributing to a sustained release of NO2- that slowly reaches a peak 
after 3 hours which then remains elevated for a further 3 hours, with levels 
remaining slightly raised at 24h after a single dose (de Winter et al., 2002).  
 
Another potential is the possible involvement of xanthine oxidoreductase (XOR), 
which is a source of reactive oxygen species (ROS) but also has NO2- reductase 
activity.  The activity of XOR becomes upregulated in conditions like CHD, where 
there is increased oxidative stress and reduced activity of eNOS (Albert and 
Ridker, 2006). As shown in previous studies, XOR expression and activity is 
increased following dietary NO3- supplementation. This results in switch of XOR 
function into a favourable increase in the production of NO2- and NO with a 
concurrent reduction in ROS generation (Garrone et al., 2009). XOR works by 
either generating NO directly from the reduction of NO2- by catalysing the reaction 
at the molybdenum site where NO2- accepts electrons. Hence, fewer electrons are 
donated to oxygen so fewer ROS are produced that can scavenge NO, leading to an 
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increased bioavailability of NO (Garrone et al., 2009). This could also explain the 
increased baseline NO2- levels observed. This also highlighted the fact that NO 
produced by XOR after NO3- supplementation would be generated specifically to 
the area of ischaemia and endothelial dysfunction to help improve vascular 
haemostasis, as opposed to the NO generated by iNOS that is widespread.  
 
Finally, the plasma concentrations of cGMP increased by 1.15-fold after NO3- 
treatment, which could reflect an increase in NO bioavailability. This was a similar 
fold increase as measured in hypertensive patients after NO3- treatment (Kapil V, 
2015). An elevation in cGMP levels after an acute dose of NO3- occurs around 3-24 
hours after ingestion (Kapil et al., 2015). The overall mean cGMP concentration at 
baseline was 28.5 nmol/L. This was 4 times higher than the values recorded in 
previous studies, but was consistent with the 4 times higher plasma NO2- 
measured in this study (Kapil et al., 2015) . As mentioned previously, iNOS and 
XOR generation of NO does possibly contribute to the higher cGMP levels 
measured. However, this could also be due to the fact that in the management of 
angina, organic NO3- such as isosorbide mononitrate and nitroglycerin are 
commonly used. These drugs are NO donors, which result in a stimulated 
production of cGMP that cause vasodilation, thus relieving symptoms of chest pain 
(Cohn and Rittinghausen, 1985). Interestingly, in our study, 21.5 % of the patients 
recruited so far are regularly taking isosorbide mononitrate and 60.5% of patients 
are taking nitroglycerin ‘when required during episodes of angina’. Hence, these 
high doses of regular and ‘when required’ doses of organic NO3- could explain the 
high levels of cGMP found in our study so far.  
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Inorganic and organic NO3- both generate NO, but their bioavailability and 
metabolic profiles are different. The acute administration of organic NO3- has 
potent immediate vasodilation effects and these compounds have a relatively 
short half life. There are two main pathways for bioactivation of organic NO3- 
Firstly, enzymes of the cytochrome P450 system (McDonald and Bennett, 1990) 
mediate the low potency pathway which produces measurable NO from 
nitroglycerin (Kleschyov et al., 2003). The second pathway, which is a high 
potency pathway, involves the enzyme aldehyde dehydrogenase-2 (ALDH-2). This 
pathway was identified following the use of ALDH-2 inhibitors, cyanamide and 
chloral hydrate (Chen et al., 2002). These inhibitors blocked the production of NO2- 
and glyceral dinitrate from nitroglycerin, which had previously been shown to be 
intermediates in production of NO-related vasodilation by organic nitrate 
compounds (Sage et al., 2000). Inorganic NO3- in contrast produces more 
sustained and subtle effects throughout at 24h period. In addition, another key 
difference is that a major limitation of the organic NO3- is that tolerance develops 
with chronic use resulting in the attenuation of their pharmacological effects. 
There are several causes of this effect.  Firstly, the organic NO3- require 
metabolism to generate NO. Nitroglycerin is metabolised by mitochondrial ALDH-
2 generating NO and ROS simultaneously. ROS scavenges bioavailable NO, 
uncouples eNOS and inhibits aldehyde dehydrogenase activity (Sage et al., 2000; 
Shu et al., 2015). This thus impairs further nitroglycerin metabolism, further 
aggravating NO3- tolerance. In addition, the organic NO3- have been shown to cause 
endothelial dysfunction per se with chronic use.  The mechanism behind this 
process is not completely understood, although ROS generation with O2-∙ seems to 
be an important factor. In a model with rabbits, there was twice as much O2-∙ 
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generation compared to the controls after a 3 day application of transdermal GTN 
(Munzel et al., 1995). In patients undergoing CABG who were pre-treated with 
GTN, there was an increase in O2-∙, which was associated with endothelial 
dysfunction (Schulz et al., 2002). In contrast, inorganic NO3- improves endothelial 
function, with no reports of tolerance (Dejam et al., 2007; Haverkate et al., 1997).  
 
Thus, a dietary NO3- approach could prove to be a cost-effective strategy in 
reducing the rates of adverse effects in patients with stable angina and could also 
improve treatment compliance of patients, although completion of the trial and 
additional investigation is warranted. 
 
6.2.1 Future analysis for this part of the study 
Even though there is a significant rise in [cGMP], [NO3-] and a trend in plasma and 
saliva [NO2-] from baseline to 6 months, it is important to complete the 
measurements of [cGMP], [NO3-] and [NO2-] to ensure accurate interpretation of 
the trends. As the NO2-:NO3- ratio found in this study was higher than previous 
studies it would be interesting to analyse the oral microbiota from saliva samples. 
This is because, our lab recently conducted a clinical trial in patients with 
hypercholesterolemia and detected a significant shift in microbiome structure 
following 6-weeks of NO3- – rich beetroot juice. In this study, there were significant 
increases in both Neisseria flavescens and Rothia mucilaginosa (NO3--reducing 
bacteria) associated with improvements in NO3- reduction which suggests that 
dietary NO3- supplementation “pushes” the oral microbiome composition towards 
one characterised by higher presence of NO3- –reducing bacteria (Velmurugan et 
al., 2016). Whether this is a characteristic of dietary NO3- treatment that might be 
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used to promote cardiovascular health in healthy volunteers or improve outcome 
in patients with CVD is unknown. In NITRATE-OCT, we have collected similar 
saliva samples to assess the microbiome but it would be useful to collect additional 
samples from age-matched healthy volunteers to determine whether differences 
in oral microbiome composition occur between health and disease, whether 
dietary NO3- - feeding might be useful in enhancing the efficacy of microbial NO3- 
metabolism and whether shifts in microbiome composition return to baseline 
with removal of the dietary intervention. We intend to use both next generation 
sequencing and where possible whole genome sequencing approaches adapted 
for microbiome analyses to assess these possibilities. 
 
6.3 Determining whether dietary NO3- might improve intimal hyperplasia 
and thereby restenosis rates post PCI and stent implantation 
To date there have been no clinical studies investigating the role of orally ingested 
NO3- in reducing restenosis in patients undergoing PCI for stable angina. 
NITRATE-OCT study is the first clinical study assessing the safety and efficacy of 
oral NO3- in a dietary form (beetroot juice) in this group of patients. Recruitment 
in my trial to date is only slightly behind the projected schedule and should be 
completed at a provisional date of December 2019. Hopefully this study will 
translate to humans the impressive effects of inorganic NO2- on reducing 
hyperplasia in animal studies (Alef et al., 2011).  
 
The proposed mechanisms of these benefits of inorganic NO3- are thought to be 
through a number of mechanisms with effects demonstrated on both platelet 
reactivity, and inflammation. However, this thesis has demonstrated that 
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inorganic NO3- influences the expression of adhesion molecules on monocytes, and 
subsequent monocyte activation, and thus potentially reducing the inflammatory 
component of restenosis. This issue and were several other aims set out by the 
NITRATE-OCT Study, which are ongoing, are discussed below.   
 
6.3.1 Ingestion of dietary nitrate has no clinical adverse effects  
The ingestion of dietary NO3- has not resulted in any adverse effects in the cohort 
so far. Due to the known vasodilator (Cosby et al., 2003) and BP lowering effects 
(Dejam et al., 2007; Pluta et al., 2011) of raised circulating NO2- levels, BP was 
measured in all our patients. In NITRATE-OCT so far there is a trend towards a 
reduction in BP at 6 months compared to baseline but no evidence of any negative 
hypotension effects. This suggests that some of the patients are likely to be taking 
the NO3- - rich beetroot juice confirming findings from our previous studies (Kapil 
et al., 2015; Velmurugan et al., 2016). 
 
Levels of methaemoglobin were also measured in NITRATE-OCT because of the 
known interaction of NO2- with oxyhaemoglobin to generate methaemoglobin  
(Beck, 1909; Roe, 1933). Levels of methaemoglobin were not clinically significant 
indicating that the circulating levels of NO2- that are likely to be required to achieve 
beneficial functional effects, from the dose we have used in this study, upon the 
cardiovascular system are much lower than the levels associated with their 
detrimental effects.    
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6.4 Determining whether dietary NO3- ingestion exerts anti-inflammatory 
effects and the mechanisms involved in this effect following PCI for stable 
angina 
The second key aim of the NITRATE-OCT study is to investigate the potential anti-
inflammatory mechanisms by which dietary inorganic NO3- may reduce 
restenosis. In this study, patients showed a trend towards a reduction in hsCRP at 
6 months compared to baseline in the whole cohort. We are yet to see whether 
there is a statistically significant difference between the two treatment arms at 6 
months compared to baseline and this will be analysed once the whole study is 
completed and unblinding. 
 
Epidemiological studies have demonstrated that serum CRP levels can be a tool to 
detect low-level systemic inflammation and are a strong predictor of the 
occurrence of cardiovascular events such as MI in apparently healthy subjects 
(Ridker et al., 1997; Ridker et al., 2000) and in patients with a recent coronary 
event (Ridker et al., 2005). Although there is a suggestion that “the overall and 
local inflammatory status at the time of PCI plays a significant role in the 
development of restenosis” (Toutouzas et al., 2004), previous studies of 
inflammatory marker levels and restenosis have shown conflicting results. There 
may be several explanations for this, including differences in the population 
studied (stable angina versus unstable angina), concurrent use of medications that 
may blunt the inflammatory response (statins, glycoprotein IIb/IIIa inhibitors, 
thienopyridines), timing of inflammatory marker measurement (pre-PCI versus 
post-PCI), PCI procedure (balloon angioplasty versus stent deployment), and 
outcomes studied (angiographic restenosis versus clinical restenosis or events) 
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(Bhatt, 2004). The relevance of statin use is of particular importance as a number 
of patients had their dose of statins increased following PCI, which could explain 
the generalised reduction in majority of cytokines and chemokines (IL-6, CXCL-1, 
CXCL-5, CXCL-8, CXCL-2, CCL-2 and CX3CL-1) at 6 months compared to baseline in 
the overall groups. I will be able to check this because I can analyse the change in 
the dose of statins at discharge and 6 months compared to baseline as we are 
collecting this data as part of the study. 
 
The mechanisms that underlie coronary events following PCI are distinct from the 
mechanisms that underlie restenosis (Bhatt and Topol, 2003), so it is possible that 
inflammatory marker levels could be predictive of clinical events following PCI but 
not of restenosis.  Larger studies (de Winter et al., 2002; Dibra et al., 2003) have 
shown that pre-PCI CRP levels predict 1-2 year cardiac event rates in stable angina 
patients undergoing PCI. Therefore, although CRP is not predictive of restenosis 
per se in stable angina patients, it does appear to be predictive of plaque instability 
and, consequently, of clinical manifestations of ischaemia. This is consistent with 
our current understanding of atherosclerosis and the pathogenesis of ACS (Libby, 
2005), and with observations that CRP levels are also predictive of medium to long 
term cardiac events in asymptomatic individuals (Ridker et al., 2002), in patients 
with stable angina (Haverkate et al., 1997), and in patients with ACS not 
undergoing PCI (Lindahl et al., 2000).  
 
6.4.1 Inflammatory marker response to PCI 
Previous studies that have confirmed that in stable angina patients, PCI leads to a 
systemic inflammatory response. CRP levels can be higher 48 hours post-PCI than 
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pre-PCI, which then return to pre-PCI levels somewhere between one week and 
one month post-PCI (Gomma et al., 2004; Segev et al., 2004). There is also some 
evidence to suggest that that post-PCI inflammatory marker levels may be more 
predictive of restenosis than pre-PCI levels (Bhatt, 2004). and that higher post-PCI 
CRP levels may be associated with angiographic restenosis in stable angina 
patients (Gottsauner-Wolf et al., 2000). In the largest study to date (which 
included 1,321 stable angina patients), the association between the post-PCI CRP 
rise and angiographic restenosis was significant in patients with stable angina 
(p=0.05) (Dibra et al., 2005). In addition, there are a number of studies that have 
reported a significant increase in inflammatory marker levels after PCI (Azar et al., 
1997; Cipollone et al., 2003; Quinn et al., 2004; Segev et al., 2004).  Our 
assessments at this stage in the study have found that there was trend towards a 
reduction in hsCRP levels at 6 months compared to baseline in the overall cohort 
of patients. It might be the case that once all the patients have been recruited and 
the data is unblinded, there could be a significant reduction in hsCRP in the NO3- -
rich beetroot juice group compared to the placebo group, which in term could help 
to explain a reduction in restentosis rates in this group compared to the placebo if 
our hypothesis is confirmed.  
 
6.4.2 Effects of the ingestion of inorganic NO3- on circulating immune cells 
The reduced number of macrophages within plaque regions could be related to 
lower monocyte recruitment to the vessel wall, which is a direct effect on the 
endothelial cell or the monocyte, or an indirect effect of reduced neutrophil 
accumulation. We also know that the recruitment of neutrophils in atherosclerosis 
occurs in the early stages of atherogenesis before monocyte recruitment (van 
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Leeuwen et al., 2008; Zernecke et al., 2008) and it is believed that these 
neutrophils play an important role in instructing other key leukocytes, especially 
monocytes, to accumulate at vascular sites with a preference for atheroma 
formation (Doring et al., 2015). Once our study has been unblinded, our data 
assessing inflammatory cell numbers and activation state will indicate whether 
inorganic NO3- treatment results in a reduction in circulation leukocyte numbers 
at 6 months compared to baseline, as well as whether treatment influences the 
activation state of these cells (CD11b, CD62L and CD162). However, so far with 
the data grouped together, there is no evidence of a change in expression of any of 
the activation markers at 6 months compared to baseline in any other cell subtype. 
  
As mentioned pre-clinical studies from our lab have demonstrated that inorganic 
NO3- therapy of ApoE KO mice reduces neutrophil recruitment followed by 
consequent reduction in the number of inflammatory monocytes in a model of 
peritonitis. We speculated that this effect was due to an elevation of IL-10 levels 
(Khambata et al., 2017). These studies also demonstrated that within lesions in 
the ApoE KO mice there was a reduction in inflammatory load in inorganic- NO3- 
fed ApoE KO mice associated with elevated IL-10 mRNA levels. We speculated that 
this effect could result in a reduction in neutrophil-dependent recruitment of 
monocytes into the atherosclerotic plaque and potentially an acceleration of the 
resolution of inflammation, driven by elevations in IL-10 expression and 
consequent activity (Couper et al., 2008; Mosser and Zhang, 2008). Although not 
statistically significant, in the patients to date in NITRATE-OCT there is an overall 
reduction in IL-10 levels at 6 months compared to baseline. It will be interesting 
to see if the levels of IL-10 are significantly lower in the treatment arm compared 
328 
 
to the placebo arm at 6 months compared to baseline, once the study has been 
completed and the results are unblinded.  
 
6.4.3 Improved vascular health at 6 months in nitrite treated patients 
We hypothesise that patients in the placebo arm are more likely to have 
endothelial dysfunction compared to the treatment arm at 6 months, which in turn 
would support the concept of impaired vascular health and endothelial 
dysfunction in these patients. Higher levels of MCP-1 have also been shown to 
predict adverse events and reflect elevated levels of inflammation (Martinovic et 
al., 2005). A study by Huang and colleagues has shown that endothelial vasodilator 
dysfunction in patients with suspected coronary artery disease is associated with 
elevated hs-CRP and MCP-1 compared to patients with a normal chronotropic 
response to exercise and no endothelial dysfunction (Huang et al., 2006).   
Therefore, it would be interesting to see how this combination of factors are 
affected in the whole cohort of patients at 6 months compared to baseline in the 
NO3--rich group. We would predict that there would be reduced platelet reactivity, 
lower levels of hs-CRP and MCP-1 levels coupled with higher levels of NO2-/ NO3- 
and cGMP, which are likely to reflect reduced inflammation, improved endothelial 
function and vascular health in these patients and therefore could result in a 
reduced rate of major adverse cardiac events in the cohort at this time-point.   
 
6.5 Future Work from the NITRATE-OCT Clinical Trial  
Recruitment for NITRATE-OCT, will be completed by the end of 2018 (December). 
The primary endpoint will be completed at 6 months after the last patient is 
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recruited with 1 year’s follow-up (visit 5) by December 2019. Over the next few 
months, the remaining stored samples will be analysed, which will include plasma 
samples being analysed for cGMP, NO2- and NO3- levels, plasma markers of 
inflammation; hs-CRP and urate.  Analysis of flow cytometry data for each 
subjects’ PMA and p-selectin expression will be performed.  QCA analysis of the 
angiographic data and OCT analysis will be performed.   
 
All patients will be telephoned at 1 year (visit 5) after their 1 year follow-up visit 
to assess for any symptoms, hospitalisations and major-adverse cardiac events. 
 
6.5.1 Study limitations 
So far, the low clinical event rate is unlikely to demonstrate a significant difference 
between the two groups to detect associations between the intervention and 
MACE.  However, once this study is completed, our assessments suggest that it will 
be adequately powered to detect a difference between the intervention and 
placebo groups in terms of MACE as well as powered to assess restenosis (through 
late lumen loss) using quantitative coronary angiography.  
 
In some patients, missing inflammatory marker levels and quantitative coronary 
angiographic results may have introduced unappreciated bias, although the 
baseline clinical and angiographic characteristics of these patients were similar to 
those of the main study cohort. Furthermore, our study included a relatively 
homogeneous population of patients with stable coronary disease undergoing 
elective PCI for a de novo native coronary lesion, limiting the likelihood of 
confounding or systematic bias. Other strengths of this study include 
330 
 
randomisation with even distribution of the use of statins as well as stratification 
to diabetes status, both of which allowed us to exclude the possibility that use of 
these agents and/or diabetes masked a positive association between 
inflammatory markers and possible restenosis between the groups. We are also 
using an objective measurement of restensosis using late lumen loss on QCA 
angiography at 6-month angiographic follow-up with assessment of angiographic 
restenosis. This avoids the potential for observer bias that arises with use of less 
objective outcome measures such as clinical restenosis (Buffon et al., 1999). In 
addition, results from the platelet markers is yet to be analysed as the data 
collection is still ongoing. 
 
This study has been powered for a sample size of 246 but since patient 
recruitment is still ongoing, the results of only 200 participants at baseline have 
been included in this thesis. Also, as the study remains blinded, the basis of the 
discussion was limited to an overall combined effect of the two arms and therefore 
this has limited the depth of data that can be analysed until the end of the trial.    
 
6.6 Conclusions  
This study demonstrated that the enterosalivary circuit remains intact throughout 
the 6 months of treatment, in patients with stable angina. There is a clear increase 
in the concentrations of NO2-, NO3- and cGMP in the overall group, likely to be due 
to half the patients being treated with NO3-. The increase in cGMP levels after 
treatment in the intervention arm reflected the overall increased NO 
bioavailability. Moreover, the raised levels of baseline plasma cGMP and NO2- has 
been attributed to the use of isosorbide mononitrate and upregulation of iNOS and 
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XOR activity. We have also found that patients with stable angina have a 
generalised baseline systemic inflammatory response with high circulating levels 
of the inflammatory marker hsCRP. In addition, there was a trend towards a 
reduction in hsCRP levels at 6 months compared to baseline, likely to be due to 
half the patients being on the intervention of inorganic NO3- (beetroot juice). 
Finally, in addition to completing the study with analysis of the primary endpoint 
of late lumen loss via angiography and OCT, further work needs to be conducted 
to categorically explain the mechanisms involved with dietary NO3- treatment. 
Consequently, this will provide further evidence of the benefits of inorganic NO3- 
and specifically with the aim of improving endothelial function and reducing rates 
of restenosis in patients with stable angina.  
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Appendix 1: Patient Information Leaflet for the NITRATE-OCT Study 
 
 
 
 
 
 
Patient Information Sheet 
 
NITRATE-OCT: A randomised, double-blind, placebo-
controlled study investigating the effects of dietary nitrate on 
vascular function, platelet reactivity and restenosis in stable 
angina  
 
Part 1 
Invitation paragraph 
 
You are being invited to take part in a research study. Before deciding to take part it is 
important for you to understand why this research is being done and what it will involve. 
Please take time to read the following information carefully. Talk to others about the 
study if you wish. 
 
• Part 1 tells you the purpose of this study and what will happen if you take 
part 
• Part 2 gives you more detailed information about the conduct of the study 
 
One of our research team will go through the information with you to make sure that 
you understand. Ask us if there is anything that is unclear or if you would like more 
information or more time. 
 
Queen Mary University of London (QMUL) is the Sponsor of this research. 
 
 
What is the purpose of this study?  
Nitric oxide is a gas normally produced by healthy blood vessels that plays an important 
role in preventing blood vessels from hardening and blocking up. This blocking up of 
blood vessels results in block of blood flow that ultimately causes heart attacks and 
strokes. Research shows that in people who have hardening of blood vessels, that their 
blood vessels have a reduced ability to make nitric oxide. Diets rich in fruits and 
vegetables reduce the risk of heart attack and strokes.  Many vegetables, particularly 
the green leafy ones and beetroot, are rich sources of dietary nitrate. Our recent research 
in healthy volunteers shows that consuming dietary nitrate results in more nitric oxide 
being produced in the body. In this study we want to find out whether consuming nitrate 
in the form of beetroot juice (since beetroot juice has a high concentration of inorganic 
nitrate) might improve blood levels of nitrate and therefore nitric oxide in individuals 
with hardening of blood vessels and blockages of vessels. 
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What is the substance that is being tested? 
The test substance is inorganic nitrate. Inorganic nitrate is present in our food 
(especially in vegetables) and we also produce it ourselves in our body. We are able to 
transform inorganic nitrate, in our mouths, to inorganic nitrite, which can then be further 
converted to nitric oxide within our blood vessels.  Inorganic nitrate is found in high 
concentrations within vegetables such as beetroot but also lettuce and cabbage.  After 
you have your angioplasty and stent insertion, there is a risk of re-narrowing (known as 
restenosis) and sudden complete blockage (called stent thrombosis) which can result in 
a heart attack.  Although the new drug coating on the stents are thought to cause less 
re-narrowing than previous generations of drug-coated stents, there is a small but 
significant risk that complications will still occur.   We believe that the inorganic nitrate 
found in beetroot can reduce the amount of re-narrowing and reduce the risk of stent 
thrombosis by improving the degree of re-growth of coronary artery (the blood vessels 
providing blood to the heart) lining cells (endothelium) over the stent as well as by 
reducing the stickiness of blood.  The degree of re-growth of coronary artery lining cells 
(endothelium) over the stent is a major determinant of both restenosis and stent 
thrombosis, and we will assess the degree of re-growth of endothelium with a technique 
called optical coherence tomography (OCT). OCT is a tiny device that is passed into 
the coronary artery and inside the stent. OCT is emerging as the new best test for 
imaging of stents and endothelium. It provides extremely detailed pictures of the 
coronary arteries and stent and in this way a clear measure of re-narrowing. We will 
perform OCT 6 months after your surgery.. Previous studies suggest that this is the 
optimal time to perform OCT evaluation of these new drug coated stents. Performing 
OCT means that you will need to undergo a second angiogram procedure with OCT 
assessment 6 months after the stent is implanted. 
 
Why have I been chosen? 
You have been chosen because you have been diagnosed with stable angina and are due 
to undergo planned coronary angioplasty and stent insertion. 
 
We are inviting potential participants by means of posters displayed in hospital 
departments within Barts Health NHS Trust including general outpatients, Accident 
and Emergency Reception in The Royal London Hospital and in King George Hospital. 
A general advertisement has also been placed in a London based newspaper.  
 
This study will aim to recruit 246 patients like you who are having coronary stents 
inserted within Barts Health NHS trust within the next 3 years. 
 
Do I have to take part? 
NO. It is up to you to decide whether or not to take part. The purpose of this information 
sheet is to help you make a decision. The study will also be explained to you by a 
member of the research team. If you decide to take part you will be asked to sign a 
consent form. You are free to withdraw from the study at any time without giving a 
reason. A decision to participate, not participate or withdraw from the study will not 
affect your medical treatment or planned stent insertion.  
 
What will happen to me if I take part? 
This study will take place at The William Harvey Clinical Trials Centre in Barts & The 
London Medical School, Queen Mary University of London in Charterhouse Square 
and at The Barts Heart Centre, St. Bartholomew’s Hosptial (Barts Health NHS Trust) 
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and will be overseen by the Imperial Clinical Trials Unit. When you come for your first 
visit (Screening visit) we will explain the study to you, obtain your written consent, 
take a brief medical history, take some blood, collect a urine sample and do a basic 
physical examination. If you pass screening and you provide full consent you will then 
be entered for our study.  
 
On the day of each study visit you will need to arrive in the morning after an overnight 
fast, so you will have to miss breakfast. You will also be asked to avoid caffeine or high 
nitrate-containing food or drink (such as green leafy or root vegetables or beetroot juice) 
for 12 hours before each study visit, and avoid taking strenuous exercise for 24 hours 
before the study. We will give you advice on high nitrate containing foods but this 
includes green leafy vegetables and processed meats such as bacon and sausages.  
 
This study is a randomised placebo-controlled, double blind, clinical trial. This means 
that you will be randomly selected to receive either nitrate rich beetroot juice or a 
special nitrate-deplete juice as placebo. The studies are classified as “blinded” as neither 
you or the investigators know which type of juice you are taking. This is kept 
confidential until the whole study is complete. The aim of doing a study in this way is 
to prevent bias and ensure the results we get are as accurate as possible.  
 
After the screening you will need to visit the Clinical Trials Unit four times in total and 
once to the Barts Heart Centre, St.Bartholomew’s Hospital. What will happen to you 
on each of these visits is detailed below: 
 
Study Visit 2 
Visit 2 will take place at a convenient time for you but not less than 1 month after 
successful screening and successful consent has been completed.  On visit 2 you will 
have to fast from  midnight the night before.  
 
After you have arrived we will collect a urine and saliva sample from you, which we 
will freeze, for measurement at a later time of the levels of nitric oxide..  
 
After this we will perform special techniques called pulse wave velocity and pulse wave 
analysis to get a measure of how stiff your arteries are. You will be lying on a couch 
and  special cuffs placed on your brachial (arm) artery, your carotid (neck) artery and 
femoral (groin) artery. We will use a measuring tape to measure distances from your 
neck to your collar bone and from your collar bone to your belly button and from your 
belly button to your groin artery. You won’t be exposed as you will not be asked to 
undress - so don’t worry. The whole process takes around 20 minutes and doesn’t 
involve any needles.  These cuffs will only inflate slightly and you should not feel any 
tightness around your neck. However, if you feel any discomfort then the cuffs will be 
removed immediately.   
 
After this we will take 40 ml of blood from your arm vein (this is approximately 3 
tablespoons). This shouldn’t be too uncomfortable and is not dissimilar to a routine 
blood test. Taking 40 ml of blood will not harm your blood count. We will use this 
blood to study your blood’s stickiness and measure your blood levels of nitric oxide. 
We will also measure the levels of a substance called thromboxane A2, and two proteins 
called P-selectin and CD40L which tell us about your platelets (the cells that make 
clots).  The samples will be processed and disposed within 3 years of collection.  
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After this you will be free to leave but we will also offer you a light lunch of a sandwich 
and a drink. 
 
You will then take the juice at home (either nitrate rich or nitrate deplete beetroot juice) 
and continue this every day for 6 months in total. The juice will have been couriered to 
your preferred address.  We will provide you with a diary for you to keep a daily record 
of taking the juice over the 6 month period. 
 
You will then have your scheduled balloon angioplasty and stent implantation at The 
Barts Heart Centre, St. Bartholomew’s Hospital as planned.  The trial will not affect 
any routine care given around the time of your coronary stent procedure. The planned 
angioplasty and stenting procedure will be performed as usual.  
 
Study Visit 3 
6 months ± 2 weeks after your procedure, you will return to The William Harvey 
Clinical Trials Unit for your third visit.  During this visit we will repeat all of the things 
that you did on the second study visit although we won’t expect you to take any further 
juice. This will enable us to see if the nitrate ingestion has had a beneficial effect on the 
stickiness of your blood and whether there has been an increase in nitrate levels in your 
blood.  
 
 
Study Visit 4 
 
Study visit 4 will take place at The Barts Heart Centre, St.Bartholomew’s Hospital.  
Here, you will undergo another angiogram procedure 6 months (± 1 month) after the 
stent was implanted. We will also study the stent with OCT during this procedure. We 
will ask you to come to the Barts Heart Centre, St. Bartholomew’s Hospital for one day 
for this procedure to be performed. You should not need to stay overnight. The 
angiogram will be performed as usual with a small tube being inserted from either the 
wrist or top of the leg. The OCT requires a tiny wire to be advanced down the coronary 
artery. Over this wire the OCT probe can be advanced giving extremely detailed 
pictures of the stent and coronary artery. The procedure should last between 30 minutes 
and 1 hour. All the tubes and wires are removed at the end of the procedure. You may 
find the tubes being put into the wrist or leg a little uncomfortable but once the tubes 
are in the body you should not feel any pain.  
 
On this visit, one of the research team will discuss with you how you have been over 
the six month period since the stent was implanted. This consultation should take no 
longer than 30 minutes. 
 
We do not plan to use the OCT images to make any changes to your health care. 
However, if you have new concerning symptoms, or significant changes with your 
angiogram, we may organise additional cardiac tests and cardiology follow up as 
necessary. 
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Study Visits 5 
 
At 12 months after your initial procedure, you will return to The Clinical Trials Unit 
for your final visit.  During this visit we will repeat the urine, saliva and blood collection 
and the blood pressure measurements that we did on the second study visit.  This will 
again enable us to see if the nitrate ingestion has had a beneficial effect on the stickiness 
of your blood, your blood vessel function and whether there has been an increase in 
nitrate levels in your blood. 
 
In total, you will visit the Clinical Trials Unit four times and once to The Barts Heart 
Centre, St.Bartholomew’s Hospital as part of the study. 
 
Following this, you will be contacted by telephone after 1 year (after your last visit) to 
ask about your health. 
 
The whole duration of the study will be 2 years in total. 
 
 
What are the alternatives for treatment? 
If you were not taking part in the study your angioplasty and stenting procedure will 
proceed as normal with your Consultant Cardiologist deciding further management 
during your procedure as planned. Any changes to your health care will be fully 
discussed with you prior to anything being organised. 
 
By agreeing to tissue storage, you will only be giving us permission to store your blood 
for future research of the type described above. Any other use that we may want to 
make of your sample in the future will require approval by a Research Ethics 
Committee, which is an independent panel of experts who assess all research projects 
for safety, ethical acceptability and who protect volunteers’ interests. None of the work 
that we are proposing will have any direct implications for your personal health. You 
do not have to agree to the storage of your tissue.  
 
 
 
What are the possible risks and side effects of any treatment received 
when taking part? 
For the blood sampling, inserting a needle in a vein causes a stinging sensation, after 
which blood sampling is usually painless, although there may be some mild aching from 
the needle. If this becomes uncomfortable the needle will be removed.    Also, we will 
be placing a cuff around your neck, thigh and arm, although these will inflate slightly, 
it should not cause too much discomfort. If you feel any discomfort at any point, then 
these will be removed immediately. 
 
The trial also involves a repeat coronary angiogram and OCT at 6 months, which is 
associated with a small risk of adverse events. This procedure requires a catheter to be 
introduced into the coronary artery via a small cut in the artery at the top of the leg or 
in the wrist. Rarely there may be injury to the artery of the leg or wrist. This occurs in 
< 1 in 100 procedures. Once the catheter is in the coronary artery a tiny wire is advanced 
down the coronary artery, over which the OCT catheter is passed. There is a risk of a 
serious complication (including heart attack, stroke and need for urgent heart bypass 
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surgery) in <1 in 200 of patients. These procedures will be undertaken by trained senior 
medical staff in the angiography department, where this is considered a standard 
procedure.  During this study you will receive approximately 44% more exposure to 
radiation from X-rays than if you did not participate and this will be at 6 months for the 
OCT. It is estimated that the total dose of radiation gives an additional risk of cancer of 
approximately 1 in 2000. The risk from the dose additional to standard care (i.e. from 
the OCT at 6 months) is approximately 1 in 4000. The total dose is equivalent to about 
5 years natural background radiation dose. The regulatory body (PHE Radiation 
Protection Division) describes this risk as low risk. 
 
What do I have to do? 
We need to know whether you are taking any medication or if you have had any 
reactions to drugs in the past as this may exclude you from the study.  
  
The day before your study visits, we would ask you to keep to a low nitrate diet (avoid 
green vegetables, beetroot and processed meats – advice will be given), avoid alcohol 
and caffeine, and fast after your evening meal (except water) until you are finished with 
us the following morning. We will provide tea/ coffee and toast at the end of each visit, 
or a light lunch, if you require after each study visit. You should avoid strenuous 
exercise on the day before the study. If you feel unwell (e.g. have a cold, fever, sore 
throat, headache) you should inform the researcher. If you are a blood donor you should 
refrain from giving blood from one week before you start the study until one week after 
you have finished the study.  
 
We also ask that you avoid paracetamol and any non steroidal anti inflammatories eg. 
ibuprofen and diclofenac for 1 week prior to study visits. This is because these tablets 
can affect the way your blood cells respond. We know this can be difficult so if once 
you are enrolled in the study you happen to take a paracetamol tablet for example for a 
headache, please let us know. For example if you are due for a study visit we would 
simply delay the visit for a further 1 week to ensure the effect of the tablet on your body 
would have worn off. Please note: If you take regular aspirin or clopidogrel to reduce 
the stickiness of your blood that is ok. 
  
We also need to know whether you are pregnant. Women of childbearing age in whom 
the possibility of being pregnant cannot be otherwise excluded must have a negative 
pregnancy test before their participation begins and this will be done by the investigator. 
Women who are not pregnant must use an effective form of barrier contraception or be 
on the oral contraceptive pill. If you suspect that you may have become pregnant during 
the study in which you are taking part, you must immediately inform the investigator 
who will advise and help you. If necessary, you will be referred to other clinicians and 
counsellors for specialist care. 
  
You will be given either nitrate rich beetroot juice or a placebo juice (which is nitrate-
deplete beetroot juice), to take during the study. You will be chosen to receive 
whichever juice by a random process and both you and the investigators won’t know 
which juice you will have been consuming at each stage until the study has ended and 
all results analysed. This makes for a fairer and more scientific study. The ingestion of 
either nitrate rich or deplete (i.e. placebo) beetroot juice will take place for 6 months in 
total. 
 
426 
 
What are the benefits of taking part? 
It is possible that your blood vessel stiffness and blood stickiness may improve after 
you have taken the nitrate, however it is also possible that the study may be no benefit 
to you at all.   It is hoped that the results of this and similar studies will help treat patients 
in the future.   
 
Although we do not plan to use the OCT data to make changes to your health care, the 
repeat angiogram may give us use useful information about changes in your heart 
arteries over the 6 month period from the stent implantation. We may make changes to 
medications or organise further cardiac testing and/or cardiology follow up based upon 
the results of the angiogram.  
 
 
Expenses and Payments 
A payment of up to £80 will be organised for travel expenses for visits within Greater 
London, on provision of receipts. Payment is by cheque (payable from Barts and the 
London School of Medicine and Dentistry): this may take 2-3 weeks; or may be made 
in cash on the day, depending on the arrangements at the time. 
 
 
What if new information becomes available? 
Sometimes new information becomes available during the course of a research project 
that is directly relevant to participants within the research. If significant new 
information came to light that had a bearing on the study and your participation, then 
this information would be considered by a committee who oversee the conduct of the 
trial and you would be informed. 
 
 
What happens when the research study stops? 
When the study is completed you will not be required to continue with any of the study 
procedures and your care will continue as usual. 
 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in 
part 2 of the patient information sheet. If you have a complaint please contact the 
following in the first instance: Dr Krishnaraj Rathod or Professor Amrita Ahluwalia. 
 
 
Who will have access to the research notes? 
Only the researchers, representative of the Sponsor and regulatory bodies and a 
representative of the Research Ethics Committee will have access to the data collected 
during the study. Personal data about you will only be stored in the (paper) clinical 
study notes and (paper) case report form. Personal data will not be stored or transmitted 
electronically, and will not be used in any presentations or publications about this 
research, so it will not be possible for you to be identified as a result of having taken 
part in the study. The findings of this study will be published in a scientific journal, 
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which is freely available, and discussed at international scientific meetings, but again it 
will not be possible to identify you from these sources.   
 
 
Will my taking part in this study be kept confidential? 
All the information that is collected about you during the course of the study will be 
kept strictly confidential and will be kept in a locked room and stored on a password-
protected computer. Only the investigators will have access to the data. Any 
information about you that leaves the centre will have your name and address removed 
so that you cannot be recognised from it. 
 
Your GP will be notified of any important results, namely blood pressure readings, in 
the study, if you agree. 
 
Contact Details: 
If you require any further information please contact 
 
Dr Krishnaraj S Rathod,    Professor Amrita Ahluwalia,  
Clinical Research Fellow   Professor of Vascular Pharmacology 
Clinical Pharmacology,    Clinical Pharmacology,  
Charterhouse Square,     Charterhouse Square,  
London,     London, 
EC1M 6BQ     EC1M 6BQ 
Tel: 020 7882 5720 / 8931    Tel: 020 7882 8377;  
Email: k.s.rathod@qmul.ac.uk    Email: a.ahluwalia@qmul.ac.uk 
 
This completes Part 1 of the information sheet. If the information in Part 1 has interested 
you and you are considering taking part, please continue to read the additional 
information in Part 2 before making any decision. 
 
 
Part 2 
 
What will happen if I don’t want to carry on in the study? 
You are free to withdraw from the study at any time although we would be happy to 
assist you to stay and complete the study with us. If you become ill for any reason 
during the study your health would obviously come first and we may advise you to 
withdraw from the study. We must stress that beetroot juice or placebo juice are not 
known to have made anyone seriously ill. 
 
What if something goes wrong? 
The chances of any harm befalling you in this study are very small. However, Queen 
Mary University London (QMUL) have provided indemnity/insurance against 
negligent harm and if you are harmed through your participation in this study, you will 
be entitled to compensation.  
 
If you are harmed by taking part in this study and it is not the fault of the Investigators, 
then you may have grounds for a legal action but you may have to pay for it. Regardless 
of this, if you wish to complain, or have any concerns about any aspect of the way you 
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have been approached or treated during the course of this study, then you should first 
of all discuss this with Dr Rathod, Prof Mathur or Prof Ahluwalia. If you would rather 
discuss any problems with individuals independent of the study at QMUL / Barts Health 
NHS Trust you can contact Professor Mark Caulfield on 020 7882 3402.    
 
Who has reviewed the study? 
This study has been reviewed by the NRES Committee London - City Road & 
Hampstead, South West REC Centre  Research Ethics Committee. 
 
Complaints 
You will always be able to contact an investigator to discuss your concerns and/or to 
get help: 
  
Dr Krishnaraj S Rathod, Clinical Pharmacology, Charterhouse Square, London EC1M 
6BQ 
Telephone number: 020 7882 5720 / 8931; Email: k.s.rathod@qmul.ac.uk  
or  
Professor Amrita Ahluwalia, Clinical Pharmacology, Charterhouse Square, London 
EC1M 6BQ, Telephone number: 020 7882 8377; Email: a.ahluwalia@qmul.ac.uk 
or 
Professor Anthony Mathur, Clinical Pharamcology, Charterhouse Square, London 
EC1M 6BQ, Telephone number: 020 7882 5906; Email: a.mathur@qmul.ac.uk 
or 
Imperial Clinical Trials Unit, Professor Neil Poulter, Professor of Preventative 
Cardiovascular Medicine, International Centre for Circula, 59/61 North Wharf Road, 
St Mary's Campus  Telephone number: 020 7594 3446; Email: 
n.poluter@imperial.ac.uk 
  
Alternatively, you may wish to speak someone who is independent of the study (not 
actively involved), but knows about the study and the techniques involved. We suggest: 
 
The INVOLVE organisation.  This is a national advisory group that supports greater 
public involvement in NHS, public health and social care research. INVOLVE shares 
knowledge and learning on public involvement in research.  They can be approached 
via their website: 
  
http://www.invo.org.uk/ 
  
What happens to the results of the research study? 
The results from each volunteer will be pooled to obtain average results, so that no 
individual or their results will be identifiable in any form of publication. The results 
from the research will be presented as a talk (or poster) at a local meeting within the 
University of London, or a national meeting, or possibly a European or international 
meeting. The results will also be written up as a full paper and be submitted for 
publication in an international journal. These events will most likely occur 2-3 years 
after your participation in the study. If you would like a copy of the paper you can 
contact the researcher to send you one when it becomes available. 
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Who is organising and funding the research? 
The research is being organised by the Centre of Clinical Pharmacology of Queen Mary 
University London and Sponsored by Queen Mary University of London. It is being 
performed by doctors at the Barts Health NHS Trust who have time allocated to 
undertake research at The William Harvey Research Institute which is part of Queen 
Mary University of London.  The study is funded by the National Institute for Health 
Research. 
 
None of the doctors will be paid for including you in this study. 
 
Thank you for taking the time to read this patient information sheet. If you decide to 
take part we will ask you to sign a consent form. You will be given a copy of the signed 
consent form and the patient information sheet. 
 
Thank you for taking the time to read this. Please ask if there are any 
questions.  
 
